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The aetiology of hemifacial microsomia is uncertain; vascular, metabolic, teratogenic 
and genetic factors have been proposed as aetiological influences. The evidence for a 
genetic basis comes from observations of the phenotype in individuals carrying 
chromosomal rearrangements, and from a small number of studies involving families in 
whom the condition appeared to be transmitted in a Mendelian fashion. Malformations 
reminiscent of hemifacial microsomia have also been seen in knockout and mutant 
animal models, and these have given rise to a number of candidate genes for the disease.
Two main objectives were defined at the start of this project. The first of these was to 
expand upon the currently available clinical data by interviewing and examining 
patients with hemifacial microsomia or isolated microtia who presented to two specialist 
treatment centres in London, Great Ormond Street Hospital and Mount Vernon 
Hospital. Alongside this a genome scan was performed on a family in which hemifacial 
microsomia appeared to be segregating in an autosomal dominant manner. Whilst 
definite linkage to a single locus could not be inferred from the results of the genome 
scan, a few regions of interest were identified, and linkage to a large proportion of the 
genome was excluded. One area of particular interest, 2q32 -  2q37, was analysed in 
greater detail, and other regions together with their potential disease genes have been 
highlighted.
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141. IntroductionThe term hemifacial microsomia has been used to describe a range of abnormalities that 
results from the abnormal development of anatomical structures which are derived from 
the first and second branchial arches, and it is one of the most common craniofacial 
malformations observed in humans.
The disorder includes a wide spectrum of anomalies primarily affecting the external and 
middle ear, the mandible and the maxilla; therefore, patients with hemifacial 
microsomia are managed by a number of different medical specialties e.g. ENT surgery, 
plastic surgery, maxillo-facial surgery, ophthalmology, and clinical genetics.
Some children are bom with microtic ears, but have none of the other features 
associated with hemifacial microsomia, and debate continues as to whether these cases 
of isolated microtia constitute an aetiologically distinct condition or a mild form of 
hemifacial microsomia.
The aim of this work is to investigate the genetic basis of hemifacial microsomia.
161.1  Incidence & Epidemiology
Many patterns of craniofacial malformation have been observed in man, and amongst 
these hemifacial microsomia is relatively common with only the cleft lip and palate 
deformities having a higher reported incidence. The incidence of hemifacial microsomia 
is most often quoted as 1/5600 births {Grabb, 1965 46 /id}. This figure was determined 
by a retrospective review of the records of 39,492 births in Michigan, USA, amongst 
whom there were 7 infants with hemifacial microsomia. Stoll et al (Stoll, 1984 60 /id} 
quoted an incidence of 1/19,500 consecutive births in France, Melnick (Melnick, 1980 
5 /id} reported a frequency of 1/26,550 live births in a prospective study in America, 
and Higurashi et al (Higurashi, 1990 157 /id} reported a single case of Goldenhar 
syndrome in 27,472 consecutive births in Tokyo, Japan. The variations in prevalence 
quoted are likely to be due, at least in part, to differences in the inclusion criteria used 
by different research groups, and thus their ascertainment of cases, although true 
geographical variation cannot be discounted.
The prevalence of isolated microtia also varies greatly between different reports. 
Mastroiacovo et al (Mastroiacovo, 1995 105 /id} reported a rate of 1.46/10 000 using 
data collected from the Italian Multicentre Birth Defects Registry. A report from South 
America (Castilla, 1986 62 /id} suggested a prevalence of 17.4/10,000. Data from three 
registries of congenital malformations in France, Sweden and America were examined 
by Harris, Kallen and Robert (Harris, 1996 175 /id}, who found prevalence rates for 
isolated microtia/anotia of 0.57, 1.58 and 1.01 per 10,000 in each of these countries
17respectively. A significant difference in prevalence rates between racial groups was 
noted within the group of patients from California, USA, included in this analysis; the 
prevalence was highest in Hispanics (3.23/10,000) and Asians (2.18/10,000), and lower 
in blacks and whites, 1.22 and 1.17 per 10,000 respectively. These differences suggest a 
genetic component to the aetiology of microtia as they are unlikely to be due to 
variations in inclusion criteria or case ascertainment, both of which are important 
considerations when comparing figures from different registries.
The International Clearinghouse for Birth Defects Monitoring Systems records data 
submitted voluntarily from 31 participating programmes around the world, with cases of 
anotia and microtia being amongst the birth defects monitored. Within this database the 
rate of anotia and microtia per 10 000 births for the year 2000 ranged from 20.85 
(Canada: British Columbia) to 0 (Dublin, Malta, North Netherlands, United Arab 
Emirates), though most rates are close to the mean of 2.55/10 000  (ICBDMS, 2002 61 
/id}. The incidence of anotia in England and Wales in 2000 as reported to the ICBDMS 
was 0.13/10 000 (8 cases in 604,130 births), and 3 cases of microtia were documented, 
which was equivalent to an incidence of 0.05/10 000. However, the differentiation 
between anotia and severe microtia is imprecise; in our personal experience in the 
microtia clinic at Great Ormond Street Hospital we have already recorded five patients 
who were bom in 2000 who we classified as having isolated microtia, but we have not 
seen any cases that we would consider to be anotia.
181.2 Clinical features
The clinical phenotype of hemifacial microsomia is highly variable. Although no 
minimal diagnostic criteria have been agreed upon, the principle features of the defect 
are those of asymmetric facial and auricular abnormalities.
1.2.1  Facial abnormalities
The facial asymmetry that is a feature of hemifacial microsomia may result from a 
deficiency of both the skeletal and soft tissue components of the facial structures that 
are derived from the first branchial arch. Hence, the temporomandibular joint, mandible, 
maxilla, and muscles of mastication may all be hypoplastic. Facial asymmetry may not 
be readily apparent at birth, but differential growth of the normal and affected structures 
will produce an evident deformity by the age of four {Rollnick, 1987 2 /id} (Kearns, 
2000 163 /id} (Gorlin 2002 49 /id}. In cases of unilateral facial involvement, several 
reports suggest that the right side of the face is more commonly affected than the left; 
Rollnick and Kaye reported that 40% of patients showed right sided laterality in their 
series of 202 patients with mandibular hypoplasia and microtia, compared to 28% with 
the opposite laterality (Rollnick, 1987 2 /id}. Bilateral facial involvement occurs in 6- 
31% of cases with one side of the face being more severely affected than the other in 
almost all patients (Grabb, 1965 46 /id} (Rollnick, 1987 2 /id}.
19Macrostomia is sometimes present and is almost always unilateral and ipsilateral to the 
more affected side of the face. Cleft lip and/or palate occurs in up to 19% of patients 
either unilaterally or bilaterally {Feingold, 1978 16/id} {Rollnick, 1987 2 /id}.
1.2.2  Ear abnormalities
The abnormalities of the external ear that are seen in patients with hemifacial 
microsomia range from pinnae that are normally shaped but abnormally small, to cases 
in which the external ear is represented by a small, ill-defined mass of tissue located 
antero-inferiorly to the normal site of the pinna, and to anotia in the most extreme cases. 
A number of grading systems classifying the different degrees of microtia have been 
proposed {Rollnick, 1987 2 /id} {Meurman, 1957 102 /id} {Ogino, 1979 140 /id} {Jani, 
1998 150 /id}. The grade of microtia may provide an indication of the degree of middle 
ear maldevelopment in patients with aural atresia {Kountakis, 1995  106 /id}, but apart 
from this, the grading of microtia has limited clinical importance since the microtic 
deformity in hemifacial microsomia is not a progressive condition and the management 
of microtia is highly dependent upon the individual patient’s subjective need for 
treatment, and less dependent on the precise anatomical deformity.
The deformities required to define an individual as having hemifacial microsomia vary 
between different authors, and this renders it difficult to assign a frequency for the 
occurrence of any particular deformity in hemifacial microsomia. This is particularly
20true of microtia as some authors have used microtia as their minimal diagnostic criterion 
for the inclusion of individuals into studies of hemifacial microsomia, whilst others 
would not exclude the diagnosis of hemifacial microsomia in the absence of a deformity 
of the external ear {Ardingen, 1988 197 /id}. One of the papers often cited in respect of 
this controversy is that written by Bennun et al {Bennun, 1985 50 /id} in which the 
argument is made that microtia is a microform of hemifacial microsomia on the basis of 
similarities between the two conditions with regards to the incidence and pattern of 
facial nerve weakness and hemipalatal palsy, the presentation of asymmetry, and a male 
prevalence, together with a knowledge of the embryological origins of the ear and face. 
Bennun reviewed the data on 74 patients with isolated microtia. The series contained a 
2:1 male to female preponderance, and a similar unequal sex distribution had been noted 
in other reports of hemifacial microsomia patients {Grabb, 1965 46 /id} {Rollnick, 1983 
57 /id}. Twelve percent of Bennun’s patients had facial nerve weakness, which was 
always ipsilateral to a severe microtia. The incidence of facial palsy in hemifacial 
microsomia was also high in another report {Murray, 1984 83 /id}. Hemipalatal palsy 
was seen in both microtia and hemifacial microsomia and it has been suggested that this 
weakness is due to defective innervation of the levator veli palatini muscle by a 
proximal branch of the facial nerve. Asymmetry was common in both microtia and 
hemifacial microsomia; both conditions usually occurring in a unilateral form, and when 
bilateral involvement occurred it was always asymmetrical. The right side of the head 
was affected in 57% of cases of microtia and in 56% of hemifacial microsomia patients.
21At present the relationship of isolated microtia to hemifacial microsomia remains 
undefined, but elucidation of the genetic basis of hemifacial microsomia would allow 
resolution of this uncertainty.
Stenosis or atresia of the external auditory canal is sometimes found in association with 
anomalies of the pinna. A conductive hearing loss may be caused by atresia of the ear 
canal and also by malformation of the ossicular chain.
1.2.3  Central nervous system abnormalities
A range of central nervous system defects has been reported in association with 
hemifacial microsomia. The most common neurological defect is a facial nerve palsy 
that is seen in 10-22% {Carvalho, 1999 51 /id} and which is likely to be due to 
distortion of the bony facial nerve canal. In a series of 40 patients with hemifacial 
microsomia, temporal bone computed tomographic scanning revealed abnormalities of 
the facial nerve canal in 35 patients (88%)  {Rahbar, 2001  86 /id}. The facial nerve was 
said to be anteriorly displaced in 25 patients, and could not be identified in 10 patients.
Mental retardation is estimated to occur in 5-15% of patients with hemifacial 
microsomia {Shokeir, 1977 152 /id}.
221.2.4  Eve abnormalities
Choristomas, which are tumours composed of normal tissue not normally found at the 
site of the tumour, are the most common ocular abnormality in hemifacial microsomia. 
They contain a combination of fat, hair follicles and sebaceous cysts, and they are 
sometimes divided into dermoids and lipodermoids depending on the amount of fat they 
contain. Mansour et al {Mansour, 1985 84 /id} noted epibulbar choristomas in 32% of a 
series of 57 consecutive patients with facioauriculovertebral sequence. An earlier 
review of 127 patients compiled from a number of published series of Goldenhar’s 
syndrome found that 53% had unilateral epibulbar dermoids and 23% had bilateral 
dermoids {Baum, 1973 85 /id}. That review also found an incidence of 47% for 
lipodermoids, but there was, no doubt, a degree of bias towards ocular abnormalities in 
the cases reviewed since epibulbar dermoids are one of the defining features of 
Goldenhar’s syndrome {Goldenhar, 1952 155 /id}.
Other eye signs associated with hemifacial microsomia include eyelid colobomas, 
ocular motility disorders, anophthalmia and microphthalmia {Baum, 1973 85 /id}.
1.2.5  Skeletal abnormalities
Cervical spine and skull base abnormalities occur as cervical vertebral fusions (20%- 
35%), Klippel-Feil syndrome, platybasia and occipitalization of the atlas {Avon, 1988 
199 /id}. Vertebral anomalies such as spina bifida, hemivertebrae, butterfly vertebrae,
23vertebral fusion, vertebral hypoplasia, and scoliosis occur in 30% of patients. Talipes 
equinovarus has been reported in about 20% of patients. Radial limb deformities in the 
form of a hypoplastic or aplastic radius and/or thumb, or bifid or digitalised thumb, 
occur in about 10% {Gorlin, 1963 109 /id}.
1.2.6  Other abnormalities
Various forms of cardiac anomaly, most commonly ventricular septal defects and 
tetralogy of Fallot, have been reported in individuals with hemifacial microsomia. 
Cardiovascular abnormalities such as these and anomalies of the great vessels are 
present in between 5% and 30%  of cases {Pierpont, 1982 177 /id} {Rollnick, 1987 2 
/id} {Morrison, 1992 156/id}.
Other congenital defects have occurred occasionally on a background of hemifacial 
microsomia, but in view of the limited number of reports of each combination of defects 
it is uncertain whether these represent true associations or merely coincidental findings.
Occasional reports have been made of cranial nerve palsies other than facial nerve 
weakness, and of intracranial anomalies including occipital and frontal encephalocoeles, 
hydrocephaly, lipoma of the corpus callosum, dermoid cyst, teratoma, Amold-Chiari 
malformation, lissencephaly, arachnoid cyst, holoprosencephaly, porencephalic cyst,
24unilateral arrhinencephaly, and hypoplasia of the corpus callosum {Aleksic, 1975 87 
/id} {Aleksic, 1984 200 /id}.
Bronchopulmonary defects that have been reported in patients with hemifacial 
microsomia and these include incomplete lobulation, hypoplasia and agenesis, and 
tracheo-oesophageal fistulae (Sutphen, 1995 176/id}.
Renal involvement may be manifested as renal agenesis, duplex systems, 
hydronephrosis, and renovascular anomalies {Bowen, 1971  88/id} {Shokeir, 1977 152 
/id} {Rollnick, 1987 2 /id}. Imperforate anus with or without rectovaginal fistula has 
also been described in association with hemifacial microsomia {Bowen, 1971  88 /id}.
251.3  Nomenclature
As a result of the variable clinical presentation seen in these patients, and the lack of an 
agreed diagnostic standard, a number of different terms have been coined that probably 
identify variants of the same spectrum of anomalies; hence, oculo-auriculo-vertebral 
dysplasia, oculo-auriculo-vertebral spectrum, Goldenhar-Gorlin syndrome, first arch 
syndrome, first and second branchial arch syndrome, lateral facial dysplasia, and a 
number of other terms have all been recorded in the literature. The combination of facial 
asymmetry, microtia and co-existent eye anomalies, particularly epibulbar dermoids, 
and vertebral anomalies usually acquires the eponymous label of Goldenhar syndrome, 
though Goldenhar concentrated his report on the triad of epibulbar dermoids, auricular 
appendages and preauricular fistulae {Goldenhar, 1952 155 /id}.  The characteristic 
features assigned to each of these appellations differ between authors and this is, no 
doubt, a source of ascertainment bias between individual series. The proliferation of 
terms attests to the fact that none is obviously superior when attempting to encompass 
the large number of different phenotypes observed. The nosologic difficulties are 
compounded because of the likely heterogeneous aetiology and pathogenesis of this 
group of malformations. I have chosen to use the term hemifacial microsomia to 
encompass all of the above conditions in this thesis.
261.4  Embryology
The structures of the face and ear that are abnormal in hemifacial microsomia are 
derived from the first and second branchial arches in the embryo. During the fourth post 
conceptual week segmentation of the mesenchyme of the ventral foregut region 
produces five distinct bilateral swellings called the pharyngeal, or branchial, arches. 
Each arch has a core of mesoderm surrounded by neural crest tissue that has migrated 
ventrally from the hindbrain. The neural crest cells give rise to skeletal and connective 
tissues, whilst the muscular tissue is derived from the mesoderm. Externally the 
branchial arches are separated by the pharyngeal clefts or grooves, and there are five 
corresponding internal sulci termed the pharyngeal pouches (figure 1).
Figure  1.  Schematic drawing of the pharyngeal arches, (from {Sadler, 1985 202
/id})
Pharyngeal pouch
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27The external ear (auricle or pinna) is derived from six auricular hillocks (figure 2) that 
develop at the caudal end of the first and second branchial arches (O'Rahilly, 1996 47 
/id}. The hillocks initially appear at 5 weeks and soon fuse to form the auricle.
Figure 2.  Lateral view of the head of an embryo showing the six auricular 
hillocks (from (Sadler, 1985 202 /id})
Auricular
Hillock*
The external acoustic meatus (ear canal) develops via deepening of the first pharyngeal 
cleft through a core of epithelial cells that fills the deep part of the first pharyngeal cleft 
initially. Canalisation of this plug of epithelial cells occurs in the 26th week (Larsen, 
1993 48 /id}. The medial end of the core of epithelial cells becomes the external layer 
of the tympanic membrane.
28The first pharyngeal pouch elongates to form the tubotympanic recess, which then 
differentiates into the tympanic cavity and the eustachian tube. As the developing 
ectodermal external auditory meatus and the endodermal tubotympanic recess approach 
one another the auditory ossicles arise from the intervening mesenchyme. During the 
seventh week the three ossicles condense from the mesenchyme of the first and second 
arches, the first arch gives rise to the incus and the head of the malleus, and the second 
arch to the stapes and the long process of the malleus. The ossicles remain embedded in 
mesenchyme until the ninth month when the mesenchyme disappears and the tympanic 
cavity enlarges to include them (figure 3).
Figure 3: Schematic representation of the development of the middle ear
structures.
A: 5 week old embryo.  B:7 week old embryo.  C: Fully developed 
middle ear. EAM=extemal auditory meatus, TB=temporal bone, M=malleus, 
Mncus, SA=stapes arch, SF=stapes footplate, OW=oval window, IE=inner ear, 
TM=tympanic membrane, MEC=middle ear cavity, (from {Mallo, 2001  201 
/id})
ivesicle
mesenchyme
29The first arch also gives rise to the bony structures of the mandibular and maxillary 
regions of the face, the muscles of mastication, the anterior belly of digastric, the 
mylohyoid, tensor tympani and tensor palatini muscles. The motor innervation to the 
muscles derived from the first pharyngeal arch is from the mandibular branch of the 
trigeminal nerve. The blood supply to the first pharyngeal arch comes via the maxillary 
artery.
The second arch cartilage, Reichert’s cartilage, as well as contributing the stapes gives 
rise to the styloid process of the temporal bone, the stylohyoid ligament and the superior 
portion of the hyoid bone (figure 4). The muscles of the second branchial arch are 
stapedius, stylohyoid, the posterior belly of digastric, the auricular muscles, and the 
muscles of facial expression, and these muscles are innervated by the facial nerve. A 
small branch arises from the second and first aortic arches to form the stapedial artery in 
the 35 day old embryo, and this becomes the arterial supply of the second branchial 
arch. The peripheral branches of the stapedial artery form connections with other 
branches of the internal and external carotid arteries, and the main trunk of the stapedial 
artery involutes, disappearing towards the third month of foetal life.
30Figure 4: Schematic representation of the derivatives of the first three branchial 
arches (modified from (Sadler, 1985 202 /id})
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Thus, a disruption of the normal progress of development of the first and second 
branchial arch tissues could be expected to cause malformations of the pinna, the 
auditory meatus, the ossicles, and the bony and soft tissue elements of the maxillary and 
mandibular regions of the face, and might also be associated with a seventh cranial 
nerve defect that would present as a facial palsy. These malformations are typical of 
those found in patients with hemifacial microsomia.
311.5  Aetiology
It is likely that the aetiology of hemifacial microsomia is multifactorial, and it is 
possible that hemifacial microsomia is the result of the interplay between several 
genetic and environmental influences. Several theories about the causal mechanisms 
underlying hemifacial microsomia have been proposed and these include vascular, 
metabolic, teratogenic and genetic factors.
1.5.1  Vascular
Poswillo created a phenocopy of hemifacial microsomia in an animal model in which an 
expanding haematoma in utero damaged tissues in the region of the ear and jaw 
{Poswillo, 1973 59 /id}. Administration of triazene diluted in arachis oil to mice on day
10.5  of gestation produced 100% affected offspring with the characteristic defects of 
hemifacial microsomia. Serial studies of the developing vascular tree showed that the 
haematoma originated at the junction of the ascending pharyngeal and hyoid arteries, 
the site of the primitive stem of the stapedial artery {Poswillo, 1975 8 /id}. The timing 
of the commencement of proliferation of the stapedial artery on day 14.5 coincided with 
the appearance of haemorrhage in this region. Poswillo observed a range of phenotypes 
with variable involvement of the outer and middle ear, mandible, and facial soft tissues. 
Poswillo proposed that the obstructive and destructive effects of an extravascular blood 
clot would result in focal cell death, repair and redifferentiation, producing the observed
32malformations. Variable degrees of haematoma formation would account for the 
spectrum of extent and severity found in hemifacial microsomia. However, the factors 
which led to the onset of haemorrhage were not apparent.
Werler et al {Werler, 2004 181 /id} interviewed the mothers of 230 patients with 
hemifacial microsomia, and compared them to controls matched for age and paediatric 
practice. The multivariate odds ratios were significantly increased for exposure to 
pseudoephedrine (2.0, 95% Cl 1.2-3.4), and for exposure to any of the following 
vasoactive medications, pseudoephedrine, phenylpropanolamine, aspirin or ibuprofen 
(1.9, 95% Cl 1.2-2.9).
1.5.2  Metabolic
Maternal diabetes is well known to have teratogenic effects and has been linked to 
anomalies such as caudal dysgenesis, congenital heart defects, renal anomalies and 
neural tube defects. Craniofacial anomalies such as cleft lip and palate have been 
reported occasionally in infants bom to diabetic mothers. The malformations that are 
characteristic of hemifacial microsomia have also been reported in infants of diabetic 
mothers (Grix, 1982 78 /id} {Johnson, 1982 168 /id} {Ewart-Toland, 2000 79 /id}. Since 
the association is not a common finding a number of other factors such as an underlying 
genetic predisposition must be involved if there is a true link between the two 
conditions.
33Wang et al {Wang, 2002 189 /id} analysed data from a congenital birth defects registry 
in Spain that surveyed a total population of 1,731,791 consecutive live-born infants, and 
which included 157 cases of oculo-auriculo-vertebral sequence. The data suggested that 
the odds ratio for oculo-auriculo-vertebral sequence in infants of mothers with 
gestational diabetes mellitus was 2.28 (95% Cl, 1.03-4.82). A greater risk of hemifacial 
microsomia in relation to maternal diabetes was calculated by Werler et al {Werler, 
2004 181 /id}. They calculated a multivariate odds ratio of 6.0 (95% Cl 2.5-14.3).
The mechanism by which maternal diabetes produces malformations has not been 
defined, but hypotheses include hyperglycaemic damage to vessels, or mutagenesis via 
the production of excess reactive oxygen species {Reece, 1996 182 /id}.
1.5.3  Teratogenic
The exposure of pregnant women to certain environmental agents, termed teratogens, 
may produce malformations in their offspring. The drug thalidomide was administered 
as an anti-nausea treatment to pregnant women from 1958 to 1961. The children of 
these mothers were bom with facial anomalies that included anotia, microtia, meatal 
stenosis and atresia, ear tags, facial palsy, and eye abnormalities; other features of 
thalidomide exposure were limb defects, cleft palate, choanal atresia, cardiac defects 
and oesophageal or duodenal atresia {Gorlin, 2001  148 /id}. Poswillo reported studies
34which showed that the otomandibular defects produced by thalidomide in Macaca irus 
monkeys were closely comparable to those found in thalidomide embryopathy in man 
{Poswillo, 1975 8 /id}, and that the malformations recorded resembled the features of 
hemifacial microsomia. Examination of thalidomide-affected embryos revealed 
haematomas involving the tissues of the outer and middle ear and mandible. Thus, 
Poswillo proposed that haemorrhage and self-limiting haematoma formation were the 
common causal mechanism for the phenotypes noted in both sporadic and thalidomide 
induced hemifacial microsomia, though the factors leading to the onset of haemorrhage 
remained unclear.
Some features of the hemifacial microsomia phenotype have been associated with the 
exposure of pregnant women to other teratogens, namely primidone {Gustavson, 1985 
76 /id}, retinoic acid {Lammer, 1985 77 /id}, tamoxifen {Cullins, 1994 158 /id}, and 
cocaine {Lessick, 1991  169/id}.
Thus, vascular, metabolic and teratogenic factors have all been implicated in the 
aetiology of hemifacial microsomia, and each may interact with genetic influences in a 
particular affected individual.
351.5.4  Multiple gestations
The frequency of embryonic malformations is increased in twins compared to singleton 
gestations, and this excess is due to an increased incidence of malformations in 
monozygotic twins alone {Schinzel, 1979 89 /id}. There are three potential causes for 
the increased liability of twins to congenital malformations. The first of these is that the 
underlying cause of twinning could also cause malformations. Secondly, most 
monozygotic twins have a conjoined placenta producing vascular connections between 
the two foetuses; unequal vascular interchange between the twins could result in a 
reduced perfusion pressure in one twin and resultant disruption of inadequately perfused 
tissues. Also, following the death of one monozygotic twin in utero, clots or detritus 
from the dead twin may enter the circulation of the live twin and form an embolus, 
leading to the development of malformations in the surviving co-twin. Thirdly, the 
presence of two foetuses within the constrained limits of the uterus can produce 
structural deformations. It is unlikely that this last factor is important in the aetiology of 
hemifacial microsomia since the defects such as complete anotia, auditory meatal 
atresia, and facial palsy, which are found in hemifacial microsomia suggest an 
intrinsically abnormal developmental process rather than the effects of external 
mechanical forces.
36Lawson et al {Lawson, 2002 90 /id} found an increased prevalence of twin maternities 
amongst 145 cases of microtia and hemifacial microsomia (3.96%, 95% Cl 0.79 to 7.13) 
compared to the age standardised prevalence rates for England and Wales (1.06%). The 
report by Lawson et al included some information from the database of patients that was 
collected as part of the work on which this thesis is based.
Multiple gestation was associated with a large increased risk of hemifacial microsomia 
in the patients studied by Werler et al {Werler, 2004 180 /id}, with a multivariate odds 
ratio of 10.5 (95% Cl 4.2-26.2).
1.5.5  Bleeding in Pregnancy
Vaginal bleeding in pregnancy has been reported to be associated with adverse 
outcomes including pre term delivery, low birth weight, and increased perinatal death 
rates. Gestational vaginal bleeding has also been associated with an increased risk of 
congenital malformations in the resultant offspring. Sipila et al  {Sipila, 1992 91 /id} 
reported a prospective study of 8718 singleton pregnancies in Finland, and found that 
congenital malformations were significantly more common in women who had suffered 
from bleeding during pregnancy, odds ratio 2.9 (95 per cent Cl 1.7-4.7). Strobino and 
Pantel-Silverman {Strobino, 1989 92 /id} prospectively studied 3,531 women in New 
York. They calculated an odds ratio of 1.7 (95 per cent Cl 1.0-2.9) for the association of
37first trimester bleeding and the presence of a congenital malformation in a live or still 
birth that was not due to a  chromosomal anomaly; however, their confidence interval 
was wide and included parity. Batzofin et al {Batzofin, 1984 21 /id} found similar rates 
of congenital malformations in the offspring of 7229 mothers when a retrospective 
analysis of gestational bleeders versus non-bleeders was performed.
The only analysis reported in the literature of bleeding rates during pregnancy amongst 
mothers of hemifacial microsomia patients is that included in the study by Werler et al 
{Werler, 2004 181 /id}. First trimester bleeding was not associated with an increased 
risk of hemifacial microsomia. Second trimester vaginal bleeding was associated with 
an increased odds ratio of 13.2 (95% Cl 2.3-75.8), but the numbers involved were small, 
8 cases and 2 controls. Such an analysis involving a larger group of patients would be of 
interest in view of the vascular theory of the aetiology of hemifacial microsomia 
proposed by Poswillo.
381.5.6  Other aetiological theories
Lam {Lam, 2000 183 /id} observed that the pattern of abnormalities seen in hemifacial 
microsomia is similar to that seen in occult spinal dysraphism, a condition that presents 
as skin pits, tags, lipomas, and bony abnormalities in the lumbar region. It has been 
suggested that occult spinal dysraphism arises because of a failure of ectodermal 
separation, possibly because of a defect of cell adhesion molecules such as N-CAM and 
L-CAM, and Lam theorised that the same mechanism could be true for hemifacial 
microsomia. The ectodermal otic pit invaginates into mesenchyme, and normally its 
edges fuse to create the otic vesicle. The otic vesicle then migrates away from the 
surface ectoderm to eventually form the membranous labyrinth. Lam proposed that 
there was faulty separation of the otic vesicle from the surface ectoderm in hemifacial 
microsomia, and that the surrounding tissues are tethered and growth restricted. 
However, no experimental evidence exists to either confirm or refute this suggestion.
391.6  Genetic aspects
1.6.1  Mendelian and non-Mendelian inheritance
The expression of some genetic characters is dependent on the genotype at a single 
locus. These characters are termed Mendelian, named after the work of Gregor Mendel 
in the 1860’s. The inheritance of a Mendelian character is said to be dominant if the 
character is expressed in a heterozygous individual, and recessive if it is only present in 
homozygotes. Mendelian characters may be determined by loci on the autosomal 
chromosomes or on the sex chromosomes, X and Y; X-linked characters may be 
dominant or recessive. It is often possible to distinguish which mode of inheritance is 
operating for a Mendelian character in studies of animals or plants. The advantages of 
these models over studies in humans include greater family sizes, shorter periods 
between generations, and the ability to perform test crosses in experimental animals or 
plants. However, when studying human families it is often difficult to identify the mode 
of inheritance of a character with any certainty. This uncertainty is further exacerbated 
by difficulties of data collection from individuals who made be widely separated in both 
time and place, and the possibilities of ascertainment bias, reduced penetrance, variable 
expression, imprinting, and the occurrence of new mutations.
Many characters in humans are not inherited in a simple Mendelian pattern. Obvious 
examples of this type of character include quantitative traits such as height, strength and 
intelligence. These characters, instead of being determined by the genotype at a single 
locus, may be governed either by a small number of loci, oligogenic, or a large number
40of loci, polygenic, and they may also t»e influenced by environmental factors. The terms 
multifactorial or complex are used to describe these non-Mendelian characters. 
Multifactorial determination may also be involved in the inheritance of dichotomous or 
qualitative characters. The inheritance of a dichotomous character that is determined by 
multiple genes has been explained by the use of a polygenic threshold model; if the 
susceptibility to the character inferred by an individual’s combination of genes is above 
a certain threshold then that character will be apparent, otherwise the character will be 
absent. Again, environmental influences may also play a role.
1.6.2  Mode of inheritance of hemifacial microsomia
Most cases of hemifacial microsomia are sporadic, with no evidence of Mendelian-like 
inheritance. However, some familial instances have been reported and examination of 
the pedigrees of these affected families most commonly suggests an autosomal 
dominant trait with variable expression {Hermann, 1969 108 /id} {Summit, 1969 107 
/id}{Setzer, 1981 203 /id} {Regenbogen, 1982 52/id} {Godel, 1982 159/id} {Taysi,
1983  167 /id} {Robinow, 1986 166 /id} {Singer, 1994 53 /id},  {Stoll, 1998 54 /id}, 
{Kelberman, 2001 55 /id}. Overall, autosomal dominant inheritance is thought to occur 
in 1-2% of cases.
Rollnick and Kaye {Rollnick, 1983 57 /id} established pedigrees for 97 patients with 
microtia or hemifacial microsomia and found that 45% had relatives with ear anomalies,
41mandibular hypoplasia, and/or early onset hearing loss. This seems to be a high 
proportion of cases with a positive family history, but examination of the data studied 
shows that the relatives classed as affected often had very mild ear malformations (see 
section 4.8). These findings may be interpreted as reflecting a multifactorial 
determination or autosomal dominant inheritance with variable penetrance. Kaye et al 
{Kaye, 1992 82 /id} performed segregation analysis on seventy four families with 
hemifacial microsomia and concluded that an autosomal dominant mode of inheritance 
was most likely; recessive and polygenic models of inheritance were not 
distinguishable, and the hypothesis of there being no genetic transmission was rejected.
Other pedigrees are more suggestive of an autosomal recessive mode of inheritance 
{Saraux,  1965 63 /id} {Krause, 1970 64 /id}. Brady et al reported the combination of 
hemifacial microsomia, external auditory canal atresia, deafness and Mullerian 
anomalies associated with acro-osteolysis, in a pedigree suggestive of autosomal 
recessive inheritance with variable penetrance {Brady, 2002 81 /id}.
Concordance and discordance have both been observed in monozygotic twins. 
Hemifacial microsomia has been reported in one of a pair of monozygotic twins in 14 
cases {Burck, 1983 56 /id} {Stoll, 1984 60 /id} {Boles, 1987 161 /id}. Keusch et al 
{Keusch,  1991 204 /id} retrospectively identified 13 twin pairs wherein one individual 
exhibited hemifacial microsomia or hemifacial hypoplasia, but the zygosity was not 
identifiable from the data presented. There are three reports of hemifacial microsomia in 
one of a set of triplets following in vitro fertilisation {Yovich, 1985  13 /id} {Ferraris,
421999 205 /id} {Roesch, 2001 206 /id}. Concordance for the phenotype in monozygotic 
twins has been reported four times {Terhaar,  1972 153 /id} {Schweckendiek, 1976 65 
/id} {Ryan, 1988 11 /id} {Keusch, 1991 204 /id}. Discordance of the signs of hemifacial 
microsomia in dizygotic twins has been found in 5 instances {Burck, 1983 56 
/id} {Boles, 1987 161 /id}, whilst concordance for hemifacial microsomia is yet to be 
reported in dizygotic twins. These findings may be interpreted as supportive of a genetic 
cause for hemifacial microsomia, but could also indicate that environmental factors are 
more important (see section 4.10). Once the genetic loci involved in the development of 
hemifacial microsomia have been identified, and the disease genes are cloned, it should 
be possible to identify the inheritance pattem(s) for the deformity with some certainty, 
and it is likely that this will reveal a heterogeneous group of conditions with similar 
phenotypes.
431.6.3  Investigation of human disease genes
All the information required for cellular organisms to develop, function and reproduce 
is contained in cells in the form of deoxyribonucleic acid (DNA). The sequence of 
nitrogenous bases along the DNA molecule holds the information as a genetic code. The 
complete DNA sequence of an organism is termed its genome. Segments of the code, 
genes, can be deciphered by the intracellular apparatus to guide the synthesis of 
ribonucleic acid (RNA) which in turn specifies the production of polypeptides. 
Mutations of certain genes cause identifiable disease states, and much research effort is 
directed towards identifying these disease genes.
1.6.4  Chromosomal rearrangements
The starting point for identification of a disease gene may be a consideration of its 
chromosomal location. A candidate region for the location of a disease gene may be 
suggested by the occurrence of the disease in association with a chromosomal 
rearrangement that can be detected by cytogenetic analysis. A number of chromosomal 
rearrangements have been described in association with the hemifacial microsomia 
phenotype including pericentric inversion of chromosome 1   {Stahl-Mauge, 1982 160 
/id}, del(5p) {Ladekarl, 1968 94 /id} {Neu, 1982 66 /id} {Choong, 2003 207 /id}, 
unbalanced translocation (5;8)(pl5.31;p23.1){Josifova, 2004 172 /id}, del(6q) 
{Greenberg,  1987 141 /id}, trisomy 7 mosaic  {Hodes, 1981 95 /id}, dup(7q) {Hoo,
441982 96 /id}, trisomy 9 mosaic {Wilson, 1983 42 /id} {de Ravel, 2001  162 /id}, 
pericentric inversion 9 {Stanojevic, 2000 170 /id}, tetrasomy 9p {Tonk,  1997  164 /id}, 
trisomy 18  {Bersu, 1977 97 /id} {Greenberg, 1987 141 /id} {Verloes, 1991  165 /id}, 
trisomy 18 mosaicism {Clarren, 1983 98 /id}, recombinant chromosome 18 {Sujansky, 
1981  110/id}, ring 21 chromosome {Greenberg, 1987 141 /id}, del(22q) {Greenberg, 
1987 141 /id} {Herman, 1988 68 /id}, dup(22p) {Hathout, 1998 69 /id}, trisomy 22 
{Kobrynski, 1993 70 /id} {Pridjian, 1995 171 /id} {de Ravel, 2001  162 /id}, 49,XXXXX 
{Schroeter, 1980 71 /id}, 49,XXXXY {Kushnick, 1975 72 /id}, and 47,XXY 
{Poonawalla, 1980 73 /id}. These reports may represent coincidental occurrences or 
actual relationships; a true association is more likely where multiple instances of the 
same link have been identified i.e. del(5p) and trisomy 18.
Potential loci for the disease gene may also be identified through mapping techniques, 
and these are discussed below. During the search for the gene that causes a particular 
disease, those genes that are most likely to be involved are selected for investigation and 
are termed candidate genes. Within a region of interest candidate genes can be selected 
according to their expression pattern or on the basis of their known functions.
451.6.5  Genetic mapping
The first attempts at identifying human disease genes involved strategies that did not 
require the localisation of a candidate chromosomal region as the first step. Genes were 
identified via knowledge of the protein product, which could be used to develop a gene- 
specific oligonucleotide probe, or through knowledge of a gene’s DNA sequence or 
normal function. These position-independent strategies were adopted because sufficient 
mapping information was not available until the 1980s. Nowadays, the process of 
identifying a novel gene such as one involved in a genetic form of hemifacial 
microsomia usually begins with consideration of the chromosomal location of that gene.
Each copy of the human genome is organised into 23 chromosomes and most human 
cells are diploid, containing two copies of the human genome, one copy having been 
inherited from each parent. Thus, somatic cells contain two variants, alleles, of each 
gene. Diploid germ cells undergo a specialised form of cell division called meiosis to 
produce gamete cells that are haploid, containing only one copy of the human genome. 
During meiosis each pair of maternal and paternal homologous chromosomes become 
closely associated and may exchange segments; such crossover of DNA is termed 
recombination. These recombination events create the possibility of separation of any 
combination of genes on a single parental chromosome, and as a result any offspring 
will inherit a mixture of their parents’ genes for each chromosome instead of an 
identical copy of one chromosome from one of their parents.
46Mapping the location of a Mendelian disease gene is accomplished by the use of genetic 
markers. A genetic marker can be any Mendelian character which has a known 
chromosomal location. The aim in mapping is to discover how often the marker and the 
disease are separated by meiotic recombination; if the loci for the marker and the 
disease lie very close together on the same chromosome then recombination will rarely 
separate the two characters.
An individual possesses two alleles of the gene for a marker character and will pass one 
allele onto their child; in order to be able to determine which particular allele the child 
has inherited it is necessary for each parent to be differently heterozygous for that 
marker. Thus, a marker character must be polymorphic in order to be useful, and a 
marker with a greater number of alleles has a greater likelihood of being helpful in a 
mapping study. When it is possible to identify which variant of the marker is located on 
the same chromosome as the disease allele in an individual, the phase of linkage of the 
two characters is said to be known. If it is possible to determine whether or not a 
recombination has occurred between the marker and the disease locus in the course of a 
meiotic division, then that meiosis is said to be informative. Human genetic mapping 
requires the use of polymorphic genetic markers that are distributed throughout the 
genome. Currently, microsatellite markers are the standard tool for linkage analysis; 
these markers are repeats of a simple DNA sequence such as cytosine and adenine 
(CA)n. Initial investigations into the usefulness of microsatellite markers concentrated 
on dinucleotide sequences because of their particular abundance; however, since 
microsatellite alleles may differ by only a single repeat the use of tri- and
47tetranucleotide repeats has become increasingly popular since they are less prone to the 
production of multiple bands after polymerase chain reaction amplification and 
electrophoresis. Variations in the number of repeated blocks produce length 
polymorphisms. In the human genome there are 50 000 -100 000 interspersed (CA)n 
blocks {Weber, 1989 111 /id}. The polymerase chain reaction is used to amplify target 
DNA sequences containing the microsatellite markers, allowing a relatively small 
amount of an individual’s DNA to be typed for markers that are chosen to be evenly 
spaced across the genome.
In recent years nucleotide variations at a single nucleotide site in the genome have also 
been used for genotyping. These single nucleotide polymorphisms are abundant 
throughout the genome, and whilst their mostly biallelic nature means that they are less 
informative than microsatellite markers it also renders them amenable to automated 
assessment.
1.6.6  Recombination fractions
For any two loci the proportion of meiotic divisions in which crossover of DNA 
between the loci occurs is known as the recombination fraction (0) between the loci.
The recombination fraction is a measure of the genetic distance between two loci 
located on the same chromosome; two loci that show recombination in 1  in 100 meioses 
(recombination fraction = 0.01) are defined as being lcentimorgan (cM) apart. Two
48genes located on separate chromosomes (or far apart on the same chromosome) have a 
50% probability of segregating together during meiosis and the recombination fraction 
between these loci is 0.5.
Recombination fractions do not exceed 0.5 however great the physical distance between 
the loci. The recombination fraction across a genetic map is not simply the sum of the 
recombination fractions between loci identified within that region. A mathematical 
conversion, the mapping function, is used to calculate the relationship between 
recombination fraction and genetic distance.
The physical distance, i.e. the number of nucleotides, represented by a unit of genetic 
distance is not constant across the genome, though the approximation of lcM=lMb 
averaged across the genome is often useful.
1.6.7  Linkage
If a disease gene and a marker are located on the same chromosome and their DNA 
sequences tend to be inherited together because of their physical proximity there is said 
to be linkage between the two loci.
Once a family is identified in which a Mendelian disease is segregating, and the 
individuals have been typed for an informative genetic marker, it is often impossible to
49categorise every meiosis definitively as either recombinant or non-recombinant. 
However, if it is assumed that the loci are either linked (recombination fraction = 0) or 
not linked (recombination fraction = 0.5) a calculation can be made of the likelihood of 
the pedigree occurring. The ratio of the likelihoods at recombination fraction = 0 and 
recombination fraction = 0.5 gives the odds of linkage, and the logarithm of this is the 
lod score. A positive lod score gives evidence in favour of linkage, a negative lod score 
gives evidence against linkage. Lod scores are usually calculated for a range of 
recombination fractions between 0 and 0.5, and the lod score will be highest at the most 
likely recombination fraction. A lod score of 3 is regarded as giving significant evidence 
of linkage, a lod score of -2 allows linkage to be rejected. These thresholds for 
significance are equivalent to 95% confidence limits. Computer programs are required 
for the calculation of lod scores for all but the very simplest of pedigrees because of the 
large number of calculations required.
Using data from multiple loci simultaneously may help to overcome problems due to 
some markers being limitedly informative. Typically a lod score is calculated for the 
unmapped disease locus at each marker position along a region of interest and a plot of 
marker location versus lod score can be generated; the highest peak indicates the most 
likely location of the disease locus.
50Lod score calculations provide a powerful tool for performing linkage analyses, but they 
are not without their problems. Data errors and computational difficulties amongst other 
factors can lead to spurious results, and these difficulties are discussed further in section 
6.2.
1.6.8  Genetic mapping in hemifacial microsomia in humans
Kelberman et al {Kelberman, 2001 55 /id} performed a genome wide search in a single 
family that displayed apparent autosomal dominant inheritance, and produced data that 
were highly suggestive of linkage to a region on chromosome 14q32.
Graham et al reported a large family that also exhibited likely autosomal dominant 
transmission of a Goldenhar-like syndrome (Graham, 1995 80 /id}. The affected 
members of the family had variable features including microtia, ear tags and ear pits, 
hearing loss, ocular and periocular dermoids, micrognathia, and seizures, but some 
individuals also had branchial cysts. The details of the study of this family have only 
been published in limited form as an abstract, and no mention is made of facial 
asymmetry. Linkage to 8ql 1  -8ql3 was identified in this family (maximum lod score 3.3 
at 0 = 0), and this is the same region that harbours the gene that underlies branchio-oto- 
renal syndrome. The branchio-oto-renal syndrome is characterised by branchial arch
51anomalies, e.g. pre-auricular pits, branchial fistulae or cysts, hearing loss, and renal 
dysplasia, and abnormalities of the pinna are also common {Jones, 1997 149 /id}. The 
syndrome is an autosomal dominant condition with variable expression, and the gene 
had been localised to chromosome 8ql3 as noted above {Wang, 1994 195 /id} at the 
time of Graham et al’s report. Since then the disease gene, EYA1, has been identified 
{Abdelhak, 1997 154 /id}. Hemifacial microsomia and branchio-oto-renal syndrome 
obviously share some clinical features, and a definitive clinical differentiation between 
the two conditions is not always possible in some individuals.
Chromosome 11 ql2-l3 has also been proposed as a potential locus following analysis 
of an affected Australian family. The clinical details of this family have been published 
{Singer,  1994 53 /id} and they include nine affected individuals with varying features 
including microtia, pre-auricular skin tags, mandibular and soft tissue hypoplasia, 
macrostomia, and epibulbar dermoids. A genome wide scan produced a maximum 
multipoint lod score of 2.1 for the stated region on chromosome 11  {Kelberman, 2001 
55 /id}, with the limited size of the family precluding the possibility of achieving a 
greater lod score.
521.6.9  Investigation of the genetic basis of complex diseases
As noted above, the inheritance of a genetically determined characteristic or disease 
may not follow a simple Mendelian pattern, but instead may be dependent upon the 
interaction of a number of separate genes and the environment. Segregation analysis 
may be used to estimate the most likely genetic contribution to a particular complex 
disease. Segregation analysis requires the collection of data from a large number of 
families affected by the non-Mendelian disease under investigation. The data is then 
analysed by a computer generated comparison of different modes of inheritance, gene 
frequencies, penetrances etc, to determine the mix of parameters which gives the highest 
overall likelihood for that data. Once the most likely genetic model has been defined, 
data from affected families can be subjected to parametric linkage analysis in a search 
for susceptibility loci. Segregation analysis has been performed for hemifacial 
microsomia as mentioned in section 1.6.2 and favoured autosomal dominant 
inheritance.
When mapping a complex disease in which there is no single major disease locus, 
traditional LOD score analysis of most affected families is unlikely to yield a significant 
result. However, sometimes families may be found that display a pattern consistent with 
near-Mendelian inheritance of the disease and standard parametric linkage analysis may 
be performed on data from these families. If disease gene loci are identified as a result 
of these analyses, they may relate only to a subset of the affected population that has a 
Mendelian condition which is phenotypically indistinguishable from the non-Mendelian
53condition, or, because of chance occurrence of other determinants of the disease in the 
families studied, the identified loci may relate to susceptibility genes for the non- 
Mendelian condition. An example of this process is the identification of interferon 
regulatory factor 6 (IRF6) as a disease gene in isolated cleft lip and palate. IRF6 was 
first discovered to be the cause of an autosomal dominant form of cleft lip and palate, 
Van de Woude syndrome, in which pits of the lower lip are the only additional 
remarkable feature {Kondo, 2002 194 /id}. A common single-nucleotide polymorphic 
variant was identified in this gene, and the same research group then performed 
transmission disequilibrium testing in 8003 individuals, which included 1968 families 
with a history of isolated cleft lip and palate. Strong evidence of over transmission of 
one allele of IRF6 was found in families of probands with cleft lip with or without cleft 
palate, and the authors concluded that IRF6 was responsible for 12 per cent of the 
genetic contribution to cleft lip and palate {Zucchero, 2004 193 /id}.
When a precise genetic model cannot be applied to an affected population or to a subset 
of the population, non-parametric linkage analyses e.g. affected sib pair analysis can be 
used to identify linkage to a chromosomal region. These analyses are based upon the 
non-random inheritance of a parental haplotype that is associated with the disease. 
Siblings who are affected by a genetic disease are likely to share a segment of the 
chromosome that carries the disease locus, and regions are therefore sought that are 
shared more frequently by the affected siblings than would be expected by chance.
54Non-parametric genetic analysis can be applied to populations as well as to pedigrees, 
and these analyses are termed association studies. Association studies are based upon 
the assumption that alleles close to a disease locus tend to be co-inherited by affected 
individuals who have descended from a common ancestor. Thus, a search is made for 
linkage disequilibrium between known marker loci and the disease of interest in order to 
localise a disease susceptibility gene. The characterisation of an association is usually 
dependent on an appropriately chosen control group that allows calculation of the 
normal frequencies of the alleles and phenotypes under consideration. Association 
studies can also be conducted without a separate control population provided that the 
parents of the affected probands are available for typing. The transmission 
disequilibrium test is an example of this type of study. In this test probands and their 
parents are typed for the marker being studied. Parents who are heterozygous for the 
particular marker are selected, and the transmission disequilibrium test statistic 
examines the frequency with which the parents transmit the test allele to the probands 
compared to transmission of the other allele present in the parents. The practical 
application of this analysis has been mentioned above in the discussion of the genetic 
contribution of IRF6 to isolated cleft lip or palate.
An example of a classically oligogenic disease is Hirschsprung disease (HSCR), in 
which there is congenital absence of ganglia in the large intestine. This disease provides 
a good model of the genetic analysis of a complex disorder. Segregation analyses 
initially suggested a dominant susceptibility to isolated HSCR in the long segment (L- 
HSCR) form of the disease, but other forms of the disease appeared to be either
55multifactorial or due to a recessive gene with very low penetrance {Badner, Sieber, et 
al.  1990 91 /id}. Following the finding of an interstitial deletion of chromosome 10 in 
two patients, the disease susceptibility locus was mapped to lOql 1.2 by pairwise and 
multipoint linkage analysis with microsatellite markers in 15 HSCR families {Lyonnet, 
Bolino, et al.  1993 92 /id}. Within this region the RET proto-oncogene was identified as 
a good candidate gene because it was known to be disease causing in multiple endocrine 
neoplasia type 2, which occurs concurrently with HSCR in some families. Mutations in 
RET were identified in HSCR patients, and subsequently mutations of the proto­
oncogene RET have been identified in 50% of familial and 15-20% of sporadic cases of 
HSCR. Glial cell line derived neurotrophic factor (GDNF) was shown to be the RET 
ligand by phenotypic similarities between  Ret T and GdnfT knockout mice, and 
GDNF mutations have been found in a small number of HSCR patients, often in 
association with RET mutations or other contributory factors such as trisomy 21. 
Similarly a mutation of another RET ligand, neurturin {NTN) has been identified in one 
family in conjunction with a RET mutation. A separate susceptibility locus was mapped 
to 13q22 using genome-wide association studies {Carrasquillo, 2002 186 
/id} {Puffenberger, 1994 187 /id}, and the positional candidate gene endothelin B 
receptor (EDNRB), that showed homology to a murine model of aganglionosis -  the 
piebald-lethal gene, has since been implicated in HSCR. A mouse model for HSCR, 
dominant megacolon (Dom), associated with Waardenburg syndrome allowed 
identification of the human homologue SOX10 as another HSCR disease gene 
(Southard-Smith, 1998 188 /id}, though this is unlikely to be a major gene in isolated
56HSCR. Presently eight genes have been shown to be involved in isolated Hirschprung’s 
disease {Amiel & Lyonnet2001 93 /id}.
As mentioned above, an important recent development in genetic mapping techniques 
has been the use of single nucleotide polymorphisms (SNPs) as genetic markers. These 
markers have only two alleles, but are more abundant than other commonly used genetic 
markers with an estimated average density in the human genome of 1  per 1000 base 
pairs (Wang, 1998 185 /id}. Genotyping using SNPs is amenable to automation because 
their bi-allelic nature allows simple plus/minus assaying, and it is possible to place 
thousands of oligonucleotide primers for different SNPs on a single solid state array. 
These DNA microarrays are called DNA or SNP chips, and whole genome analysis can 
be performed in a single hybridisation of the test DNA to such a SNP chip.
Hemifacial microsomia is most likely to be a complex disease; indeed, in view of the 
wide range of phenotypes that have thus far been diagnosed as hemifacial microsomia it 
is quite possible that a number of aetiologically different conditions are currently 
included in the discussions of this condition and its synonyms. The identification of 
families in which the condition is inherited in a Mendelian fashion suggests that a 
genetic influence is important in at least a proportion of cases, and added weight is 
given to this by the empirical recurrence risk of 1-2%. Evidence that more than one 
genetic locus is involved consists of the occurrence of features of the disease in 
association with a number of different chromosomal rearrangements, and from previous 
studies of dominantly affected pedigrees that have suggested linkage to three different
57loci. However, it is also likely that environmental factors and the effects of non-disease 
genes have a major role in the pathogenesis of hemifacial microsomia as evinced by the 
great preponderance of sporadic over inherited cases, the modest concordance rate in 
monozygotic twins, and the increased incidence of affected children bom to mothers 
with diabetes, or who have been exposed to various teratogens. The goal of this project 
was to use some of the methods of investigation described above to clarify our 
understanding of the genetic basis associated with hemifacial microsomia.
581.6.10  Animal models
As a result of close evolutionary relationships many different species have genes that 
possess significantly related sequences and functions, and these are termed homologous 
genes. Another approach for selecting candidate genes in the study of one species is to 
identify those genes in another species that are known to produce a similar phenotype, 
and then to study the structural and functional homologues of those genes. This method 
of investigation is commonly applied to the investigation of human disease genes via 
knowledge of the genetics of other animals which are more amenable to genetic studies. 
The mouse has been extensively genetically explored, and orthologous gene mutations 
are likely to produce similar phenotypes in the mouse and human. An example of the 
use of human-mouse phenotypic homology to identify a human disease gene is 
Waardenburg’s syndrome type 1  (WS1). The Splotch (Sp) mouse mutant has 
pigmentary abnormalities, as has Waardenburg’s syndrome in humans. Linkage analysis 
suggested localisation of the gene for WS1 to the distal part of human 2q, and the Sp 
gene mapped to mouse chromosome  1 that showed conservation of synteny with distal 
human 2q. The Pax-3 gene was identified as a positional candidate gene mapping to the 
region of the Sp locus. The sequence of Pax-3 was almost identical to an unmapped 
human genomic clone HuP2. These genes were shown to be orthologs and HuP2 was 
re-named PAX-3.
Knockout and mutant animal models have been produced whose phenotypes include 
some of the craniofacial malformations characteristic of hemifacial microsomia. Otani
59et al have reported a transgenic mouse line carrying an autosomal dominant insertional 
mutation that results in unilateral microtia and/or abnormal biting {Otani, Tanaka, et al. 
1991  6 /id}. Histological examination of transgenic embryos displaying a second 
branchial arch malformation revealed haemorrhage in this region on the 9th day of 
gestation, which supports Poswillo’s proposal of haemorrhage being the causal 
mechanism for hemifacial microsomia. The same research group {Naora, Kimura, et al. 
1994 74 /id} mapped the site of integration of the transgene to chromosome 10 of the 
mouse and designated the mutational locus as “hemifacial microsomia-associated locus” 
or Hfm. The phenotype of this mouse model was extended by Cousley et al to include 
external auditory meatus hypoplasia, ossicular defects, tubotympanic hypoplasia, and 
temporomandibular joint underdevelopment {Cousley, Naora, et al. 2002 75 /id}. Hfm 
appears to be a strong animal model for hemifacial microsomia, but a disease gene 
within this region has not been identified as yet.
Juriloff et al reported that some mice that were heterozygous for the mutant gene first 
arch {Far) had hemifacial deficiencies as juveniles. Homozygotes for the Far mutation 
in another strain of mouse had bilaterally deficient maxillae, cleft palates, deficient 
lower eye lids and facial skin tags, but most heterozygotes with the same genetic 
background were normal {Juriloff, 1987 100 /id}. The Far gene has been mapped to 
chromosome 2 of the mouse {Juriloff, 1994 19 /id} .The general region in the mouse 
genome to which Far maps has homology with human chromosome 2q and 22 {Lyon, 
1994 174 /id}, but the human homologue for the Far gene remains unidentified at 
present.
60There are a number of mouse genes with known human homologues that have been 
shown to be involved in craniofacial development, and for which mouse mutants have 
been produced that display some of the characteristics of hemifacial microsomia. These 
genes are, therefore, potential candidate genes for hemifacial microsomia in man.
The genes that are involved in the regulation of hindbrain segmentation are important in 
the development of the ear and face. The mesenchymal tissue of each branchial arch 
consists of a core of cells derived from paraxial mesoderm surrounded by neural crest 
cells. The hindbrain is the source of the neural crest cells that populate the branchial 
arches {Fekete 1999 1  /id} and thus, abnormal hindbrain development can result in 
branchial arch anomalies reminiscent of hemifacial microsomia. The HOX genes are 
involved in the control of hindbrain segmentation and specification, and aplasia or 
hypoplasia of second arch derivatives, an absent or rudimentary auricle, and ossicular 
abnormalities were amongst the defects produced in Hoxal/Hoxbl double mutant mice, 
but not in Hoxal null mutants and Hoxbl null mutants (Gavalas, Studer, et al. 1998 3 
/id}.
More candidate genes are to be found amongst the homeobox genes. These genes all 
contain a common DNA motif of about 180kb, and they have been shown to play 
important roles in early embryogenesis. Mice in which the homeobox gene, goosecoid 
(Gsc), has been knocked out display numerous craniofacial and rib cage abnormalities, 
including shortening of the mandible, underdevelopment of the muscular derivatives of 
the first pharyngeal arch, ossicular malformations, aplasia of the external auditory canal,
61and a reduction in the size of the pinna {Rivera-Perez, 1995 101 /id} {Yamada, 1995 
112 /id}. The GSC gene is located in the region 14q32, to which linkage has been 
suggested in a single, autosomal dominantly affected family with hemifacial 
microsomia; however, no mutations of the GSC gene were detected in the dominantly 
affected family or in 120 sporadic cases of hemifacial microsomia {Kelberman, 2001 55 
/id}.
The Dlx homeobox gene family is also expressed within the embryonic craniofacial 
ectoderm. Qiu et al generated mice with mutations in Dlx-1, Dlx-2, and both Dlx-1 and - 
2; all three mutants showed absence of the stapedial artery {Qiu, 1997 116 /id}. The 
three mutants also showed abnormalities of the derivatives of the maxillary division of 
the first arch, but the mandibular structures were normal.
The fibroblast growth factor 8 gene, FgfS, has also been implicated as an epithelial 
signal that regulates gene expression during development of first branchial arch 
derivatives, and both Dlx-1 and Dlx-2 are targets for FgfS {Shigetani, 2000 190 
/id} {Thomas, 2000 133 /id}. Failure of development of the cartilaginous and skeletal 
structures derived from the first branchial arch was reported by Trumpp et al {Trumpp, 
1999 119 /id} in mice in which FgfS had been inactivated by cre-recombination. A 
proportion of mice heterozygous for this disruption was affected on only one side of the 
head and displayed a less severe phenotype.
62Murine models have also suggested a possible role for abnormalities in endothelin 
regulation in the development of hemifacial microsomia. Endothelin-1  (Edn-1) is a 
signalling peptide expressed in the epithelial layer of the branchial arches. Edn-1 7" 
homozygous mice die at birth and have severe craniofacial malformations including 
poorly formed mandibles, hypoplastic auricles and absent auditory ossicles {Kurihara, 
1994 113 /id}. Edn-1 localises to human chromosome 6p24.
Deficiency of one type of endothelin receptor, Ednra, in mice mimics human 
velocardiofacial syndrome. The typical features of velocardiofacial syndrome include 
typical facies of a long face with vertical maxillary excess, malar flatness, prominent 
nose, and mandibular retrusion, narrow palpebral fissures, small auricles, cardiac 
anomalies especially ventricular septal defects, cleft palate and learning difficulties. 
Pharyngeal arch expression of Gsc is absent in Ednra receptor deficient mice suggesting 
that Gsc is a downstream signal triggered by activation of the Ednra receptor 
{Clouthier, 1998 115/id}.
Edn-1 signalling is also relevant to another potential candidate gene, Dhand. Dhand is a 
transcription factor that is expressed in the mesenchyme underlying the branchial arch 
epithelium. Dhand homozygous null mice have hypoplastic branchial arches, though 
this appears to affect the third and fourth branchial arches more than the first and second 
arches. It has been found that Dhand is down regulated in the branchial arches of Edn-1 
null embryos {Thomas, 1998 114/id}.
63The retinoic acid receptor (Rar) family also provides candidates for hemifacial 
microsomia suggested by murine phenotypes. The family is comprised of three types of 
receptor, Rar a, /?and y and their isoforms. Neural crest cell derived craniofacial 
skeletal elements were altered in double mutants of ay {Lohnes, 1994 117 /id}. Many 
of the first, second and third pharyngeal arch-derived skeletal elements were 
malformed, though the mandible, temporomandibular joint and malleus appeared 
normal. A number of Rar double mutants also exhibited ocular abnormalities such as 
microphthalmia, retinal colobomas and corneal and conjunctival abnormalities.
Transcription factor Ap-2, also known as Ap-2a, is a retinoic-acid responsive gene. 
Homozygous disruption of the Ap-2 gene results in complete failure of closure of the 
cranial neural tube; major alterations in the craniofacial skeleton, failure of closure of 
the ventral body wall, and forelimb anomalies are also seen. Chimeric mice composed 
of both wild-type and Ap-2 null cells often had craniofacial anomalies independent of 
any neural tube closure defect {Nottoli, 1998 118 /id}. Malformations included cleft lip 
with or without cleft palate, mandibular and maxillary hypoplasia and dysmorphology. 
Ahituv et al {Ahituv, 2004 213 /id} used ENU-induced mutagenesis to produce a 
dominant mutation of Ap-2 a named Doarad (Dor). Dor homozygous mice died 
perinatally with abnormal facial structures and ocular lens and retinal defects. Dor 
heterozygotes had ossicular malformations without any other observable phenotype.
64Thus, there are a number of mouse gene mutations that produce phenotypes with 
deficiencies of first and second branchial arch derivatives similar to those described in 
hemifacial microsomia, and the human homologues of these genes are obvious 
candidates for the hemifacial microsomia disease gene in humans. The location of these 
genes should be borne in mind when examining the results of a linkage study for 
hemifacial microsomia.
65Table 1.  Summary of murine and human candidate genes for hemifacial microsomia
Candidate gene / locus Murine chromosome
Far 2
Hfm 10, B1-3
Candidate gene Human chromosomal region
DLX-2 2q31
DLX-1 2q31
RAR-P 3p24
EDNRA 4q32.2
DHAND 4q34
AP-2a 6p24
EDN-1 6p24
HOXA1 7pl5.2
FGF8 10q24
RAR-yl 12ql 3
GSC 14q32
RAR-a 17q21
HOXB1 17q21.3
661.7 Aims of Project
In order to investigate the genetic basis of hemifacial microsomia we set out to locate 
and identify the disease gene in a family ascertained by Dr R.J.Gorlin in which the 
features of the condition appeared to segregate in an autosomal dominant fashion. 
Linkage to disease gene loci suggested by other studies, i.e.  14q32,  8ql 1-13 and 1  lql2- 
13, was excluded in this family (M.Bitner-Glindzicz and J.Tyson personal 
communication). Therefore, we undertook a whole genome scan in order to identify the 
most likely locus for the disease gene, which would then allow a focused approach to 
the selection of candidate genes for further investigation.
We also decided to gather demographic, phenotypic and family information together 
with DNA samples from other patients with either hemifacial microsomia or isolated 
microtia, most of who would present as sporadic instances of these conditions, though 
we expected to identify some further familial cases. At Great Ormond Street Hospital a 
specialised multidisciplinary clinic has been established in order to optimise the 
management of patients with microtia. The clinic is attended by ENT surgeons, plastic 
surgeons, clinical geneticists, audiologists and prothetists, and receives referrals from 
across the United Kingdom. Since October 1998 a clinical research fellow has also 
attended the clinic with the prime aim of collecting data on the population of patients 
seen in the clinic.
67The data from these patients would add valuable epidemiological data to that already 
within the public domain, and would allow comparison with similar data from other 
case series. In an attempt to gain a clearer understanding of the underlying mechanisms 
that cause hemifacial microsomia we collected data regarding those pregnancies that 
resulted in the birth of an individual with hemifacial microsomia, with particular 
attention to bleeding during pregnancy, and the occurrence of multiple gestations. The 
DNA samples were collected with a view to analysis for any specific genetic defect 
identified from the study of the large autosomal dominant pedigree.
682.  Materials & Methods2.1 Method of patient data collection
Children with microtia and/or hemifacial microsomia were identified from the group of 
patients referred to Great Ormond Street Hospital for assessment of these conditions in 
either the specialised microtia clinic, or in separate ENT, plastic surgery, clinical 
genetics, or maxillo-facial surgery clinics. Great Ormond Street Hospital in London is a 
paediatric tertiary referral centre and children are referred for treatment of microtia from 
all regions of the country. I attended all the bi-monthly microtia clinics and personally 
identified patients who were suitable for the study. The details of patients who were 
initially seen in the individual speciality clinics were sent to me by the consultants 
responsible for those clinics. I also attended the outpatient clinics of Mr David Gault at 
Mount Vernon hospital on a regular basis in order to identify other patients, both adults 
and children, with microtia and/or hemifacial microsomia. Mr Gault is a plastic surgeon 
with a particular interest in reconstructive surgery for microtia using autologous rib 
cartilage grafting, and patients with microtia are referred to him from around the 
country.
Ethical approval for the collection of patients’ personal details, phenotype, past medical 
history and family history had been obtained from the Ethics Committees of Great 
Ormond Street Hospital and Mount Vemon Hospital by a previous research fellow 
attached to the ENT department of Great Ormond Street Hospital, and I updated these 
approvals as required during my period of data collection. I approached eligible patients 
and their families at their attendance in the outpatient department, or during an inpatient
70admission, or by post, and obtained informed consent for their participation in this 
research project. The purpose and nature of the research project was explained verbally 
to the patients and their families, and each patient was given a printed information sheet 
(Appendix A). Patients and their accompanying family members were interviewed in 
order to obtain the following data: date of birth, sex, hospital identification number, 
contact details, general practitioner details, phenotype, past medical history including in 
utero and peri-partum details, and family history. Blood samples were collected from 
consenting probands and their available parents. Blood samples were also requested by 
post from parents who were not in attendance when the proband was seen at the 
hospital. DNA was extracted from all blood samples and stored by the North East 
Thames Regional Molecular Genetics Laboratory at Great Ormond Street for future 
DNA analysis. All of the collected data and details of the DNA samples obtained were 
recorded on a pro forma (Appendix B), and the data were then collated on a 
computerised database.
A subset of patients underwent reconstructive surgery for their microtia. During this 
type of surgery redundant skin in the region of the microtic remnant is often excised and 
discarded, and, again following informed consent, this tissue was collected together 
with a blood sample from the patient. Fibroblasts were extracted from the tissue samples 
and cultured in vitro. The resultant fibroblasts were stored in anticipation of a loss-of- 
heterozygosity study.
712.2  Materials
Taq polymerase, 10 x N H 4 reaction buffer, 50mM MgCl2 and dNTPs were supplied by 
Bioline.
Electrophoresis grade agarose and lOObp ladder were supplied by GibcoBRL. 
MegaBACE formamide loading solution, MegaBACE 10 x LPA buffer, MegaBACE 
long read matrix and ET-400R size standard were supplied by Amersham Biosciences. 
All other chemicals were obtained from Sigma.
Primers
Research Genetics supplied microsatellite markers forming the publicly available 
Research Genetics Mapping Set 8.0. Polymerase chain reactions were performed at an 
annealing temperature of 51°C - 55°C with 1.5 mM -  3.0 mM MgCL2. Primer 
sequences for additional markers were obtained from the Genome Database (www. 
gdb.org) as shown below, and these primers were synthesised by MWG Biotech. The 
annealing temperature for all the additional markers used was 55°C, with a magnesium 
concentration of 1.5mM.
72Details of markers used that were not included in the Research Genetics Mapping 
Set 8.0
D2S117
D2S325
D2S371
D2S2361
D2S2382
Forward  5’ GAGATCAGGTATATTCAATCCAC 3’ 
Reverse  5’ CAGAAAATGACAAACTTTAGAGAG 3’ 
Expected product size 186-212 bp  Heterozygosity 81 % 
Label used: Tet
Forward  5’ AGCTTCAGAAATGCCGTTG 3’
Reverse  5’ CCAGTCTTCAGAGATAACAGGG 3’ 
Expected product size 190-214 bp  Heterozygosity 79% 
Label used: Hex
Forward  5’ AGAATAACTAACTTTGAGCAAGGTG 3’ 
Reverse  5’ TCTGTATTGCATTATCTCTGTGTGT 3’ 
Expected product size 148-156 bp  Heterozygosity 61 % 
Label used: Tet
Forward  5’ CTGGACGACCAAGATTCTTCTAACC 3’ 
Reverse  5’ CCTGGGCTCAAGCAATTCTC 3’
Expected product size 235-255 bp  Heterozygosity 63% 
Label used: Tet
Forward  5’ ACATGCAACCGTGTGG 3’
Reverse  5’ AGCACTCTTCAGTCCGAAC 3’
Expected product size 221-279 bp  Heterozygosity 8 8% 
Label used: Fam
73D2S164
D2S2179
D2S2151
D2S1242
D2S339
Forward  5’ GTCCTAACAGGCCACAGACC 3’
Reverse  5’ GCTGGCAGTATCACATGACA 3’ 
Expected product size 265-303 bp  Heterozygosity 93% 
Label used: Tet
Forward  5 ’ TCCCCAGTGTCATTTCC 3 ’
Reverse  5’ GCAGACTTGTTCAGAGAGC 3’
Expected product size 106— 122 bp  Heterozygosity 56% 
Label used : Tet
Forward  5’ CCTGCACTCTCATGTATATTG 3’
Reverse  5’ GTGCCTGACTTATTTTACTTTG 3’ 
Expected product size 208-252 bp  Heterozygosity 46% 
Label used: Hex
Forward  5’ TGACATAGCGAGACCCTGTC 3’
Reverse  5 ’ CCATTCTCATCCAGCAGGA 3 ’
Expected product size 117-172 bp  Heterozygosity 85% 
Label used: Hex
Forward  5’ GAAGTCATGGGAAGGC 3’
Reverse  5’ AAGCAAAATGCAATCAGA 3’
Expected product size 123— 133bp  Heterozygosity 89% 
Label used: Fam
74D2S2228  Forward  5 ’ AGCTGTAAGGAAGCAGCAC 3 ’
Reverse  5 ’ AAAAGGACTTATTCTGGGGA 3 ’
Expected product size 191 -215 bp  Heterozygosity 71 %
Label used: Tet
Solutions
5 x TBE  0.089M Tris, 0.089M Boric acid, 2mM EDTA, pH 8.0
Agarose gel loading dye  50% glycerol, lOmM EDTA, 0.5% Orange G
752.3  Methods of genome scan
Details of a family from North America, in which successive generations showed 
characteristics of hemifacial microsomia, were supplied by Dr Robert Gorlin, University 
of Minnesota, USA. DNA samples from a number of family members were also 
provided by Dr Gorlin.
2.3.1  Clinical details of patients studied in genome scan
Family R is the North American family identified by Dr R. J. Gorlin. Some details were 
provided about 6 generations of the family in which hemifacial microsomia appears to 
segregate in an autosomal dominant manner with apparently full penetrance (figure 5). 
Clinical details of the family were also supplied by Dr Robert Gorlin; individual IV4 has 
left-sided mandibular hypoplasia, with masseter underdevelopment, preauricular skin 
tags, an unstable temporomandibular joint, and a small right-sided preauricular fistula. 
Individuals IV13, Vg and V9  were all said to be affected, and all exhibited preauricular 
skin tags. The first information received stated that individual V 7 was unaffected. 
Further details were then supplied that included the fact that V 7 had skin tags, and we 
chose to include him as an affected individual at the start of the genome scan. However, 
later examination of individual V 7 by Dr M. Bitner-Glindzicz revealed that he exhibited 
no other features of hemifacial microsomia, and, thus, his affection status was called 
into question during the course of this study.
76Figure 5.  Pedigree of family R exhibiting autosomal dominant hemifacial microsomia.
Arrows indicate individuals for whom DNA samples were initially available.
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A genome scan was performed using the above details and the available DNA from 
family R. The Research Genetics Mapping Set version 8.0 that was used contains 496 
markers covering the autosomal chromosomes. These markers are spaced at an average 
interval of 1  OcM across the genome. A series of polymerase chain reactions was 
performed on each individual’s DNA with each marker in turn. The products of the
77polymerase chain reactions were analysed using a combination of gel electrophoresis 
and automated analysis in the MegaBACE 1000 instrument.
2.3.2  Polymerase chain reaction
The polymerase chain reaction mix consisted of 25-50ng of DNA in a lOpl final volume 
containing 10-20pmol of each primer, 1  x NH4 reaction buffer (Bioline), 1.5-3.0mM 
MgCb, 200pM dGTP, dCTP, dTTP, dATP, and 0.1-0.2 units of Taq polymerase 
(Bioline). Each sample was overlaid with a single drop of mineral oil to reduce 
evaporation. PCR reactions were performed in 96-well Omniplates (Hybaid), or 0.5ml 
eppendorf tubes.
The reaction was carried out on a Hybaid Omn-E thermal cycler.
Conditions for thermal cycling consisted of denaturation at 95°C for 5 minutes, 
followed by 35 cycles of 95°C for 30 seconds, 30 seconds at the annealing temperature 
specific to each primer pair which ranged from 51 °C to 55 °C, and 72°C for 30 seconds, 
followed by a final extension step of 10 minutes at 72°C.
782.3.3  Gel electrophoresis
lg of electrophoresis grade agarose was dissolved in 50ml 1  x TBE by boiling in a 
microwave to produce a 2% agarose gel. On cooling 3 pi of lOmg/ml ethidium bromide 
solution was added to the mix and the gel was poured into an NBL gel tray.  lOpl of 
PCR product were mixed with 3 pi of loading dye, loaded onto the gel and 
electrophoresed at 100 volts for 25-45 minutes in 1  x TBE.  The gel image was captured 
using Chemilmager 4000 software (a Innotech) under ultraviolet (UV) light. Products 
were sized by comparison to a lOObp ladder loaded at the same time as the PCR 
products.
2.3.4  Capillary array electrophoresis
The MegaBACE 1000 instrument was used to perform automated capillary gel 
electrophoresis. The MegaBACE capillary tips were rinsed with deionised filtered water 
according to the manufacturer’s protocol, and then the capillaries were filled with 
MegaBACE long read matrix. The PCR products to be run in the same capillary were 
pooled in equal ratios and diluted to between 1  in 10 and 1  in 30 in order to desalt the 
pools. 4.0pl of diluted PCR pooled products were added to 5.5pi of formamide loading 
solution and 0.5pi ET-Rox 400 size standard ladder. The prepared samples were loaded 
onto Thermo-Fast 96 well skirted PCR plates (ABgene) and denatured at 95°C for 1  
minute and placed immediately on ice prior to injection into the capillaries and
79electrophoresis according to the MegaBACE protocol. Electrophoresis was performed 
for 75 minutes at 44°C running at 750 volts.
2.3.5  Data analysis
The data acquired from the PCRs and electrophoreses were analysed using the Genetic 
Profiler vl.l analysis software (Amersham). The electropherograms generated by this 
software were individually assessed in order to call and size alleles appropriately. Two 
point lod score analyses of the family’s genotypes for each microsatellite marker were 
performed using the MLINK program from the LINKAGE software package 
(www.hgmp.mrc.ac.uk). The number of alleles of each marker present in the general 
population and their frequencies were obtained from the database of the Laboratory of 
Population Genetics at the National Cancer Institute (http://lDg.nci.nih.gov ) and CEPH 
genotype database (www.cephb.fr/cephb/). The disease penetrance was set at 100%, 
and the hemifacial microsomia disease gene frequency was set at 1  in 5000.
Parametric multipoint lod score analysis was performed with GENEHUNTER version
2.0  (www.hgmp.mrc.ac.uk ), using Kosambi mapping units, and an increment distance 
of lcM.
803.  Results of patient data collectionOver a four year period until October 2002 two hundred and sixty one patients with 
either isolated microtia or hemifacial microsomia gave their informed consent to be 
interviewed and examined, as described in the methods section above, and for their data 
to be retained on the database; I personally recruited 107 of these patients to the 
database. Ninety five patients displayed clinical features consistent with a diagnosis of 
hemifacial microsomia, and one hundred and sixty six patients appeared to have isolated 
microtia.
823.1  Age and sex distribution
The year of birth of the patients recruited to the database is shown in figures 6 and 7. 
The number of patients recruited from each year of birth is modest, as expected 
considering the total number of patients in the study. Most of the patients were recruited 
at Great Ormond Street Hospital which is a tertiary referral centre for paediatric 
patients. Mount Vernon hospital accepts both adult and paediatric patients, and 29 
patients, 20 children and 9 adults, of the 166 patients with microtia were recruited from 
Mount Vernon Hospital, as were 13 of the 95 patients with hemifacial microsomia of 
whom 8 were children at the time of presentation. Therefore, 95% of our patients 
presented in childhood, and one might intuitively expect this pattern to occur, though 
the likelihood of an early presentation may have been accentuated in our study by the 
nature of the institutions from which we recruited patients. However, some patients do 
present in adulthood, the oldest patient in each group being in their mid forties at their 
first assessment in clinic.
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Figure 6.  Year of birth distribution of microtia patients
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Figure 7.  Year of birth distribution of hemifacial microsomia patients
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Year of birthMale patients were more common than females, with an overall ratio in the 261 patients 
of 1.4:1 male:female. There were 58 male (61%) and 37 female (39%) patients within 
the hemifacial microsomia group. Similarly, 57% (94 patients) of those with isolated 
microtia were male compared to 43% (72 patients) who were female. These proportions 
are consistent with the suggestion of a male preponderance by other authors in both 
microtia {Bennun, Mulliken, et al 1985 50 /id} (Okajima, Takeichi, et al 1996 123 /id} 
and hemifacial microsomia (Grabb 1965 46 /id} {Rollnick, Kaye, et al 1987 2 /id}.
863.2  Laterality
A predominance of right sided facial asymmetry has been reported in most published 
series of patients with hemifacial microsomia {Grabb 1965 46 /id} {Rollnick, Kaye, et al 
1987 2 /id} or microtia {Bennun, Mulliken, et al 1985 50 /id} {Okajima, Takeichi, et al 
1996 123 /id}.
Right sided laterality was more common in our patients with isolated microtia, with 96 
out of 166 patients (58%) displaying an isolated right microtia, 42 patients (25%) 
showing unilateral left microtia, and 28 patients (17%) presenting with  bilateral 
microtia.
There was also a right sided preponderance in the hemifacial microsomia patients in 
terms of both facial hypoplasia and microtia. In 53 patients (56%) of the 95 with 
hemifacial microsomia the right side of the face was hypoplastic, in 37 patients (39%) 
only the left side of the face was affected, and in 3 patients (3%) there was bilateral 
facial microsomia; in two patients the side of facial hypoplasia was unrecorded. 47 
(49%) of the 95 hemifacial microsomia patients had unilateral right sided microtia, 32 
patients (34%) had unilateral left microtia and 9 patients (9%) had bilateral microtia.
The microtic ear was always on the same side as the facial hypoplasia in those patients 
with unilateral hemifacial microsomia. 7 patients had facial asymmetry in the absence 
of microtia.
873.3 Grade of microtia
We have graded the severity of microtia in our patients using a modification of the 
grading system proposed by Meurman {Meurman 1957 102 /id}. In this system grade I 
microtia is defined as a small pinna in which all parts of the normal  ear can be 
identified; grade II is a pinna in which some but not all parts of a normal ear are 
observed, and in grade III microtia the pinna is represented by ill defined mass of tissue 
or anotia is present. Other grading systems have also been described, but none has any 
clear diagnostic or prognostic advantage, and the Meurman system has the advantage of 
simplicity. The grade of microtia was recorded for 83 of the patients with hemifacial 
microsomia, 9 of whom had bilateral microtia, and in 159 patients with isolated 
microtia, 26 of who had bilateral microtia. The number of ears assigned to each grade of 
microtia is shown below.
Table 2.  Laterality and grades of microtia observed
Grade of 
microtia
Hemifacial microsomia 
patients 
Right ear  Left ear
Microtia patients 
Right ear  Left ear
Grade 1 15 9 30 19
Grade 2 16 9 67 29
Grade 3 20 23 21 193.4 Skin tags
Pre-auricular skin tags were a common finding in both groups of patients, but the 
incidence of skin tags was higher in the hemifacial microsomia patients than in the 
isolated microtia patients, 48 (51%) of the 95 patients with hemifacial microsomia had 
skin tags compared to 36 (22%) of the 166 patients with isolated microtia. The numbers 
of skin tags and their sides of presentation are shown in table 3.
Table 3.  Number and laterality of pre-auricular skin tags.
(percentages are of the total number of patients in either the hemifacial 
microsomia or isolated microtia groups)
Number of skin 
tags
Hemifacial microsomia 
natients 
Right  Left
Microtia patients 
Right  Left
1 15(16%) 16(17%) 22(13%) 14 (8%)
2 13(14%) 6 (6%) 4 (2%) 3 (2%)
3 2 (2%) 3 (3%) 0 0
4 1  (1%) 1  (1%) 0 0
89Unilateral skin tags were most commonly seen to be ipsilateral to a microtic ear, though 
in some patients the skin tag was located on the opposite side to the microtic ear. These 
contralateral skin tags were found in 9 of the 29 patients who had isolated microtia and 
unilateral skin tags. For the purpose of this study these patients were considered to have 
unilateral microtia. Out of the 38 hemifacial microsomia patients who had unilateral 
skin tags and microtia, ipsilateral skin tags were seen in 26 patients and contralateral 
skin tags occurred in 12 patients. One hemifacial microsomia patient had two unilateral 
skin tags contralateral to the side of facial hypoplasia in the absence of any microtia.
Bilateral skin tags were reported in 9 patients with hemifacial microsomia, 2 of whom 
had bilateral facial hypoplasia and bilateral microtia, whilst another patient had 
unilateral facial hypoplasia with bilateral microtia; bilateral tags were seen in 7 patients 
in the microtia group, 3 of who also had bilateral microtia.
903.5 Abnormalities of the external auditory meatus
Stenosis and atresia of the external auditory meatus were common findings in both 
groups of patients. The majority of patients had unilateral narrowing or occlusion of 
their ear canals as shown in table 4.
Table 4.  The incidence of unilateral and bilateral narrowing of the auditory 
meatus  (percentages are of the total number of patients in either the 
hemifacial microsomia or isolated microtia groups)
External auditory meatus 
stenosis or atresia
Hemifacial
microsomia
Microtia
Bilaterally normal 17(18%) 37 (22%)
Unilaterally affected 70 (74%) 112(67%)
Bilaterally affected 8 (8%) 17(10%)
91The number of normal, stenotic and atretic ear canals found in our populations is shown 
in table 5 below. The incidence of atresia of the external auditory meatus is greater than 
that of canal stenosis, though the later character was only subjectively assessed.
Table 5.  Distribution of variations in patency of external auditory meati 
(percentages are of the total number of ears in either the 
hemifacial microsomia or isolated microtia groups)
External auditory meatus
Hemifacial
microsomia
Microtia
Normal 104 (55%) 171 (52%)
Stenosis 28(15%) 20 (6%)
Atresia 58 (30%) 141 (42%)
Tables 6 and 7 below detail the number of patients with either ear canal stenosis or 
atresia for whom the grade of associated microtia had been recorded. These figures 
appear to suggest that meatal atresia is more common in association with the more 
severe degrees of microtia in both groups of patients.
92Table 6.  Relationship of ear canal narrowing to grade of microtia in hemifacial 
microsomia patients, (percentages are of the total number of ears for 
each grade of microtia)
Hemifacial microsomia 
patients
Microtia grade
External auditory canal 
Stenosis  Atresia
Normal 1  (1%) 0
I 12 (50%) 8 (33%)
II 7 (28%) 14 (56%)
III 6 (14%) 35 (81%)
93Table 7.  Relationship of ear canal narrowing to grade of microtia in isolated 
microtia patients, (percentages are of the total number of ears for 
each grade of microtia)
Microtia patients 
Microtia grade
External auditory canal 
Stenosis  Atresia
Normal 0 0
I 10 (20%) 19(39%)
II 6 (6%) 82 (85%)
III 4 (10%) 33 (83%)
No instances were recorded of canal atresia in relation to a normal pinna. Only one 
patient from either group was noted to have auditory canal stenosis ipsilateral to a 
normal pinna, and the contralateral ear was microtic. I have classed this patient as 
having unilateral microtia.
943.6 Facial nerve palsv
A number of patients were noted to have a seventh cranial nerve palsy. This was seen 
more commonly in the hemifacial microsomia group of patients, of whom 42% had a 
facial palsy, whilst only 3% of the 166 patients with isolated microtia were similarly 
affected. The facial palsy was always ipsilateral to the side of microsomia or microtia.
A right sided facial palsy was seen in 23 patients (24%) of the 95 with hemifacial 
microsomia, and in 2 patients (1%) from the isolated microtia group. A left facial palsy 
occurred in 17 (18%) hemifacial microsomia patients and in 3 (2%) microtia patients.
3.7 Cleft lip and palate
Five patients (3%) of the isolated microtia group had some form of clefting of the lip or 
palate. One had a bilateral cleft lip and palate, one patient had a submucous cleft palate, 
two patients had midline palatal clefts, and one had a bifid uvula.
Eleven per cent of the hemifacial microsomia group had a cleft lip and/or palate; there 
were four patients with midline cleft palates, two patients had bilateral cleft lips, there 
was one right sided palatal cleft, and three left sided clefts.
953.8 Affected relatives
The majority of patients appeared to be sporadic occurrences of hemifacial microsomia 
or microtia. However, a number of probands had isolated relatives who also had 
microtia or another malformation that could be a feature of hemifacial microsomia, and 
these are summarised in tables 9 and 10. There were two cases in which a significant 
family history of multiple affected relatives was elicited.
The pedigree of one proband with hemifacial microsomia included facial asymmetry 
affecting his mother, maternal grandmother and mother’s first cousin, and pre-auricular 
skin tags were present in a maternal cousin (figure 8).
Microtia was reported in the father, great grandfather and great great grandfather of a 
separate patient who had bilateral grade III microtia, and his great uncle had pre­
auricular skin tags. This family has been reported in the literature as familial microtia 
suggestive of autosomal dominant inheritance with variable expression and low 
penetrance (Gupta & Patton 1995 208 /id}. Unfortunately there was no opportunity to 
confirm the findings in these two pedigrees by direct examination of the affected 
individuals.
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Figure 8.  The pedigree for the family with hemifacial microsomia affecting 
three generations. Facial asymmetry was present in IV:9,111:9,11:3 and 111:2, 
and pre-auricular skin tags were present in IV:6.
'O <»The incidence of all relatives bearing ear deformities or facial asymmetry is shown in 
table 8 below.
Table 8.  Relatives with ear deformities or facial asymmetry
Affected relatives Hemifacial microsomia Microtia
First degree 5 (5%) 2(1%)
Second degree 4 (4%) 6 (4%)
Third degree 3 (3%) 5 (3%)
98Table 9.  Congenital anomalies present in relatives of hemifacial microsomia 
probands
Proband database ID number
Sibling with cupped ear 398516
Maternal grandfather with cupped ear 398516
Maternal grandmother with facial asymmetry 646495
Sibling with clinodactyly 646495
Mother’s cousin with cleft palate 566242
Mother’s uncle with cleft palate 566242
Sibling with microtia B0203068
Sibling with unilateral hearing loss 665190
Mother with facial asymmetry 598360
Mother with cleft lip and palate 597036
Father with pre-auricular skin tags 535057
Father with microtia, mandibular hypoplasia and 
iris coloboma
150897
Father with unilateral microphthalmia 661139
Maternal grandfather with microtia 589824
Maternal great grandfather with microtia B0216064
Mother’s cousin with microtia 100565
Sibling with Down’s syndrome, 
family history of hearing loss
665227
Paternal uncle unilateral hearing loss from childhood 736939
99Table 10.  Congenital anomalies present in relatives of probands with isolated 
microtia
Proband database ID number
Sibling with pre-auricular skin tags  n=4 629918, B0177003 
703417, B0179123
Mother with cupped ears 717088
Mother with pre-auricular skin tags 723907
Father with pre-auricular skin tags 730766
Father with pre-auricular pit 723929
Paternal grandfather with bilateral microtia 710285
Paternal grandmother with pre-auricular skin tags  705196
Maternal grandmother with microtia B0173804
Cousin with pre-auricular skin tags 733483
Paternal cousin with lop ear 617231
Maternal cousin ‘malformed ears’ B0196611
Maternal cousin once removed with microtia, 
mandibular hypoplasia and facial palsy
B0196611
Cousin with microphthalmia 646714
Maternal aunt with microtia  n=2 B0213781,740005
Maternal uncle with microtia 715733
Paternal aunt with microtia 669645
Maternal aunt with syndactyly 662352
Sibling with solitary kidney 650167
1003.9  Bleeding in pregnancy
Bleeding during pregnancy was reported more frequently by mothers of patients with 
hemifacial microsomia than isolated microtia. In the hemifacial microsomia cohort 27 
of the 95 mothers (28%, 95%CI 19%-37%) reported bleeding in their first trimester of 
pregnancy, and 3 (3%, 95%CI 0%-7%) recalled bleeding in the second trimester. The 
numbers of mothers of microtia patients reporting bleeding were 14 (8.4%, 95%CI 
4.2%-12.7%), 4 (2.4%, 95%CI 0%-4.7%) and 2 (1.2%, 95% Cl 0%-2.9%) in each 
trimester of pregnancy respectively.
Mothers were also questioned about bleeding during other pregnancies for comparison. 
70 mothers of children with hemifacial microsomia gave a history of 121 other 
gestations, and all of these mothers had at least one other live bom child. 5 of these 70 
mothers reported bleeding during one of their other pregnancies, which equates to 
bleeding in 4% of these mothers’ other gestations. Only one mother reported bleeding 
during the gestation of their child with hemifacial microsomia and also during another 
gestation. 2 mothers of individuals with hemifacial microsomia reported spontaneous 
first trimester miscarriages.
119 mothers of children with microtia reported 225 other gestations, of which 213 
ended with a live birth.  13 (6%) of these 213 pregnancies were complicated by bleeding, 
though one mother accounted for four of these pregnancies.  6 of the pregnancies with 
bleeding occurred in mothers who also noted bleeding during their carriage of the child
101with microtia, including the woman mentioned above whose five gestations were all 
associated with spotting in the first trimester; 7 pregnancies were complicated by 
bleeding in 6 women who had not noticed bleeding during their pregnancy that gave rise 
to the child with microtia.
3.10  Incidence of twinning
Six (6%, 95% Cl 0%-13%) of the hemifacial microsomia patients and eight (5%, 95%
Cl 2%-8%) of the microtia patients were bom as one of a pair of live bom twins. All of 
the twin siblings of affected individuals were phenotypically normal. In each group one 
mother of an affected individual was said to have had two foetuses in utero early in their 
pregnancy, but by the second trimester only a singleton foetus remained, and another 
patient was delivered with two sets of amniotic membranes.
1024. Discussion of patient data collection
103Hemifacial microsomia is a complex disorder that presents with a highly variable 
phenotype consisting particularly of facial and auricular abnormalities. It is quite 
probable that the spectrum of abnormalities that has been encompassed by the epithet of 
hemifacial microsomia actually includes a number of aetiologically distinct disorders. 
Whether patients with isolated microtia represent the mildest form of hemifacial 
microsomia, or whether they constitute a separate diagnostic condition is unclear at 
present, and this distinction will only be made with certainty once the aetiology and 
pathogenesis of both defects have been defined. We have collected data on a large 
number of patients of whom roughly a third have clinical features consistent with 
hemifacial microsomia, whilst two thirds have microtia without overt hypoplasia of the 
mandible or maxilla. The presence or absence of other malformations in association 
with microtia was determined by history taking and clinical examination alone. We did 
not perform cephalometric radiography or photography routinely, and it is possible that 
minor degrees of facial asymmetry could have been overlooked, especially in small 
infants. Also it has been noted that facial asymmetry may only become apparent in 
some patients following the differential growth of the normal and affected sides of the 
face in the first few years of life; on-going planned review of our patient set in the 
dedicated microtia clinic at Great Ormond Street Hospital and continued updating of the 
database should allow any such individuals to be correctly reclassified.
1044.1 Age and Sex distribution
The demographic distribution of our patients reflects the referral pattern to the microtia 
clinic at Great Ormond Street Hospital at which most of the patients were recruited. 
Hence, most of the patients were under 16 years of age at presentation. In keeping with 
the non progressive nature of microtia and hemifacial microsomia, and the absence of a 
need for early assessment of affected patients, many patients were first referred in mid 
childhood, and we would expect more patients who were bom in the late 1990’s and 
2000/2001 to present to the clinic in the coming years.
A male preponderance was present in our study group, the ratio of males to females 
being 1.4 to 1, with 152 males and 109 females in total, and this difference appears to be 
significant (95% Cl’s males 52%-64%, females 36%-48%). This ratio was similar for 
both the patients with isolated microtia and for those with hemifacial microsomia. These 
findings are consistent with most other reported series. Rollnick et al {Rollnick, 1987 2 
/id} calculated a male to female ratio of 1.9 to 1  (male:female 191:103) in a series of 
patients with either isolated microtia or hemifacial microsomia, and this relationship 
was maintained when the microtia subgroup (male 64%, female 36%) and hemifacial 
microsomia subgroup (male 65%, female 35%) were inspected separately. The same 
male to female proportions, 65% to 35%, were found in 592 patients with microtia 
studied in Japan (Okajima, Takeichi, et al 1996 123 /id}, and in 74 microtia patients 
(male 66%, female 34%) in Massachusetts, USA {Bennun, Mulliken, et al 1985 50 /id}. 
Eavey {Eavey 1995  124 /id} reported a less marked male preponderance (male:female
10560%:40%) in 92 paediatric patients most of whom had microtia, though there were 21 
ears out of a total of 108 with other auricular malformations such as cryptotia. The same 
1.5:1 male:female ratio was reported by Llano-Rivas et al {Llano-Rivas, Gonzalez-del 
Angel, et al 1999 184 /id} amongst 145 patients in Mexico City with either microtia or 
hemifacial microsomia.
However, Carvalho et al {Carvalho, Song, et al 1999 51 /id} found no bias towards 
male sex (male 46%, female 54%) in their group of 99 paediatric patients with 
hemifacial microsomia, and another group from Massachusetts found a similar result in 
a smaller number of patients (male 43%, female 57%, n=40)  {Rahbar, Robson, et al 
2001  86 /id}. An earlier study of 121 patients by the same group showed equal numbers 
of affected boys and girls (male 49%, female 51%)  {Horgan, Padwa, et al 1995  125 
/id}. The series of 154 patients with hemifacial microsomia and/or microtia reviewed by 
Vento et al {Vento, LaBrie, et al 1991 209 /id} in America contained 85 (55%) female 
and 69 (45%) male patients. A more detailed analysis of the data in each of these four 
reports suggests that there is no difference in their proportions of male and female 
patients.
1064.2 Laterality
The predominantly right sided laterality of our patients’ malformations, of both isolated 
microtia and hemifacial microsomia, is in keeping with the findings of other case series. 
Unilateral microtia was seen in 138 (83%) of the 166 patients in the isolated microtia 
group, and 96 (70%, 95%CI 62%-77%) of these 138 patients had a right sided 
deformity. Rollnick et al (Rollnick, Kaye, et al 1987 2 /id} reported on 92 patients with 
microtia alone, in 42% of whom only the right ear was affected, in 18% the left ear was 
affected, and in 36% there was bilateral involvement. Harris et al (Harris, Kallen, et al 
1996 175 /id} found an excess of right sided cases amongst 615 unilateral cases of 
microtia, with 61% being right sided. Okajima et al (Okajima, Takeichi, et al 1996 123 
/id} reported a large series of 592 patients with microtia. Despite the fact that a small 
percentage of these patients had malformations consistent with known syndromes e.g. 
Treacher-Collins syndrome in 1%, a similar pattern in the sides affected by microtia was 
seen; the right side was affected in 58.4%, the left side in 32.4%, and 9.1% were 
bilaterally affected. Bennun et al’s (Bennun, Mulliken, et al 1985 50 /id} series of 74 
patients showed right laterality in 57%, left laterality in 30% and bilateral microtia in 
13%; these figures are similar to ours of 58%, 25% and 17% respectively. Amongst 87 
patients with microtia Llano-Rivas (Llano-Rivas, Gonzalez del-Angel, et al 1999 184 
/id} noted that 46% had right unilateral microtia, 23% left microtia and 31% had 
bilateral affection.
107Horgan et al {Horgan, Padwa, et al 1995 125 /id}, however, found that side 
predominance was distributed more equally in their series of 121 patients between right, 
left and bilateral cases (34% right, 38% left, 28% bilateral).
In our group of patients who had hemifacial microsomia together with microtia the 
pattern of involvement was again repeated, right, left and bilateral microtia occurring in 
53%, 36% and 10% of patients. The pattern of microtia laterality in our hemifacial 
microsomia patients is similar to that found by Llano-Rivas {Llano-Rivas, Gonzalez 
del-Angel, et al 1999 184 /id}, whose 145 patients comprised 52% right sided, 23% left 
sided and 25% bilateral. Rollnick et al {Rollnick, Kaye, et al 1987 2 /id} also reported 
199 patients with microtia and mandibular hypoplasia; they found a 31 % bilateral 
microtia rate (62 patients), with 41% (81 patients) and 28% (56 patients) of cases having 
unilateral right or left sided involvement only.
With regards to facial asymmetry the right side of the face was more commonly the side 
of hypoplasia than the left, this being the case in 57% compared to 40%. We noted 
bilateral facial involvement in only 3 patients (3%), and whilst this may represent the 
true proportion of bilaterally affected subjects, it must be borne in mind that this was 
assessed subjectively without the use of measurement and comparison to 
anthropometric normalised data. Grabb quoted a figure of 12% for bilateral facial 
involvement in hemifacial microsomia, 12 of his 102 patients being affected on 
assessment by clinical examination and, in many cases, x-ray analysis {Grabb 1965 46 
/id}. Bilateral mandibular hypoplasia was evident in 16% of the series reported by
108Vento et al {Vento, LaBrie, et al 1991 209 /id}, with little difference in the proportion 
of patients with either unilateral right (45%) or left (40%) hypoplasia.
Paulozzi and Lary {Paulozzi & Lary 1999 178 /id} examined laterality patterns in 6,390 
infants with external birth defects. A statistically significant excess of right sided cases 
was noted for six defect types, and these included microtia and preauricular sinuses. A 
significant left sided excess was present for nine defect types, one of which was 
preauricular tags.
The theories that have been expounded to account for asymmetric occurrence of 
external birth defects include the constraining effect of the uterus once the foetal head is 
engaged, since the foetus tends to face to the mother’s right side. However, this is 
unlikely to be an important factor in the development of the structural defects seen in 
hemifacial microsomia or microtia as the foetal head does not engage in the pelvis until 
the 28th week of gestation. An increased susceptibility of the right side of the embryo to 
hypoxic tissue damage has been suggested by Fantel et al {Fantel, Juchau, et al 1989 
196}. The same group has also shown that mitochondrial activity develops on the left 
side of the embryo before the right side, and this could lead to lower energy reserves 
and increased tissue damage from hypoxia on the right side {Fantel, Person, et al 1991 
198 /id). Subtle differences in the vascular patterns of the two sides of the embryo could 
also lead to an excess of hypoxic damage on one side of the body.
109The establishment of a left-right axis occurs early on in embryonic development, and 
studies have shown that some genes are differentially expressed on the two sides of the 
embryo {Ramsdell & Yost 1998 179 /id}. Such differences in gene expression could 
potentially cause one side to be more susceptible to other adverse genetic or 
environmental influences, and thus explain the generally consistent finding of the 
preponderance of right sided involvement in hemifacial microsomia and microtia.
4.3  Grade of Microtia
The assignment of certain appearances of microtic ears to distinct categories is 
somewhat arbitrary, as noted in the introduction. Most grading systems define the 
mildest form of microtia as a structurally normal ear that is small in size, and this is 
usually determined by comparison to the contralateral ear. More severe grades of 
microtia are defined by the increasing loss of normal parts of the ear, with the severest 
form being complete loss of any tissue representing an ear, i.e. anotia. The very mildest 
forms of microtia might go unrecognised, especially if there is bilateral involvement. A 
small but normally shaped ear may not be of great concern to an individual or their 
parents, or may not be deemed worthy of referral to a tertiary centre by the local 
medical services, and thus our population may be skewed towards the more severe end 
of the spectrum of microtia deformities. Only 30 (18%) of the 166 patients with isolated 
microtia had a unilateral grade one deformity of the pinna, and 6 (4%) had bilateral 
grade one microtia.
110Few other authors have reported the distribution of severity of microtia in their case 
series. Rollnick and Kaye’s population of hemifacial microsomia patients had a fairly 
even distribution between the different grades of microtia; of the 47 microtic ears 17 
(36%) were grade I, 19 (40%) were grade II, and 11 (23%) were grade III (Rollnick & 
Kaye 1983 57 /id}. Okajima et al divided their 592 patients with microtia into 5 groups 
according to the classification of Ogino published in Japanese. They reported that grade 
III microtia, peanut-shell type, was the most frequent type having been observed in 
56.8%. Grade II microtia was seen in 20.6%, and grade I microtia in 13.9% (Okajima, 
Takeichi, etal 1996 123}.
4.4  Skin Tags
Pre-auricular skin tags were a more common finding in the hemifacial microsomia 
group of patients than in the isolated microtia group. 49% (n=47) of the 95 people in the 
hemifacial microsomia cohort had associated skin tags, compared to 22% (n=36) of the 
166 people with isolated microtia. The incidence of skin tags in both groups of our 
study appears to be much higher than that observed in the general population, an 
incidence of 1.5% being quoted by Altmann (Altmann 1951  173 /id}, but it remains 
unclear as to whether skin tags have an aetiology which is directly related to the cause 
of hemifacial microsomia.
Ill21 of the 24 Canadian patients with Goldenhar syndrome studied by Shokeir had 
preauricular skin tags {Shokeir 1977 152 /id}. 40% of the 154 hemifacial microsomia 
patients reported on by Vento et al {Vento, LaBrie, et al 1991 209 /id} had preauricular 
skin tags. A much lower percentage of patients was found to have preauricular sinuses 
or tags in the study by Llano-Rivas {Llano-Rivas, Gonzalez del-Angel, et al 1999 184}, 
either in association with microtia alone (17.2%), or in their patients with hemifacial 
microsomia (18.9%).
We found the presence of skin tags contralateral to the side of microtia in 12 (15%) of 
79 patients with hemifacial microsomia and unilateral microtia, and in 9 (7%) of 138 
patients with unilateral isolated microtia, and until there is a greater understanding of 
the development of the microtic defect it is debatable as to whether such patients should 
be categorised as being unilaterally or bilaterally affected.
4.5  Abnormalities of the External Auditory Meatus
Amongst the patients with hemifacial microsomia the external ear canal was stenotic in 
15% of ears (28/190) and atretic in 31% (58/190). The comparative figures for the 
isolated microtia group were 6% (20/332) and 42% (141/332) respectively. These 
proportions are statistically significantly different (% 2 0.01> p >0.001), with most of the 
difference being attributable to the increased rate of stenosis observed in the hemifacial 
microsomia patients. Higher rates of atretic ear canals were found by Llano-Rivas
112{Llano-Rivas, Gonzalez del-Angel, et al 1999 184 /id} in their patients, with 57% of 
their microtia patients and 52% of their hemifacial microsomia patients displaying this 
defect.
We made the assessment of the presence of stenosis of the ear canal subjectively, and 
minor degrees of stenosis may have been missed. However, minor stenosis of the ear 
canal is likely to be clinically unimportant. Atresia of the external auditory meatus is 
clinically more likely to be associated with a significant conductive hearing loss, and 
presents a greater barrier to the treatment of any associated hearing impairment.
4.6  Facial nerve palsy
Facial nerve palsy was found to occur much more commonly in association with 
hemifacial microsomia, 42% (95% Cl, 32%-52%), than with isolated microtia, 3% 
(95% Cl, 0%-6%). The aetiology of these facial nerve palsies is assumed to be an 
aberration of the facial nerve at some point along its intraosseous course within the 
temporal bone. The temporal bone does not originate from the first or second branchial 
arches, apart from the styloid process, but it is not hard to conceive that the 
mechanism(s) causing disruption of the normal development of the structures derived 
from these branchial arches could sequentially affect the contiguous portions of the 
temporal bone. Rahbar et al {Rahbar, Robson, et al 2001  86 /id} examined temporal 
bone computed tomographic (CT) scans of 40 patients with hemifacial microsomia, and 
found abnormalities of the facial nerve canal in 35 (88%) of these. Anterior
113displacement of the facial nerve was the most commonly noted abnormality, and was 
found in 25 patients (63%). Clinically, 20 of these patients (50%) had a facial nerve 
weakness.
Facial nerve dysfunction was found in 22 (22%) of 99 paediatric patients with 
hemifacial microsomia in a retrospective case note review performed by Carvalho et al 
{Carvalho, Song, et al 1999 51 /id}. The same incidence of facial nerve palsy was 
reported by Bassila and Goldberg {Bassila & Goldberg 1989 126 /id} in their published 
series of 50 patients with hemifacial microsomia.
Bennun et al {Bennun, Mulliken, et al 1985 50 /id} in their report of 74 patients with 
microtia found facial nerve weakness in 9 patients (12%), and Eavey {Eavey 1995 124 
/id} reported an 8% facial nerve palsy rate in his series of 92 paediatric patients with 
auricular malformations. Okajima et al {Okajima, Takeichi, et al 1996 123 /id} reported 
a much lower incidence of facial nerve palsy, 13 (2%) of their 592 patients with 
microtia having an ipsilateral facial weakness.
Thus, it appears that facial palsy is more commonly associated with hemifacial 
microsomia than with isolated microtia; this difference could be attributable either to 
different pathogeneses of the two conditions, with the pathogenesis of hemifacial 
microsomia being more likely to produce a facial nerve palsy, or because hemifacial 
microsomia represents a more severe phenotypic expression of the same condition as 
microtia, with the anatomical abnormalities being more likely to extend to the temporal 
bone and the course of the facial nerve.
1144.7  Cleft Lip and Palate
Clefting of the lip and/or palate is the commonest congenital malformation of the head 
and neck with an incidence of 1  in 1000 {Gorlin, Cohen, et al 1990, 211 /id} {ICBDMS 
2002 61 /id}. Fourteen patients in our total study group of 261 were found to have 
clefting of the lip and/or palate, which represents an incidence of 5%. Llano-Rivas et al 
{Llano-Rivas, Gonzalez del-Angel, et al 1999 184 /id} noted 4 cases (3%) of cleft 
palate amongst their 145 patients with microtia. Rollnick et al {Rollnick, Kaye, et al 
1987 2 /id} reported the incidence of cleft lip +/- cleft palate as 7% in association with 
either microtia or hemifacial microsomia. Feingold and Baum {Feingold & Baum 1978 
16 /id} had 3 patients with cleft palate in their series of 16 Goldenhar patients, and 
Shokeir {Shokeir 1977 152 /id} reported cleft lip and palate in 25% of their 24 
Goldenhar patients.
Thus, cleft lip and or palate are seen to occur in a small percentage of the larger series 
of microtia or hemifacial microsomia, though the incidence appears to be greater than in 
the general population. The incidence may seem surprisingly low if one considers that 
the lip and palate are formed from the tissues of the maxillary processes of the first 
branchial arch, and that normal fusion in the midline of these tissues occurs at the same 
time as the development of the pinna.
1154.8 Affected Relatives
The incidence of affected relatives was much less amongst our patients than has 
previously been reported in another series {Rollnick & Kaye 1983 57 /id} {Llano-Rivas, 
Gonzalez del-Angel, et al 1999 184 /id}. In our patients a family history of microtia or 
facial asymmetry was identified in 16 pedigrees in total (6%), with 8 of the probands 
having hemifacial microsomia and 8 having isolated microtia. If relatives with milder 
ear malformations e.g. cup or lop ears, preauricular skin tags, pits or sinuses, and early 
onset hearing loss are considered affected, as in the series reported by Rollnick and 
Kaye, then 31 pedigrees (12%) could be classified as showing a positive family history. 
Llano-Rivas et al {Llano-Rivas, Gonzalez del-Angel, et al 1999 184 /id} elicited a 
family history of abnormalities in 33% of their 145 patients with microtia with or 
without hemifacial microsomia. Rollnick and Kaye presented pedigree data on 97 
propositi, 44 (45%) of whom had a family history of affected relatives. Although the 
proportion of patients with an affected relative appears much greater in Rollnick and 
Kaye’s series than in our own, the difference may be mitigated by their recording of 
more extensive family histories. A comparison of the frequencies of affected first, 
second and third degree relatives reveals a much greater similarity between the two 
groups. In total the frequencies of affected first, second and third degree relatives in our 
series were 6.1%, 4.6% and 1.9% respectively, and these figures are similar to the 8%, 
3% and 1% reported by Rollnick and Kaye. A more detailed examination of the data 
presented by Rollnick and Kaye also shows that their criteria for classifying a relative as 
affected are quite broad. They considered a relative to be affected if he or she had
116hemifacial microsomia, isolated microtia, and/or unilateral mandibular hypoplasia, but 
they also included relatives who were reported to have preauricular skin tags or pits, 
cleft lip and/or palate, “crumpled” helix, “thin” pinna, large “pointed” ears, and early 
on-set hearing loss before the age of 20.
Okajima et al {Okajima, Takeichi, et al 1996 123 /id} recorded data on 592 patients 
with microtia, including six patients with Treacher-Collins syndrome; 15 of these 
patients (2.5%) had relatives with ear malformations. This percentage is lower than that 
in our series of patients, in which 7 of the 95 patients with hemifacial microsomia (7%) 
had relatives with ear malformations, and 10 of the 166 patients with microtia (6%) had 
a family history of ear abnormalities. Aase {Aase, 1980 127 /id} reported 11 familial 
cases (9.5%) amongst 116 individuals with microtia in New Mexico. A review of 92 
paediatric patients with auricular malformations, amongst whom there were 72 microtic 
ears {Eavey 1995  124 /id}, yielded a family history of external ear anomalies in 9 cases 
(10%).
1174.9  Bleeding in pregnancy
The rate of gestational bleeding in our total population of 261 patients was 19% (50 
patients, 95% Cl 14% to 24%) which is not significantly different to rates reported in 
studies of general maternity populations. Strobino and Pantel-Silverman {Strobino & 
Pantel-Silverman 1989 92 /id} noted that vaginal bleeding occurred at sometime during 
pregnancy in 22% of 3,531 women, and a survey of 17000 British births in 1970 
reported a similar incidence (21.7%). A higher rate of gestational bleeding might have 
been expected in our study; Omoy et al {Omoy, Benady, et al 1976 210 /id} reported 
rates of bleeding during pregnancy of 33% and 29%, in patients with either congenital 
abnormalities of the central nervous system, or congenital abnormalities of other 
systems respectively.
The overall incidence of bleeding at anytime during pregnancy reported by mothers of 
patients with hemifacial microsomia was 32% (95% Cl 22%-41%) and most of these 
patients’ mothers recalled bleeding during the first trimester of their affected 
pregnancies, (28%, 95% Cl 19% to 37%), which contrasts with generally reported rates 
of bleeding during the first trimester that range between 7% (Sipila, Hartikainen-Sorri, 
et al 1992 91 /id} and 12% {Williams, Mittendorf, et al 1991  128 /id}. A prospective 
survey of 550 pregnant, normal women in Hampshire recorded a 21% incidence of 
bleeding in the first 20 weeks of pregnancy, though 67 (12%) of these pregnancies 
ended in miscarriage; thus, the incidence of bleeding in those pregnancies who had a 
live birth would have been 9% (95% Cl 6.7% to 11.5%){Everett 1997 129 /id}. The
118possibility of an increased rate of early gestational bleeding in association with 
hemifacial microsomia is of interest in view of the vascular and hemorrhagic 
aetiological theories that have been mentioned above.
4.10  Incidence of Twinning
The rate of twinning in England and Wales is 1.4% {Macfarlane, Mugford, et al 2000 
147 /id}. The rates of twinning in our populations were 6.3% (n=6, 95% Cl 1.4% to 
11.2%) and 4.8% (n=8, 95% Cl 1.6% to 8.1%) in the hemifacial microsomia group and 
microtia group respectively. Only the proband was affected in each pair of twins 
identified in our study. Literature reports of discordance and concordance amongst twin 
pairs have been discussed in section 1.6.2. Overall, the concordance rate for 
monozygotic twins for hemifacial microsomia is nearly 20%. For most malformations 
or malformation complexes the concordance in monozygotic twins is usually in the 
range of 10%-20% (Schinzel, Smith, et al 1979 89 /id}. The higher concordance rate 
found in monozygotic twins compared to dizygotic twins that has been recorded in 
hemifacial microsomia can be taken as evidence of a genetic contribution. However, the 
concordance rate for monozygotic twins for hemifacial microsomia is well below 50%, 
and may mean that environmental factors have a larger influence in the development of 
the phenotype. Similarly, Schinzel (Schinzel, Smith, et al 1979 89 /id} has suggested 
that the occurrence of discordance in monozygotic twins indicates that the disorder is
119the result of a single early localised malformation rather than a genetically 
predetermined syndrome.5. Results of genome scan5.1 Analysis of candidate loci
Previous work has tried to exclude potential candidate loci as the region containing the 
disease gene in family R (M. Bitner-Glindzicz and J. Tyson personal communication). 
Candidate loci were selected on the basis of the reported linkage of two separate 
families with hemifacial microsomia to chromosomes 8ql l-8ql3  {Graham, Hixon, et 
al. 1995 80 /id} and  14q32 (Kelberman, Tyson, et al. 2001 55 /id} respectively. In 
addition a putative locus on chromosome Ilql2-llql3 had been identified in an 
Australian family with hemifacial microsomia with a maximum multipoint lod score of
2.1  {Singer, Haan, et al 1994 53 /id} (personal communication J. Goldblatt). Individuals 
from whom DNA was available were genotyped for markers flanking and within the 
above loci. The two point lod scores obtained were not suggestive of linkage and 
multipoint lod scores for all three regions were less than  -2 (personal communication 
M. Bitner-Glindzicz and J. Tyson). Thus, linkage to all three regions was excluded in 
family R.
Simulation analysis of three fully informative markers in this family, with penetrance 
assumed to be 100% and with a disease gene frequency of 0.0002, suggested a 
maximum multipoint lod score in excess of 4 was achievable. Therefore, a genome wide 
search for linkage was performed to identify the disease locus.
1225.2 Genome search
Individuals from family R for whom DNA was available were genotyped using the 
microsatellite markers comprising the Research Genetics screening set version 8.0, with 
an average density across the entire genome of approximately lOcM.
5.2.1  Two point linkage analysis
For each marker with which family R was genotyped, two point lod scores were 
calculated using the MLINK program from the LINKAGE software package 
(www.hgmp.mrc.ac.uk). Initially the analysis was performed using data from all the 
individuals (both affecteds and unaffecteds) who had been successfully genotyped. In 
order to overcome potential problems arising from the possibility of reduced penetrance 
the analysis was then repeated with the unaffected individuals IV: 10, V:6 and VI:2 
classed as genotype unknown, so that only affected individuals were included in the 
analysis. The two sets of two point lod scores produced by these two analyses are shown 
in tables 12 to 33.
The initial pedigree data we obtained indicated that individual V:7 was not affected for 
hemifacial microsomia. At the start of the project further details received from Dr 
Robert Gorlin mentioned that individual V:7 had preauricular skin tags and it was
123therefore assumed that he was affected. The MLINK lod scores were calculated on this 
basis, and individual V:7’s genotyping data was included in the affecteds only analysis. 
However, subsequent reassessment of this individual’s phenotype has cast some doubt 
as to his affection status. He had been bom with a single pre-auricular skin tag that was 
removed in childhood, and displayed no sign of facial asymmetry or any other feature of 
hemifacial microsomia (M. Bitner-Glindzicz personal communication). In order to 
determine what difference a change in the affection status of individual V:7 would make 
on the results of the lod score analysis, the GENEHUNTER version 2 software 
(www.hgmp.mrc.ac.ukl was used to recalculate two point lod scores for the same set of 
markers that were analysed with MLINK, but with the affection of individual V:7 
classed as unknown. The results of this analysis are also included in tables 12 to 33. Due 
to the memory constraints of the software used, just the affecteds only analysis was 
repeated with the GENEHUNTER program. The GENEHUNTER program only 
produces a single value for each marker at a recombination fraction of zero.
Table 11 summarises the results of the genome scan, highlighting the markers for which 
the highest two point lod scores were achieved. Tables 12 to 33 contain all of the results 
from the three sets of two point lod scores: the MLINK analysis of affecteds and 
unaffecteds (with V:7 classed as affected), the GENEHUNTER analysis of affecteds 
only (with V:7 classed as affection unknown), and the MLINK analysis of affecteds 
only (with V:7 classed as affected).
124Table 11.  Summary of notable two point lod score results.
(recombination fraction (0)=O unless otherwise stated)
Marker name Chromosomal band 
identifier
Maximum Two Point 
Lod Score 
MLINK analyses, 
either all individuals 
or affecteds only 
(V:7 affected)
Maximum Two Point 
Lod Score 
GENEHUNTER 
analysis, affecteds 
only 
(V:7 unknown)
D5S1471 5q34 -5q35 3.18 3.18
D3S4531 3q25 2.34 (0=0.1) 2.86
D5S1470 5pl4 2.17 1.87
D11S2359 1  lq25 1.86 1.87
D13S895 13q34 2.82 1.83
D2S1370 2q32 -  2q37 1.56 1.67
D8S1985 8q24 1.02 (0=0.1) 1.68
D16S749 16pl2 1.34 1.34
D3S2403 3p25 1.89 (0=0.1) -2.39
D8S1459 8q22 1.51 0.92
D10S1427 10q22 1.51 (0=0.1) -2.38
125Table 12.  Chromosome 1  two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D1S2132 4.4 -infinity -0.01 0.16 0.13 0.07 -infinity -infinity 0.43 0.35 0.19 0.06 1
D1S1612 7.2 -infinity -2.11 -0.97 -0.42 -0.13 -infinity -infinity -1.35 -0.52 -0.16 -0.02 2
ATA9B08 7.6 -infinity -1.98 -0.86 -0.36 -0.12 -infinity -infinity -1.36 -0.54 -0.21 -0.06 3
D1S1597 7 -infinity -0.13 0 0.23 0.12 -infinity -infinity -0.87 -0.34 -0.14 -0.05 4
D2S1368 8.8 0.91 0.64 0.39 0.2 0.07 0.91 0.91 0.64 0.39 0.2 0.07 5
D1S552 7.1 -infinity -0.9 -0.39 -0.17 -0.06 -3.46 -3.46 -0.31 -0.13 -0.06 -0.02 6
D1S1676 4.9 -6.27 -0.49 -0.15 -0.05 0.02 -6.57 -6.57 -0.54 -0.18 -0.06 -0.02 7
D1S1622 5.6 -5 -0.17 0.13 0.17 0.11 -6.40 -6.13 -0.33 -0.03 0.03 0.03 8
GATA137F01 11.9 -infinity -0.59 0 0.13 0.09 -infinity -infinity -0.92 -0.26 -0.04 0.01 9
GATA129H04 3.4 -infinity 0.79 0.77 0.53 0.27 -infinity -infinity 0.06 0.23 0.2 0.11 10
D1S2134 10.3 -infinity -1.34 -0.5 -0.16 -0.02 -infinity -infinity -1.62 -0.74 -0.34 -0.12 11
D1S1150 8 -infinity -1.59 -0.56 -0.18 -0.05 -infinity -infinity -2.21 -0.104 -0.49 -0.19 12
GATA165C03 9.4 -1.27 1.04 0.66 0.21 -0.08 -2.17 -1.27 1.04 0.66 0.21 -0.08 13
D1S1613 5.4 -infinity -1.05 -0.34 -0.11 -0.05 -infinity -infinity -1.75 -0.83 -0.4 -0.15 14
D1S1630 6.1 -2.38 -0.18 0.02 0.01 -0.03 -2.68 -2.68 -0.34 -0.05 0 -0.01 15
D1S1665 8.7 -2.32 0.37 0.31 0.16 0.04 -2.56 -2.56 0.07 0.08 0.04 0 16
D1S1728 2.9 -infinity -1.13 -0.43 -0.17 -0.06 -infinity -infinity -1.46 -0.64 -0.27 -0.09 17
D1S551 5.1 -infinity 0.63 0.54 0.34 0.15 -infinity -infinity 0.12 0.13 0.06 0.01 18Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D1S2129 3.5 -infinity -0.23 0.05 0.07 0.04 -2.09 -1.79 0.7 0.5 0.25 0.07 19
D1S1588 10.8 -infinity -0.95 -0.42 -0.17 -0.05 -infinity -3.51 -0.27 -0.02 0.03 0.02 20
GATA45B07 7.4 -7.39 -1.1 -0.48 -0.19 -0.05 -6.67 -6.67 -0.7 -0.27 -0.09 -0.02 21
D1S1631 2.8
GATA176G01 7.2 -infinity -0.62 0.2 0.15 0.09 -infinity -infinity -0.62 0.02 0.15 0.09 22
D1S1191 8.8 -infinity -0.41 -0.17 -0.07 -0.02 0.33 0.33 0.2 0.11 0.06 0.02 23
D1S534 10.8 -infinity -2.37 -1 -0.39 -0.1 -infinity -infinity -1.51 -0.67 -0.31 -0.12 24
D1S1653 7.1 -3.89 0.42 0.48 0.33 0.14 -2.74 -2.74 0.98 0.81 0.52 0.22 25
D1S1679 4 -infinity -1.1 -0.33 -0.07 0.01 -infinity -7.24 -0.63 -0.33 -0.2 -0.1 26
D1S1677 4
D1S1625 11.6 -infinity -0.21 -0.03 0.02 0.03 -infinity 0.44 0.45 0.31 0.17 0.06 27
D1S1589 10.3 -infinity -0.71 -0.07 0.09 0.08 -infinity -infinity -0.32 0.08 0.11 0.05 28
D1S518 8.3 -infinity -2.38 -1 -0.39 -0.1 -infinity -infinity -1.85 -0.87 -0.41 -0.16 29
D1S1660 6.3 -infinity 0.03 0.35 0.3 0.14 -infinity -infinity 0.23 0.36 0.26 0.11 30
D1S1678 10.4 0.49 0.42 0.24 0.06 -0.03 0.43 0.43 0.23 0.04 -0.07 -0.06 31
GATA124F08 8.3 -infinity 0.53 0.76 0.59 0.29 -0.80 -0.8 1.54 1.2 0.75 0.32 32
D1S2141 14.3 -2.01 0.31 0.35 0.26 0.12 -2.31 -2.31 0.05 0.16 0.13 0.06 33
D1S549 11.2
D1S3462 25.5 -infinity -1.35 -0.47 -0.15 -0.03 -infinity -infinity -1.85 -0.86 -0.4 -0.15 34
D1S547 7.4 -2.33 0.55 0.64 0.5 0.28 -3.21 -1.44 0.69 0.61 0.43 0.21 35
D1S1609Table 13.  Chromosome 2 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
GATA165C07 7.8 0.35 0.24 0.14 0.07 0.03 0.39 0.71 0.46 0.25 0.11 0.04 1
D2S1780 9.1 -2.1 0.43 0.43 0.32 0.17 -2.35 -2.35 0.21 0.26 0.2 0.11 2
GATA116B01 11.7 -infinity 0.79 0.63 0.4 0.18 1.07 -infinity 0.06 0.09 0.05 0.03 3
D2S1400 9.4 -infinity 0.13 0.32 0.26 0.13 -2.67 -2.37 0.26 0.23 0.14 0.05 4
D2S1360 10 -infinity -0.2 0.17 0.19 0.11 -1.44 -1.14 0.97 0.81 0.53 0.24 5
D2S405 9.8 -infinity 0.16 0.31 0.2 0.05 -2.36 -1.82 0.36 0.32 0.19 0.06 6
D2S1788 5.7 -5.27 0.46 0.55 0.39 0.17 -6.49 -5.98 -0.11 0.12 0.12 0.06 7
D2S1346 5.8 -5.71 0.15 0.35 0.3 0.16 -6.61 -6.31 -0.35 -0.03 0.06 0.06 8
D2S1356 10.6 -6.52 -0.72 -0.32 -0.2 -0.13 -7.43 -7.13 -1.04 -0.46 -0.22 -0.09 9
D2S2739 4 -4.69 0.94 0.9 0.61 0.27 -5.91 -5.64 0.17 0.33 0.27 0.14 10
D2S1337 8.3 -infinity -0.43 0.02 0.1 0.06 -1.75 -1.45 0.71 0.6 0.39 0.17 11
D2S441 11 -2.78 0.4 0.4 0.28 0.14 -3.10 -2.68 0.42 0.38 0.26 0.13 12
D2S1774 4.5 -infinity -1.27 -0.75 -0.44 -0.2 -7.93 -7.93 -0.74 -0.34 -0.15 -0.05 13
D2S2733 5.2 -infinity 0.44 0.54 0.37 0.14 -infinity -infinity 1.14 0.94 0.59 0.24 14
D2S1790 9.3 -infinity -1.41 -0.64 -0.28 -0.1 -3.07 -infinity -0.94 -0.39 -0.16 -0.04 15
GATA176C01 4.5 -infinity -1.63 -0.65 -0.25 -0.07 -infinity -infinity -0.72 -0.19 -0.01 0.03 16
D2S436 8.5 -infinity -1.03 -0.5 -0.28 -0.13 -infinity -infinity -1.43 -0.68 -0.31 -0.11 17
D2S410 8.7 -infinity -1.35 -0.46 -0.13 -0.02 -infinity -infinity -1.41 -0.65 -0.31 -0.12 18Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D2S1328 11.5 -infinity -1.2 -0.41 -0.09 0.02 -8.42 -8.42 -1.06 -0.44 -0.17 -0.05 19
D2S1334 4.6 -infinity -0.9 -0.22 -0.04 -0.02 -infinity -infinity -1.72 -0.82 -0.4 -0.17 20
D2S442 7.2 -10.14 -0.77 -0.19 0.01 0.05 -10.44 -10.44 -1.03 -0.39 -0.13 -0.03 21
D2S1399 12.3 -infinity -0.93 -0.38 -0.18 -0.09 -2.70 -6.8 -0.42 -0.13 -0.05 -0.03 22
D2S1353 13.3 -infinity 0.67 0.53 0.31 0.11 1.51 1.51 1.12 0.73 0.4 0.15 23
D2S1776 7 -infinity -0.44 0.11 -0.01 0.01 -2.45 -infinity -0.65 -0.25 -0.09 -0.02 24
GATA194A05 11.5 -infinity 0.5 0.54 0.37 0.16 -7.17 -infinity -0.25 0.04 0.06 0.01 25
D2S1391 5.8 -infinity -0.06 0.13 0.11 0.05 -infinity -infinity -0.54 -0.22 -0.12 -0.06 26
D2S2735 8.3
D2S1384 12 -infinity 0.77 0.59 0.35 0.14 1.66 -infinity 0.53 0.43 0.25 0.1 27
D1S1649 6.3 -infinity 0.51 0.45 0.3 0.15 1.22 -infinity 0.22 0.25 0.18 0.09 28
D2S434 9.3 0.77 0.58 0.38 0.2 0.07 1.19 1.19 0.88 0.58 0.32 0.13 29
D2S1363 4.9 -infinity -1.06 -0.41 -0.15 -0.04 -2.34 -infinity -0.62 -0.22 -0.08 -0.02 30
D2S1370 7.2 1.15 1.03 0.74 0.43 0.17 1.67 1.56 1.16 0.76 0.41 0.15 31
D2S427 10.4 -infinity -1.07 -0.52 -0.27 -0.11 1.13 -infinity 0.07 0.07 0.02 0 32
D2S1397 5.4 -infinity -0.07 0.16 0.16 0.08 -2.34 -2.04 0.26 0.26 0.16 0.07 33
GATA178G09 -infinity -1.21 -0.5 -0.19 -0.05 -2.78 -infinity -0.72 -0.29 -0.12 -0.03 34Table 14.  Chromosome 3 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D3S2387 8.5 -infinity -2.13 -0.94 0.42 -0.15 -infinity -infinity -1.39 -0.58 -0.25 -0.09 1
D3S3050 5.6 -infinity -0.08 0.22 0.2 0.1 -2.48 -2.48 0.36 0.36 0.19 0.07 2
D3S3030 10.2 -infinity -0.13 0.12 0.14 0.09 -infinity -infinity -0.63 -0.25 -0.11 -0.04 3
GATA164B08 8.5 -infinity -1.11 -0.47 -0.2 -0.07 -7.04 -6.74 -0.87 -0.39 -0.2 -0.09 4
D3S2403 8.4 -infinity 1.45 1.37 0.99 0.49 -2.39 -infinity 1.89 1.56 1.06 0.5 5
GATA140H01 4.5 -infinity -0.67 -0.09 0.1 0.11 -infinity -infinity -1.04 -0.34 -0.06 0.03 6
D3S3038 4.9 -3.16 -0.31 -0.13 -0.05 -0.01 -3.16 -3.16 -0.31 -0.13 -0.05 -0.01 7
D3S2466 7.5 -infinity -0.79 -0.26 -0.09 -0.03 -6.54 -infinity -1.27 -0.49 -0.17 -0.03 8
D3S2432 2.8 -infinity 0.66 0.7 0.52 0.28 -1.99 -infinity -0.08 0.14 0.16 0.1 9
D3S1768 11 -infinity 0.15 0.27 0.24 0.14 -infinity -infinity -0.11 0.06 0.09 0.07 10
D3S2409 7.6
D3S1766 9.8 -infinity -1.52 -0.64 -0.25 -0.06 -6.51 -infinity -1.04 -0.42 -0.17 -0.05 11
GATA148E04 10.5 -infinity -0.3 0.15 0.23 0.16 -infinity -infinity -0.55 -0.05 0.08 0.08 12
D3S2454 4.9 -infinity -0.56 -0.21 -0.06 0 -infinity -infinity -0.79 -0.36 -0.15 -0.04 13
D3S2406 8.5 -infinity -0.44 0.01 0.1 0.07 -infinity -infinity 0.26 0.41 0.32 0.17 14
D3S4529 7.5 -infinity -1.74 -0.67 -0.22 -0.03 -infinity -infinity -1.12 -0.34 -0.05 0.04 15
D3S2459 7 -infinity -0.98 -0.32 -0.09 -0.01 -infinity -infinity -0.81 -0.22 -0.03 0.02 16
D3S3045 9 -infinity -2.48 -0.106 -0.42 -0.11 -infinity -infinity -1.47 -0.54 -0.14 0.01 17Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D3S4018 5.7 -infinity -2.07 -0.89 -0.35 -0.09 -infinity -infinity -1.09 -0.39 -0.09 0.02 18
D3S2460 4.4 -infinity -1.23 -0.44 -0.13 -0.01 -infinity -infinity -0.76 -0.2 -0.01 0.04 19
ATA34G06 11 -infinity -1.08 -0.42 -0.15 -0.03 -infinity -infinity -0.88 -0.31 -0.1 -0.02 20
D3S4527 8.6 -infinity -0.88 -0.35 -0.13 -0.03 -6.61 -6.61 -0.46 -0.13 -0.03 -0.01 21
D3S1764 10.7 -infinity 0.16 0.31 0.24 0.12 -2.23 -infinity -0.01 0.19 0.17 0.08 22
D3S1744 7.6 -infinity -1.14 -0.45 -0.16 -0.03 -2.41 -infinity -0.7 -0.26 -0.09 -0.01 23
D3S4531 6.4 -infinity 2.34 1.8 1.12 0.45 2.86 -infinity 1.53 1.18 0.71 0.28 24
D3S1763 6.2 -infinity -1.49 -0.62 -0.24 -0.06 -6.36 -infinity -0.54 -0.13 0.01 0.04 25
D3S3053 8.4 -infinity -0.94 -0.27 -0.05 0.01 -3.46 -infinity -0.57 -0.11 0.01 0.02 26
D3S2427 14.6 -infinity -0.75 -0.09 0.09 0.09 -6.74 -infinity -0.51 -0.03 0.08 0.07 27
D3S2436 5.9 0.39 0.27 0.16 0.08 0.02 0.33 0.69 0.47 0.29 0.14 0.05 28
D3S2398 5.2 -infinity -0.65 -0.14 0 0.01 -7.16 -6.86 -0.26 0.1 0.16 0.11 29
D3S2418 9.5 1.41 1.04 0.7 0.4 0.16 0.81 1.11 0.79 0.5 0.27 0.1 30
D3S3054 -infinity -0.77 -0.21 -0.02 0.01 -infinity -infinity -0.31 0.01 0.09 0.07 31Table 15.  Chromosome 4 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D4S2366 16.7 -infinity -1.43 -0.68 -0.33 -0.13 -7.17 -infinity -0.89 -0.34 -0.13 -0.04 1
D4S2639 3.4 -infinity 0.67 0.69 0.49 0.24 -1.62 -1.59 0.9 0.73 0.47 0.21 2
GATA158G03 6.7 -infinity -0.4 0.09 0.19 0.15 -2.32 -infinity -0.08 0.16 0.17 0.1 3
D4S2397 3
D4S3244 6.8 -infinity 0.08 0.11 0.07 0.03 -infinity -infinity -0.18 -0.09 -0.08 -0.05 4
D4S2632 13.5 -infinity -0.54 -0.16 -0.03 0 -infinity -infinity -1 -0.48 -0.24 -0.1 5
D4S1627 6.7 -infinity 0.31 0.41 0.28 0.13 -infinity -infinity 0.06 0.23 0.17 0.08 6
D4S2379 4.2 -infinity -0.23 0.16 0.19 0.1 -infinity -infinity -0.84 -0.31 -0.13 -0.06 7
D4S1645 3.6 -infinity -1.47 -0.64 -0.28 -0.1 -3.42 -infinity -1.09 -0.55 -0.29 -0.12 8
D4S2432 3.9 -infinity -0.93 -0.25 -0.03 0.03 -6.77 -infinity -1.12 -0.44 -0.17 -0.05 9
D4S2367 5.1 -infinity 0.08 0.24 0.18 0.09 -infinity -infinity -0.41 -0.14 -0.07 -0.04 10
D4S3249 7.1
D4S3243 3.6 -3.25 -0.77 -0.29 -0.09 -0.01 -2.85 -2.85 -0.56 -0.18 -0.04 0 11
D4S2361 9.6 -infinity -1.94 -0.81 -0.31 -0.08 -infinity -infinity -1.85 -0.87 -0.39 -0.14 12
D4S2433 6.8 -infinity -0.39 0.02 0.07 0.02 -infinity -infinity -1.11 -0.51 -0.25 -0.1 13
D4S1647 8.8 -infinity -0.75 -0.27 -0.14 -0.09 -infinity -infinity -1.26 -0.62 -0.33 -0.15 14
D4S2623 16.8 -1.59 0.56 0.66 0.49 0.24 -2.50 -2.19 0.05 0.25 0.22 0.12 15
D4S2394 10.7 -10.35 -0.68 -0.1 0.08 0.1 -10.65 -10.65 -0.94 -0.31 -0.06 0.02 16Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D4S1644 5.8 -infinity -0.84 -0.26 -0.06 0 -infinity -infinity -0.45 -0.11 -0.02 -0.01 17
D4S1625 18.1 -infinity -0.94 -0.22 0 0.03 -infinity -infinity -0.85 -0.32 -0.13 -0.05 18
D4S1629 9 -infinity -0.86 -0.25 -0.05 -0.01 -infinity -infinity -1.37 -0.63 -0.3 -0.12 19
D4S2368 7.5 -infinity -0.67 -0.18 -0.03 0.01 -infinity -infinity -0.24 -0.01 0 -0.02 20
D4S2431 8.1 -infinity -1.13 -0.51 -0.25 -0.1 -infinity -infinity -1.23 -0.59 -0.3 -0.13 21
D4S2417 8 -2.44 0.04 0.14 0.1 0.03 -3.04 -2.74 -0.22 -0.05 -0.01 0 22
D4S2374 12.1 -infinity -2.45 -1.08 -0.48 -0.18 -infinity -infinity -1.54 -0.67 -0.29 -0.1 23
D4S3335 16.72 -infinity -2.55 -1.31 -0.66 -0.26 -infinity -infinity -1.27 -0.62 -0.32 -0.14 24
D4S2390 -infinity -0.97 -0.34 -0.11 -0.03 -2.86 -infinity -0.59 -0.2 -0.07 -0.02 25Table 16.  Chromosome 5 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D5S2488 4.9 -infinity -0.98 -0.32 -0.08 0.01 -2.54 -2.24 -0.05 -0.03 -0.04 -0.02 1
GATA145D10 10.2 -infinity -2.14 -0.78 -0.22 0 -infinity -infinity -2 -0.88 -0.37 -0.12 2
D5S2505 6.7 -infinity -1.53 -0.65 -0.25 -0.06 -infinity -infinity -1.13 -0.54 -0.27 -0.11 3
D5S807 5 -infinity -1.02 -0.31 -0.08 -0.01 -infinity -infinity -1 -0.42 -0.19 -0.08 4
D5S817 16.7 1.05 0.78 0.52 0.28 0.09 0.45 0.75 0.53 0.33 0.16 0.05 5
D5S1473 4.7 -infinity -1.81 -0.78 -0.3 -0.08 -infinity -infinity -1.23 -0.57 -0.27 -0.1 6
GATA145D09 7.4 0.67 0.54 0.38 0.23 0.09 -1.29 0.07 0.03 -0.01 -0.03 -0.02 28
D5S1470 5.1 -infinity 0.51 0.54 0.35 0.14 1.87 2.17 1.63 1.1 0.61 0.23 7
D5S2843 10.2 -infinity -0.16 0.07 0.07 0.02 -2.83 -2.53 -0.06 0.06 0.05 0.01 8
D5S1457 9.4 -infinity -1.07 -0.51 -0.29 -0.15 -infinity -infinity -0.62 -0.3 -0.17 -0.08 9
D5S2507 3.5 -infinity -1.16 -0.41 -0.14 -0.05 -infinity -infinity -0.27 0.01 0.05 0.03 10
D5S2500 18.6 -infinity -1.6 -0.7 -0.32 -0.13 -infinity -infinity -1.15 -0.5 -0.22 -0.08 11
D5S806 13.7 -1.51 0.99 0.8 0.52 0.23 -2.65 -2.04 0.54 0.45 0.29 0.13 12
D5S1459 3.2 -2.67 -0.25 -0.07 -0.02 0 -2.67 -2.67 -0.25 -0.07 -0.02 0 13
D5S1725 6.8 -6.06 -0.26 0.08 0.14 0.07 -6.96 -6.66 -0.77 -0.31 -0.13 -0.05 14
D5S1462 8.3 -1.47 0.8 0.66 0.41 0.16 -1.77 -1.77 0.54 0.45 0.26 0.08 15
D5S1453 2.3 -infinity 0.22 0.21 0.13 0.06 0.96 0.96 0.61 0.33 0.13 0.03 16
D5S2501 5.3 -infinity -1.94 -0.72 -0.25 -0.06 -8.91 -8.61 -1.38 -0.57 -0.25 -0.11 17Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
GATA130E01 5.6 -infinity 0.2 0.35 0.28 0.15 -2.21 -1.72 0.63 0.52 0.31 0.13 18
D5S1505 4.1 -infinity -0.16 0.2 0.19 0.08 -6.01 -5.7 -0.01 0.15 0.1 0.02 19
D5S1495 6.6 -infinity 0.69 0.55 0.35 0.15 1.26 1.56 1.12 0.71 0.38 0.14 20
D5S816 9.5 -infinity -0.29 -0.03 0.02 0.01 -2.54 -2.24 0.36 0.29 0.15 0.04 21
D5S1480 12.8 -2.95 -0.13 0 0.02 0.01 -2.99 -2.99 -0.18 -0.04 -0.01 -0.01 22
D5S820 6.7 -infinity -0.17 0.28 0.32 0.19 -1.92 -1.62 0.41 0.55 0.43 0.22 23
D5S1465 7.6 -infinity -1.36 -0.54 -0.2 -0.05 -2.49 -2.19 0.28 0.24 0.12 0.03 24
D5S1471 4.7 -infinity 1.87 1.51 1 0.46 3.18 3.18 2.56 1.91 1.22 0.55 25
D5S1456 2.4 -infinity -0.79 -0.23 -0.04 0.02 0.79 -2.83 -0.06 0.02 0 -0.02 26
D5S1713 -infinity 1.37 1.08 0.68 0.3 2.63 2.63 2.06 1.47 0.89 0.38 27Table 17.  Chromosome 6 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D6S1955 8.6 -7.37 -1.11 -0.57 -0.3 -0.13 -7.27 -7.27 -0.57 -0.21 -0.08 -0.02 1
D6S1279 6.6 -6.75 -0.56 -0.14 -0.02 0 -6.21 -6.51 -0.16 0.09 0.11 0.06 2
D6S1034 12.4 -6.5 -0.49 -0.12 -0.02 -0.01 -6.29 -6.29 -0.41 -0.08 0.01 0.02 3
D6S1959 3.1
D6S1266 8.3 -infinity -1.02 -0.4 -0.14 -0.03 -6.91 -6.91 -0.32 0 0.08 0.07 4
GATA163B10 5.8 -infinity -1.75 -0.66 -0.2 -0.02 -infinity -infinity -0.37 0.11 0.21 0.15 5
D9S1126 4.8 -infinity 1.01 0.96 0.67 0.31 -0.98 -infinity 0.25 0.38 0.28 0.13 6
GGAA15B08 8 -infinity -0.79 -0.26 -0.09 -0.04 -6.15 -6.15 -0.35 -0.06 0.01 0.01 7
D6S1017 13.6 -infinity -1.6 -0.98 -0.69 -0.38 -2.30 -6.98 -0.48 -0.17 -0.08 -0.05 8
GATA11E02 8.8 -8.55 -1.37 -0.55 -0.19 -0.03 -6.12 -6.12 -0.13 0.17 0.2 0.12 9
D6S1053 6.4 -10.78 -1.29 -0.56 -0.24 -0.09 -11.38 -11.08 -1.24 -0.58 -0.29 -0.12 10
D6S1031 5.6 -infinity 0.17 0.36 0.31 0.18 -infinity -infinity -0.05 0.18 0.19 0.11 11
D6S1270 7.5 0.57 0.38 0.22 0.1 0.03 0.57 0.57 0.38 0.22 0.1 0.03 12
D6S1043 3.3 -infinity -0.24 0.01 0.04 0.02 -infinity -infinity 0.31 0.28 0.17 0.07 13
D6S1056 2.7 -infinity -0.62 -0.13 0.02 0.05 -infinity -infinity -0.66 -0.13 0.04 0.06 14
D6S1284 5.8 -2.87 -0.02 0.09 0.07 0.04 -2.37 -2.34 0.34 0.32 0.21 0.1 15
D6S1021 10.3 -infinity 0.61 0.49 0.3 0.12 -2.97 -2.79 0.42 0.34 0.19 0.07 16
D6S474 8.1 -infinity -0.44 -0.03 0.03 0.01 -infinity -infinity -0.47 -0.16 -0.06 -0.02 17Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D6S1958 3 0.51 0.46 0.32 0.18 0.07 0.98 0.98 0.7 0.44 0.22 0.08 18
D6S1040 7.2 -infinity -1.21 -0.45 -0.17 -0.05 -infinity -infinity -0.4 -0.11 -0.04 -0.02 19
D6S1009 7.3 -infinity -0.52 -0.09 0.01 0.02 -infinity -infinity -0.27 -0.01 0.04 0.02 20
D6S1003 2.2 -3.38 -0.39 -0.15 -0.05 -0.01 -2.96 -2.96 -0.17 -0.04 -0.01 0 21
GATA184A08 9.1 -infinity -1.95 -0.82 -0.32 -0.08 -infinity -infinity -0.15 0.09 0.11 0.07 22
GATA165G02 13.8 -infinity -0.32 0.24 0.29 0.17 -infinity -7.22 0.85 0.89 0.66 0.33 23
D6S1008 3.9 -infinity -0.49 -0.01 0.1 0.07 -infinity -6.51 -0.44 -0.08 0.01 0.01 24
D6S1273 3.1 -infinity -0.82 -0.34 -0.13 -0.03 -infinity -infinity -0.99 -0.43 -0.17 -0.04 25
D6S1277 8.5 -infinity -1.56 -0.73 -0.34 -0.13 -infinity -3.23 -0.46 -0.28 -0.16 -0.08 26
D6S392 9.5 -infinity -0.53 -0.09 0.01 0.03 -infinity -1.66 0.86 0.69 0.43 0.18 27
D6S1027 -infinity -0.99 -0.28 -0.06 0.01 -infinity -infinity -0.62 -0.15 -0.01 0.02 28Table 18.  Chromosome 7 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D7S1819 6.7 -1.72 0.51 0.47 0.33 0.16 -2.02 -2.02 0.26 0.27 0.18 0.08 1
D7S2201 8 -3.05 -0.36 -0.18 -0.11 -0.06 -2.83 -2.83 -0.03 0.05 0.04 0.02 2
D7S3047 14.4
GATA137H02 3.1 -infin ty -0.59 -0.1 0.03 0.03 -6.70 -6.4 -0.46 -0.1 -0.01 0 3
D7S1802 8.2 -infin ty 0.03 0.16 0.11 0.05 -2.93 -2.9 0.53 0.41 0.23 0.08 4
GATA124D01 9.5 -infin ty -1.53 -0.55 -0.19 -0.05 -5.69 -5.39 0.25 0.36 0.25 0.1 5
D7S1808 6.6 -infin ty -1.12 -0.51 -0.27 -0.14 -3.37 -3.07 -0.18 -0.03 -0.02 -0.04 6
D7S817 7.9 -infin ty -2.55 -0.131 -0.68 -0.28 -infinity -infinity -1.43 -0.76 -0.43 -0.2 7
D7S2846 5.4 -infin ty -1.17 -0.42 -0.15 -0.04 -infinity -infinity -0.09 0.1 0.09 0.05 8
D7S3043 11.3 -infin ty -1.69 -0.8 -0.39 -0.16 -infinity -infinity -1.3 -0.62 -0.3 -0.12 9
D7S1818 9.5 -infin ty -0.08 0.2 0.23 0.15 -2.78 -infinity -0.78 -0.3 -0.11 -0.03 10
GATA118G10 7.8 -infin ty -1.89 -0.79 -0.31 -0.09 -infinity -infinity -2.09 -0.96 -0.44 -0.16 11
D7S1816 5.7 -infin ty -1.76 -0.89 -0.45 -0.17 -infinity -infinity -1.74 -0.8 -0.36 -0.13 12
D7S2204 8.3 -2.6 0.07 0.14 0.1 0.05 -2.24 -2.24 0.33 0.32 0.21 0.1 13
D7S820 6.5 -infinity -2.88 -1.4 -0.68 -0.26 -infinity -infinity -1.43 -0.62 -0.28 -0.11 14
D7S1813 6.2 -infinity -2.14 -1.1 -0.57 -0.23 -infinity -infinity -1.44 -0.71 -0.35 -0.13 15
D7S821 5.5 -infinity -1.69 -0.96 -0.61 -0.34 -infinity -infinity -1.19 -0.52 -0.26 -0.15 16
D7S1799 8.8 -infinity -1.16 -0.5 -0.22 -0.08 -2.45 -infinity -0.73 -0.3 -0.12 -0.04 17Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D7S1817 7.4 -infinity -0.12 0.12 0.12 0.05 -2.62 -2.32 0.19 0.2 0.12 0.04 18
GGAA6D03 10.5 -infinity 0.78 0.66 0.41 0.17 -infinity -infinity 0.89 0.71 0.43 0.18 19
D7S1804 6.7 -infinity -2.99 -1.48 -0.72 -0.28 -infinity -infinity -1.63 -0.75 -0.36 -0.14 20
D7S1837 12.1 -infinity -0.92 -0.36 -0.15 -0.06 -5.81 -5.81 -0.22 0.03 0.07 0.04 21
D7S1824 5.1 -infinity -2.38 -1.15 -0.55 -0.2 -infinity -infinity -1.23 -0.56 -0.25 -0.09 22
D7S2195 3.4 -infinity -0.98 -0.29 -0.09 -0.05 -infinity -infinity 0.38 0.47 0.32 0.12 23
D7S2208 9.3 -infinity -0.83 -0.34 -0.19 -0.11 -infinity -infinity -0.95 -0.43 -0.22 -0.1 24
D7S1798 1.4 -infinity -0.69 -0.28 -0.1 -0.02 -2.98 -infinity -0.68 -0.27 -0.1 -0.02 25
GATA189C06 8.2 -infinity -0.91 -0.35 -0.14 -0.05 -infinity -infinity -0.55, -0.19 -0.06 -0.02 26
D7S1807 4
D7S1823 -infinity -1.93 -0.8 -0.29 -0.07 -3.05 -infinity -1.34 -0.55 -0.2 -0.04 27Table 19.  Chromosome 8 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D8S1469 9 -infinity 0.18 0.36 0.31 0.17 -1.86 -infinity -0.29 0.01 0.07 0.05 1
D8S1130 5.6 -infinity 0.4 0.5 0.37 0.19 -1.44 -infinity -0.01 0.19 0.18 0.09 2
D8S1106 6 -infinity 0.58 0.62 0.42 0.17 -1.64 -infinity -0.09 0.14 0.13 0.06 3
D8S1145 15.4 0.94 0.67 0.43 0.24 0.09 0.68 0.69 0.44 0.24 0.1 0.03 4
D8S1989 14.1 -infinity 0.26 0.33 0.22 0.1 -2.60 -infinity -0.24 0.02 0.05 0.03 5
D8S1477 4.3 -infinity 0.17 0.31 0.23 0.1 -infinity -infinity -0.09 0.11 0.09 0.03 6
D8S1104 2.9 -1.85 0.74 0.64 0.43 0.2 -2.46 -2.16 0.49 0.44 0.3 0.14 7
D8S1110 7.1
D8S593 6
D8S1113 7.3 -infinity 0.47 0.53 0.36 0.15 -2.20 -1.9 0.65 0.51 0.29 0.11 8
D8S1136 4.8 -3.32 -0.41 -0.09 -0.03 -0.02 -1.93 -2.67 -0.21 0.04 0.07 0.03 9
D8S2323 8 -infinity -0.5 -0.12 -0.05 -0.04 -2.56 -2.26 -0.23 0.02 0.05 0.03 10
GATA14E09 4.9 -infinity -1.34 -0.66 -0.33 -0.14 -infinity -infinity -0.55 -0.2 -0.07 -0.02 11
D8S1475 5.6
D8S1119 4.5 -infinity -1.05 -0.48 -0.25 -0.11 -infinity -infinity -0.31 -0.07 -0.04 -0.03 12
D8S1988 5.5 -2.12 0.51 0.45 0.29 0.13 -2.72 -2.42 0.26 0.25 0.16 0.07 13
GAAT1A4 9.5 -infinity -0.78 -0.28 -0.13 -0.06 -infinity -infinity -1.09 -0.45 -0.18 -0.05 14
D8S1459 4.4 1.51 1.13 0.76 0.43 0.17 0.92 1.22 0.88 0.57 0.31 0.12 15Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D8S1470 2 -infinity r  -0.08 0.26 0.23 0.11 -infinity -infinity 0.37 0.46 0.32 0.14 16
D8S1471 1.3 -infinity -1.92 -0.91 -0.44 -0.17 -infinity -infinity -0.97 -0.39 -0.17 -0.06 17
D8S592 3 -infinity -1.39 -0.6 -0.3 -0.15 -infinity -infinity -0.94 -0.39 -0.19 -0.09 18
D8S1142 3.5
D8S586 10.9 -infinity -1.35 -0.72 -0.38 -0.15 -infinity -infinity -0.5 -0.2 -0.1 -0.05 19
D8S568 3.1 -9.96 -0.69 -0.23 -0.12 -0.07 -10.73 -10.43 -1.02 -0.43 -0.19 -0.07 20
D8S1179 5.5 -infinity -2.41 -1.23 -0.67 -0.31 -infinity -infinity -1.93 -0.97 -0.5 -0.21 21
D8S1128 4 -infinity -0.33 -0.11 -0.05 -0.03 -infinity -infinity -0.2 0.01 0.03 0.02 22
D8S1985 6 -infinity 1.02 0.77 0.44 0.16 1.68 -infinity 0.53 0.41 0.22 0.08 23
D8S1462 7.1 -infinity -0.73 -0.3 -0.12 -0.03 -2.86 -2.86 -0.03 0.1 0.11 0.07 24
D8S1100 1.16 0.83 0.54 0.3 0.12 0.10 0.76 0.5 0.3 0.15 0.06 25Table 20.  Chromosome 9 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
GATA62F03 9.7 -infinity -0.32 -0.04 0.02 0.02 -2.67 -2.55 -0.08 0.01 0.01 0 1
D9S921 12.4 -infinity -0.88 -0.08 0.15 0.14 -infinity -infinity -0.03 0.35 0.35 0.2 2
D9S925 12.4 -infinity 0.66 0.81 0.61 0.29 -2.04 -infinity 0.78 0.79 0.54 0.24 3
D9S932 3.8 -infinity -1.74 -0.74 -0.28 -0.07 -infinity -infinity -1.81 -0.85 -0.39 -0.13 4
D9S1121 9 -5.98 0.02 0.19 0.14 0.05 -1.90 -1.85 0.31 0.27 0.15 0.04 5
D9S304 1.7 -infinity -2.06 -0.87 -0.33 -0.08 -infinity -infinity -1.61 -0.73 -0.32 -0.11 6
D9S1118 9.2 -infinity -2.05 -0.9 -0.37 -0.11 -infinity -infinity -1.88 -0.92 -0.46 -0.18 7
D9S301 1.4 -infinity -1.09 -0.51 -0.24 -0.09 -2.71 -infinity -0.51 -0.25 -0.15 -0.08 8
D9S1124 9.2 -10.73 -1.09 -0.39 -0.1 -0.01 -10.59 -10.59 -1.09 -0.43 -0.15 -0.03 9
D9S1122 4.6 -infinity -1.21 -0.54 -0.24 -0.09 -6.86 -infinity -0.75 -0.3 -0.11 -0.03 10
D9S922 1.1 -infinity -0.52 -0.04 0.09 0.08 -1.81 -infinity -0.28 0 0.05 0.03 11
D9S303 3.2 -infinity -1.04 -0.4 -0.14 -0.03 -infinity -infinity -1.5 -0.74 -0.36 -0.14 12
D9S1119 7.7 -infinity -0.37 -0.09 0 0.02 -infinity -infinity -0.85 -0.44 -0.23 -0.1 13
D9S252 7.3 -infinity -1.22 -0.48 -0.18 -0.05 -6.71 -infinity -0.63 -0.25 -0.11 -0.04 14
D9S906 9.2 -infinity -0.28 -0.16 -0.11 -0.06 -infinity -infinity -0.28 -0.16 -0.11 -0.06 15
D9S910 5.3 -infinity -0.8 -0.22 -0.01 0.05 -2.90 -infinity -0.74 -0.35 -0.17 -0.07 16
D9S938 8.3 -infinity -0.25 0.02 0.07 0.05 -infinity -infinity -0.5 -0.18 -0.08 -0.03 17
D9S2026 1.1 -infinity -1.84 -0.85 -0.4 -0.16 -infinity -infinity -1.83 -0.87 -0.42 -0.15 18Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D9S930 3.7 -infinity 0.7 0.73 0.52 0.25 -2.55 -infinity -0.05 0.15 0.13 0.06 19
D9S907 2.8 -infinity 0.3 0.6 0.52 0.28 -5.78 -infinity -0.75 -0.23 -0.06 0 20
D9S934 2.9 -infinity -0.59 -0.27 -0.17 -0.11 -infinity -infinity -0.76 -0.37 -0.2 -0.09 21
D9S302 7.4 -infinity -1.07 -0.28 0 0.07 -7.07 -infinity -0.97 -0.39 -0.16 -0.05 22
D9S918 6.8 -6.8 -0.78 -0.33 -0.13 -0.04 -6.65 -6.65 -0.67 -0.25 -0.09 -0.02 23
D9S752 6.9 -infinity 0.19 0.34 0.26 0.13 -2.26 -1.95 0.61 0.5 0.3 0.12 24
ATA59H06 2.6
D9S915 -3.44 -0.28 -0.04 0.03 0.03 -0.93 0.03 -0.02 -0.02 0.01 0.01 25Table 21.  Chromosome 10 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D10S1435 10.3
D10S1415 11.4
D10S1412 6.7 -infinity -0.69 -0.14 0.04 0.06 -3.17 -3.17 -0.72 -0.33 -0.16 -0.07 1
D10S2325 7.1 -infinity -1.61 -0.72 -0.31 -0.09 -6.83 -infinity -1.03 -0.45 -0.2 -0.08 2
D10S674 3.6 -infinity -0.45 -0.13 -0.03 0 -3.31 -3.31 -0.47 -0.23 -0.14 -0.07 3
D10S1423 8.8 -2.19 0.37 0.33 0.21 0.08 -2.21 -2.22 0.35 0.32 0.2 0.08 4
D10S1214 4.3 -infinity -1.05 -0.45 -0.2 -0.08 -infinity -infinity -1.29 -0.63 -0.32 -0.13 5
D10S1426 4.4 -infinity -1.63 -0.75 -0.37 -0.16 -infinity -infinity -1.42 -0.7 -0.35 -0.14 6
D10S1208 6.9 -infinity -0.99 -0.22 0.04 0.08 -infinity -infinity -0.99 -0.38 -0.12 -0.02 7
D10S1220 8.3
D10S1221 1.5 -infinity -0.73 -0.26 -0.12 -0.06 -infinity -infinity 0.41 0.33 0.17 0.05 8
D10S1227 4 -infinity -0.95 -0.42 -0.22 -0.1 -infinity -infinity 0.19 0.17 0.07 0.01 9
D10S1428 7.6 -infinity -1.53 -1.02 -0.6 -0.26 -2.73 -infinity -0.75 -0.4 -0.23 -0.1 10
GATA121A08 8.2 -infinity -0.85 -0.33 -0.14 -0.04 -infinity -infinity -1.11 -0.48 -0.2 -0.06 11
D10S1432 6.7 -infinity -1.05 -0.41 -0.14 -0.02 -infinity -infinity -0.96 -0.33 -0.08 0.01 12
D10S2327 3.3
D10S1427 9 -infinity 1.24 1.06 0.69 0.3 -2.39 -infinity 1.51 1.22 0.79 0.35 13
GATA115E01 3.6Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D10S677 10
D10S1239 2.9 -infinity -0.71 -0.2 -0.04 0 0.06 -infinity -0.54 -0.18 -0.04 0 14
D10S1246 6 -1.96 0.5 0.43 0.26 0.1 -1.97 -1.97 0.49 0.42 0.26 0.1 15
D10S1237 8.3 -infinity -0.82 -0.27 -0.08 -0.02 -2.00 -infinity -0.38 -0.06 0.02 0.02 16
D10S1236 2 -infinity -0.28 -0.11 -0.03 0 -2.66 -infinity -0.5 -0.19 -0.06 -0.01 17
D10S1230 4.9 -2.43 0.28 0.32 0.25 0.14 0.24 -3.59 -0.3 -0.1 -0.04 -0.01 18
D10S1213 1.3 -infinity 0.76 0.64 0.44 0.22 1.04 -infinity 0.06 0.1 0.07 0.03 19
D10S2322 6.7 -infinity -0.4 0.05 0.15 0.12 -2.24 -infinity -0.43 -0.13 -0.04 -0.01 20
D10S1223 5.7 -infinity -1.56 -0.73 -0.3 -0.08 -2.95 -infinity -0.62 -0.24 -0.09 -0.02 21
D10S1134 6 -infinity -0.91 -0.35 -0.15 -0.06 -infinity -infinity -1.22 -0.58 -0.29 -0.12 22
D1OS1248 -infinity -0.85 -0.35 -0.13 -0.02 -2.55 -2.25 0.28 0.29 0.21 0.1 23Table 22.  Chromosome 11 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D11S1984 4.8 -infinity -1.46 -0.77 -0.42 -0.19 -infinity -infinity -0.87 -0.43 -0.23 -0.1 1
D11S2362 6.8 -2.91 -0.53 -0.34 -0.2 -0.09 -2.62 -2.62 -0.17 -0.04 -0.02 -0.01 2
D11S1999 10.1 -infinity -1.24 -0.57 -0.25 -0.07 -6.85 -infinity -1.27 -0.54 -0.21 -0.05 3
D11S1981 7.6 -infinity -0.74 -0.26 -0.09 -0.02 0.90 -3.17 0.04 0.1 0.06 0.02 4
ATA34E08 8.6 -6.82 -0.76 -0.36 -0.21 -0.12 -6.99 -6.69 -0.64 -0.25 -0.11 -0.04 5
D11S1392 12.4 -infinity -1.67 -0.88 -0.45 -0.18 -infinity -infinity -1.39 -0.69 -0.33 -0.12 6
D11S1993 4.8 -infinity -1.2 -0.33 -0.03 0.04 -1.40 -infinity 0.39 0.53 0.41 0.21 7
D11S2019 10.1
D11S2371 10.4 -infinity -1.07 -0.54 -0.29 -0.13 -0.35 -infinity -0.67 -0.31 -0.15 -0.06 8
D11S4960 3.5 -infinity -2.16 -1.08 -0.54 -0.21 -infinity -infinity -1.33 -0.65 -0.31 -0.11 9
D11S1979 5.3 -infinity -1.08 -0.42 -0.14 -0.02 -2.58 -infinity -0.34 -0.07 0.01 0.02 10
D11S4952 8.2 -infinity -2.32 -1.2 -0.61 -0.24 -infinity -infinity -2.32 -1.2 -0.61 -0.24 11
D11S2000 6.1 -infinity -1.33 -0.67 -0.32 -0.11 -10.87 -infinity -1.3 -0.57 -0.24 -0.07 12
D11S1986 9
D11S1998 10 -infinity -0.24 -0.12 -0.08 -0.04 0.32 0.62 0.41 0.23 0.09 0.02 13
D11S4464 11.8 -infinity -1.24 -0.51 -0.2 -0.05 -6.47 -infinity -1.24 -0.51 -0.2 -0.05 14
D11S4463 11.3 -infinity -0.73 -0.13 0.07 0.09 -3.00 -infinity -0.83 -0.32 -0.11 -0.02 15
D11S2359 1.7 1.34 0.97 0.59 0.25 1.87 1.86 1.47 1.06 0.65 0.28 16Table 23.  Chromosome 12 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D12S372 9.5 -2.13 0.5 0.44 0.28 0.12 -2.31 -2.32 0.32 0.28 0.17 0.07 1
D12S374 5.4 -infinity -0.96 -0.55 -0.35 -0.18 -infinity -infinity -0.88 -0.48 -0.26 -0.11 2
D3S2395 8.2
D12S391 9.6 -infinity -0.17 0.18 0.21 0.12 -1.64 -1.26 0.83 0.7 0.46 0.21 3
D12S373 7.2 -infinity -0.55 -0.15 -0.01 0.02 -infinity -infinity -0.43 -0.08 0.03 0.04 4
D12S1066 7 -6.9 -0.76 -0.34 -0.16 -0.06 -6.76 -6.76 -0.66 -0.26 -0.11 -0.04 5
D12S1042 10.6 -6.67 -0.43 -0.11 -0.05 -0.06 -3.46 -3.16 -0.3 -0.08 -0.02 -0.01 6
D12S1301 7.3 -infinity -0.96 -0.41 -0.18 -0.06 -2.11 -1.81 0.52 0.4 0.2 0.05 7
D12S2196 7.4 -infinity -1.02 -0.43 -0.18 -0.05 -2.57 -2.57 0.1 0.11 0.05 0.01 8
D12S398 5.1 -infinity 0.04 0.04 -0.01 -0.02 -0.22 0.57 0.35 0.2 0.09 0.03 9
D12S1056 4.2 -2.93 -0.3 -0.11 -0.03 0 -3.28 -3.08 -0.34 -0.1 -0.01 0.01 10
D12S1294 5.2 -infinity -0.84 -0.25 -0.05 0 -7.08 -6.78 -0.47 -0.13 -0.03 -0.01 11
D12S375 5.2 -infinity -1.89 -0.95 -0.48 -0.2 -infinity -infinity -0.5 -0.17 -0.07 -0.03 12
D12S1052 9 -infinity -1.38 -0.58 -0.26 -0.11 -3.33 -3.03 -0.46 -0.13 -0.04 -0.02 13
D12S2068 3.8 -infinity -0.74 -0.29 -0.1 -0.02 -2.83 -2.53 0.05 0.13 0.09 0.04 14
D12S1064 6.7 -infinity -0.83 -0.46 -0.3 -0.17 -3.60 -2.61 -0.14 -0.15 -0.19 -0.15 15
D12S1044 7.4 -infinity -0.74 -0.3 -0.11 -0.02 -2.68 -2.57 0.11 0.14 0.09 0.04 16
D12S1051 7.1 -infinity -0.67 -0.04 0.12 0.1 -1.75 -1.45 0.38 0.49 0.37 0.19 17Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V: 7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
PAH 18.3 -infinity -0.53 -0.16 -0.03 0.01 -2.94 -2.65 0.06 0.11 0.07 0.03 18
D12S2070 8.1 -2.95 -0.42 -0.17 -0.08 -0.03 -2.54 -2.54 -0.18 -0.04 -0.01 -0.01 19
D12S395 12.7 -4.54 -0.65 -0.3 -0.15 -0.07 -3.61 -3.61 -0.26 -0.11 -0.07 -0.04 20
D12S2078 13.2 -infinity -0.82 -0.27 -0.06 0.01 -infinity -infinity -1.28 -0.6 -0.28 -0.1 21
D12S1045 6 -infinity -1.3 -0.48 -0.16 -0.03 -infinity -infinity -1.77 -0.84 -0.4 -0.15 22
D12S392 -infinity -1.11 -0.35 -0.07 0.02 -7.42 -infinity -1.39 -0.59 -0.23 -0.06 23Table 24.  Chromosome 13 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D13S787 17.3 -2.61 -0.45 -0.26 -0.13 -0.06 -2.17 -2.16 0.29 0.37 0.27 0.12 1
D13S893 7.8 -infinity -1.21 -0.52 -0.2 -0.05 -2.58 -2.92 -0.22 -0.06 -0.02 -0.01 2
D13S894 6.5 -infinity -0.44 -0.19 -0.07 -0.01 0.43 0.44 0.25 0.12 0.05 0.02 3
D13S325 8.6 -infinity -1.04 -0.42 -0.17 -0.05 -infinity -infinity -0.84 -0.41 -0.21 -0.09 4
D13S788 5.9 -infinity -0.75 -0.05 0.11 0.08 -10.47 -10.17 -0.77 -0.21 -0.03 0.02 5
D13S318 6.8 -infinity 0.07 0.31 0.27 0.14 -2.80 -2.5 0.02 0.07 0.05 0.02 6
D13S800 12.1 -2.48 0.21 0.22 0.14 0.04 -3.07 -2.77 -0.03 0.05 0.04 0.02 7
GATA8G07 4.4 -2.96 -0.18 -0.07 -0.06 -0.06 -3.24 -2.94 -0.16 -0.04 -0.02 -0.02 8
D13S886 8.2 -infinity -0.68 -0.18 -0.04 -0.02 -7.13 -6.82 -0.58 -0.15 -0.02 0 9
D13S793 7.9 -1.8 0.78 0.67 0.45 0.22 -2.15 -2.15 0.49 0.44 0.28 0.12 10
D13S779 8.9 -infinity -0.92 -0.31 -0.08 0 -6.27 -6.27 -0.44 -0.11 -0.01 0.01 11
D13S797 7.2 -2.1 0.27 0.3 0.21 0.08 -3.13 -2.27 0.09 0.15 0.1 0.04 12
D13S895 2.82 2.22 1.61 1 0.45 1.83 2.13 1.64 1.14 0.67 0.28 13Table 25.  Chromosome 14 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D14S742 11.1 -infinity -0.28 0.03 0.1 0.08 -2.70 -infinity -0.65 -0.25 -0.08 -0.02 1
D14S1280 3.6 -infinity -0.72 -0.3 -0.11 -0.02 -2.93 -infinity -0.77 -0.32 -0.12 -0.03 2
D14S608 5.5 -infinity -0.3 0.01 0.07 0.05 -2.49 -infinity -0.6 -0.22 -0.09 -0.03 3
D14S121 8.4
D14S599 4.7 -infinity -0.21 0.07 0.12 0.09 -2.78 -infinity -0.7 -0.29 -0.11 -0.03 4
D14S306 3.5 -infinity -0.31 0.01 0.09 0.07 -2.46 -infinity -0.7 -0.29 -0.12 -0.04 5
D14S583 10.1 -infinity -0.46 -0.11 0 0.03 -2.67 -infinity -0.58 -0.18 -0.03 0.02 6
D14S587 8.8 -infinity -0.26 0 0.03 0.01 -infinity -infinity -0.26 0 0.03 0.01 7
D14S592 6.4 -infinity 0.02 0.05 0.04 0.02 0.69 -infinity -0.19 -0.05 -0.01 0 8
D14S588 11.7 1.07 0.83 0.59 0.37 0.18 0.72 0.72 0.53 0.35 0.2 0.08 9
D14S539 7.3
D14S606 4.3
D14S616 3.5 -infinity 0.47 0.55 0.41 0.21 -2.27 -infinity -0.34 -0.06 0.01 0.02 10
D14S1279 11
D14S617 6.3 -infinity -1.02 -0.36 -0.09 0.01 -6.83 -infinity -1.28 -0.56 -0.23 -0.07 11
GATA168F06 2.8 0.64 0.48 0.31 0.16 0.06 0.94 0.94 0.67 0.42 0.21 0.08 12
D14S605 5.4 -2.93 -0.14 -0.03 -0.01 0 -2.84 -2.84 -0.07 0.02 0.03 0.01 13
D14S614 4.1 -infinity -0.81 -0.38 -0.17 -0.06 -2.84 -infinity -0.58 -0.21 -0.07 -0.01 14Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D14S1426 -infinity -1.09 -0.46 -0.19 -0.06 -6.78 -infinity -0.65 -0.26 -0.1 -0.03 15Table 26.  Chromosome 15 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D15S817 8.2 -infinity -0.4 0.05 0.15 0.11 -6.87 -infinity -0.9 -0.31 -0.08 0 1
D15S217 14.6 -infinity -1.54 -0.73 -0.37 -0.15 -infinity -infinity -0.51 -0.22 -0.12 -0.05 2
D15S231 5.8 -3.08 -0.32 -0.12 -0.04 -0.01 -2.15 -2.97 -0.14 0.05 0.07 0.04 3
ACTC 2.4 -infinity -0.37 0.19 0.28 0.18 -1.16 -infinity 0.9 0.92 0.68 0.35 4
GATA50C03 9.7 -3.33 -0.11 0.01 0.02 0.01 -2.81 -3.31 -0.16 -0.02 0.01 0.01 5
D15S659 5.2 -infinity -1.09 -0.47 -0.2 -0.06 -2.10 -infinity -0.41 -0.1 -0.01 0.01 6
D15S648 6.4 -infinity -0.07 0.1 0.08 0.04 -2.38 -infinity -0.5 -0.15 -0.03 0 7
D15S643 7 -infinity -2.18 -0.98 -0.42 -0.13 -5.96 -infinity -0.89 -0.31 -0.09 -0.01 8
GATA151F03 11.1 -infinity -0.13 0.18 0.21 0.14 -2.51 -2.51 0.2 0.25 0.21 0.12 9
D15S818 8.8
D15S655 10.5 -infinity -1.51 -0.63 -0.26 -0.09 -infinity -infinity -1.43 -0.62 -0.26 -0.08 10
D15S652 8.5 -infinity -0.18 0.05 0.07 0.04 1.27 -infinity 0.2 0.17 0.09 0.04 11
D15S816 4.9 -infinity 0.31 0.4 0.29 0.14 -3.08 -infinity -0.32 -0.03 0.04 0.04 12
D15S657 6.3 -infinity -2.98 -1.47 -0.72 -0.27 -infinity -infinity -1.31 -0.63 -0.31 -0.11 13
D15S230 20.6 -infinity 0.02 -0.03 -0.09 -0.08 -infinity -infinity -0.11 -0.07 -0.08 -0.06 14Table 27.  Chromosome 16 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D16S2622 6.3 -infinity -1.1 -0.44 -0.15 -0.03 -6.93 -6.62 -0.4 -0.09 -0.01 0 1
ATA41E04 12.1 -infinity -0.67 -0.27 -0.11 -0.03 -3.63 -3.33 -0.38 -0.13 -0.04 -0.01 2
D16S748 8.7 -infinity -0.26 -0.03 0.01 0.01 -2.75 -infinity -0.68 -0.28 -0.11 -0.03 3
D16S764 9.2 -1.15 0.28 0.39 0.28 0.13 -1.29 -1.28 0.94 0.78 0.51 0.24 4
D16S749 11.2 -infinity 0.3 0.27 0.16 0.06 1.34 1.34 1 0.67 0.38 0.16 5
D16S769 7.9 -2.67 -0.23 -0.05 0 0 -2.67 -2.67 -0.23 -0.05 0 0 6
D16S753 5.8
ATA55A11 2 -infinity -1.03 -0.41 -0.15 -0.03 -6.71 -infinity -0.81 -0.32 -0.12 -0.03 7
D16S757 6.4 -infinity -1.16 -0.46 -0.15 -0.02 -2.66 -infinity -0.31 -0.03 0.03 0.03 8
D16S3253 11.2 -infinity 0.09 0.16 0.12 0.06 0.89 -infinity 0.16 0.16 0.09 0.04 9
GATA67G11 6 -infinity -0.96 -0.33 -0.1 -0.01 -6.90 -infinity -0.52 -0.18 -0.07 -0.02 10
D16S2624 16.2 -infinity -0.06 0.1 0.12 0.07 0.18 -infinity -0.16 0.05 0.06 0.03 11
D16S750 28.2 -0.4 -0.3 -0.17 -0.07 -0.01 -0.23 -0.22 -0.13 -0.06 -0.02 -0.01 12
D16S539 5.3 -infinity -1.43 -0.65 -0.29 -0.11 -5.59 -7.17 -0.23 0.07 0.11 0.07 13
D16S2621 -3.75 -0.8 -0.33 -0.13 -0.04 -2.78 -2.78 -0.11 -0.01 0.01 0.01 14Table 28.  Chromosome 17 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D17S1308 11.6 -infinity -1.1 -0.48 -0.18 -0.04 -3.05 -6.59 -0.52 -0.13 0 0.03 1
D17D1298 9.3 -3.12 -0.51 -0.29 -0.17 -0.08 -2.75 -2.75 -0.2 -0.06 -0.02 -0.01 2
D17S1537 10.2 -2.23 0.5 0.49 0.34 0.16 -2.39 -2.08 0.54 0.48 0.32 0.15 3
D17S974 4.5
D17S969 10.5 -3.04 -0.39 -0.15 -0.05 -0.01 -2.72 -2.71 -0.09 0.01 0.03 0.02 4
D17S900 9
GATA185H04 6.4 -5.24 0.43 0.52 0.37 0.17 -6.69 -6.38 -0.32 -0.04 0.01 0 5
D17S1294 5.6 -3.5 -0.52 -0.04 0.08 0.07 -3.46 -3.46 -0.51 -0.11 0.01 0.03 6
D17S1293 6.6
D17S1299 4.5 -infinity 0.24 0.28 0.22 0.12 -3.19 -3.19 -0.05 0.05 0.05 0.03 7
D17S2180 17.1
D17S1290 9.9
ATA43A10 8.6
D17S1534 9.2
D17S968 -infinity -0.68 -0.1 0.09 0.1 -2.60 -infinity -0.47 -0.13 -0.02 0.01 8Table 29.  Chromosome 18 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
GATA178F11 9.5 -infinity 0.05 0.41 0.39 0.22 -3.21 -2.91 -0.36 -0.05 0.12 0.07 1
D18S853 2.5 -3.04 -0.35 -0.16 -0.09 -0.04 -3.01 -3.01 -0.3 -0.11 -0.05 -0.02 2
D18S976 6.5 -infinity -1.21 -0.51 -0.21 -0.07 -6.57 -infinity -0.94 -0.36 -0.14 -0.04 3
D18S973 11.4 -infinity 0.51 0.42 0.25 0.1 -infinity -infinity 0.25 0.22 0.1 0.02 4
D18S843 11.2 -infinity -0.57 -0.28 -0.16 -0.07 -2.55 -infinity -0.45 -0.14 -0.04 -0.01 5
D18S542 16.1
D18S877 2.9 0.73 0.58 0.42 0.28 0.14 -1.20 0.26 0.18 0.11 0.05 0.02 6
D18S847 4.1 -2.21 -0.13 0.14 0.17 0.11 -2.34 -2.34 -0.23 0.06 0.12 0.08 7
D18S974 2.1 -infinity -0.84 -0.12 0.09 0.1 -infinity -infinity -1.3 -0.47 -0.15 -0.02 8
D18S978 2.7 -infinity -0.85 -0.51 -0.3 -0.13 -infinity -infinity -0.81 -0.41 -0.22 -0.09 9
D18S872 9.8 -infinity -1.13 -0.47 -0.19 -0.06 0.74 -infinity -0.18 -0.04 0 0.01 10
D18S851 3.9 -infinity 0.61 0.52 0.36 0.19 -2.84 -infinity 0.03 0.1 0.08 0.04 11
D18S858 9.7 -infinity -0.07 0.17 0.18 0.1 -2.49 -2.19 0.2 0.22 0.15 0.07 12
D18S1357 9.4 -infinity -0.44 -0.11 0 0.02 -2.43 -infinity -0.26 0 0.05 0.03 13
GATA26C03 1.9 -infinity -0.02 0.39 0.4 0.24 -1.55 -infinity 0.43 0.55 0.42 0.21 14
D18S969 2.5 -infinity -0.51 -0.17 -0.07 -0.03 -infinity -infinity -0.76 -0.37 -0.21 -0.11 15
D18S857 8.8 -infinity -0.44 -0.12 -0.02 0.01 -infinity -infinity -0.92 -0.47 -0.25 -0.1 16
D18S541 7.9 -2.26 0.18 0.23 0.17 0.08 -2.00 -2.02 0.35 0.36 0.25 0.11 17Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
GATA177C03 3.2 -2.52 -0.02 0.08 0.07 0.03 -2.53 -2.53 -0.05 0.04 0.04 0.02 18
D18S844 -infinity -0.87 -0.3 -0.08 0 -infinity -infinity -1.25 -0.65 -0.35 -0.15 19Table 30.  Chromosome 19 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D19S591 11.7 -infinity -0.96 -0.52 -0.29 -0.13 0.53 0.74 0.46 0.24 0.1 0.03 1
D19S1034 3.5 -0.314 -0.29 0.03 0.1 0.07 -2.57 -2.57 -0.03 0.1 0.1 0.06 2
D19S592 9.1 -infinity -1.55 -0.8 -0.42 -0.17 -infinity -infinity -0.88 -0.45 -0.24 -0.11 3
D19S586 4.1 -infinity -0.81 -0.34 -0.13 -0.03 -2.96 -3.27 -0.49 -0.15 -0.04 0 4
GATA134B01 6.3 -2.76 -0.33 -0.14 -0.07 -0.03 -2.72 -2.71 -0.29 -0.1 -0.04 -0.02 5
D19S714 3.8 -infinity -0.87 -0.31 -0.1 -0.01 -infinity -infinity -0.46 -0.18 -0.1 -0.05 6
D19S593 5.8 -infinity -1.02 -0.24 0.03 0.08 -6.94 -6.64 -0.63 -0.25 -0.11 -0.04 7
D19S1037 5.4 -infinity -0.94 -0.36 -0.14 -0.04 0.73 -2.79 -0.12 0 0 -0.01 8
D19S433 3.8 -infinity -0.82 -0.35 -0.14 -0.04 -0.01 -3.3 -0.42 -0.16 -0.06 -0.02 9
D19S431 2.5 -infinity -0.81 -0.29 -0.1 -0.03 -3.69 -3.69 -0.72 -0.31 -0.14 -0.05 10
D19S719 1.9 -infinity -0.96 -0.49 -0.24 -0.09 -3.17 -2.86 -0.09 0.01 0.01 0 11
D19S587 5.5 -2.21 0.11 0.2 0.16 0.09 -2.63 -2.63 -0.25 -0.09 -0.04 -0.02 12
GATA84G04 11.4 -infinity -0.43 0.09 0.21 0.16 -2.52 -2.22 0.39 0.35 0.22 0.1 13
D19S541 8
D19S585 4.6
D19S601 3.8 -infinity -0.73 -0.12 0.09 0.11 -2.67 -2.37 0.13 0.16 0.11 0.05 14
D19S589 -infinity -1.36 -0.54 -0.22 -0.07 -2.98 -3.77 -0.46 -0.16 -0.08 -0.05 15Table 31.  Chromosome 20 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D20S473 4 0.98 0.53 0.15 -0.07 -0.09 1.24 1.08 0.74 0.45 0.23 0.09 1
D20S482 5.9 0.79 0.32 -0.09 -0.3 -0.22 0.15 0.45 0.15 -0.03 -0.08 -0.06 2
D20S603 9.2 -infinity -2.35 -1.25 -0.73 -0.36 -infinity -infinity -1.44 -0.78 -0.45 -0.21 3
D20S162 10.2 -infinity -1.17 -0.59 -0.3 -0.12 -2.36 -2.36 -0.04 0.05 0.05 0.02 4
D20S604 6.6 -3.92 -0.11 0.01 0 -0.03 -3.51 -3.21 -0.04 0.07 0.06 0.02 5
D20S470 3.3 -infinity -0.3 -0.01 0.05 0.04 -2.44 -2.53 0.02 0.14 0.13 0.07 6
D20S471 5.1 -infinity 1.08 1.04 0.72 0.34 -infinity -infinity 1.23 1 0.63 0.26 7
D20S477 4.3 -infinity -0.23 0.13 0.18 0.12 -infinity -infinity -0.2 0.06 0.09 0.05 8
GATA65E01 2.2 -6.27 -0.27 0.05 0.08 0.03 -6.45 -6.15 -0.1 0.12 0.12 0.06 9
D20S478 2 -11.75 -1.53 -0.68 -0.31 -0.12 -10.64 -10.64 -0.95 -0.34 -0.1 -0.01 10
D20S607 7.8 -infinity 0.24 0.42 0.35 0.19 -infinity -infinity -0.52 -0.18 -0.08 -0.03 11
D20S481 3.7 -infinity 0.16 0.34 0.26 0.12 -infinity -infinity -0.24 -0.01 0.01 -0.01 12
D20S159 11.7 -infinity -0.97 -0.37 -0.13 -0.04 -infinity -infinity -1.44 -0.71 -0.35 -0.13 13
D20S480 2 -infinity -0.15 0.14 0.15 0.08 -6.99 -6.69 -0.32 0 0.06 0.04 14
D20S1085 3.7 -6.59 -0.26 0.05 0.1 0.05 -6.77 -6.46 -0.34 -0.03 0.03 0.02 15
D20S1082 -infinity -0.5 -0.16 -0.04 0 -6.99 -6.99 -0.44 -0.11 -0.01 0.01 16Table 32.  Chromosome 21 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V:7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D21S1432 6.1
D21S1433 6.8
D21S1438 6.4 0.63 0.47 0.34 0.22 0.12 0.17 0.17 0.09 0.04 0.01 0 1
D21S1435 4.2 -infinity 0.14 0.32 0.28 0.16 -2.77 -7.16 -0.59 -0.22 -0.08 -0.02 2
D21S2052 1.3 -2.45 -0.21 -0.13 -0.1 -0.06 -2.76 -2.76 -0.23 -0.04 0.01 0 3
D21S1270 15.4
D21S1439 2.5 -infinity -0.59 -0.21 -0.07 -0.02 -2.27 -2.27 0.21 0.21 0.13 0.06 4
GATA188F04 19 -infinity -1.98 -0.9 -0.41 -0.15 -infinity -infinity -1.83 -0.93 -0.49 -0.21 5
D21S1446 -infinity -0.53 -0.05 0.06 0.05 -infinity -infinity -0.11 0.12 0.12 0.05 6Table 33.  Chromosome 22 two point lod score results
Marker name
Distance 
to next 
marker 
(cM)
MLINK analysis, affecteds and 
unaffecteds, V:7 classed as affected
GENEHUNTER 
analysis, 
affecteds only, 
V: 7 classed as 
unknown
MLINK analysis, affecteds only, 
V:7 classed as affected
Multipoint
graph
locus
number
Recombination fraction Recombination fraction
0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
D22S1266 13.3 0.59 0.4 0.24 0.12 0.04 0.77 0.77 0.54 0.34 0.18 0.07 1
D22S686 4 -infinity -0.96 -0.37 -0.13 -0.03 -6.57 -6.27 -0.38 -0.06 0.02 0.02 2
D22S1685 6.8
D22S690 7.2 -11.4 -1.64 -0.8 -0.38 -0.14 -10.62 -10.62 -1.11 -0.45 -0.17 -0.04 3
D22S689 4.9 -infinity -1.32 -0.63 -0.33 -0.14 -infinity -infinity -0.37 -0.11 -0.06 -0.04 4
D22S691 3.5 -infinity -1.16 -0.48 -0.19 -0.05 -7.29 -6.99 -0.65 -0.19 -0.05 -0.01 5
D22S683 3.8
D22S692 2.6 -infinity -1.51 -0.62 -0.23 -0.05 -infinity -infinity -1.09 -0.48 -0.22 -0.08 6
D22S445 13.8 -infinity -0.39 -0.17 -0.06 0 0.28 0.58 0.39 0.24 0.13 0.05 7
D22S1267 -2.87 -0.22 -0.06 -0.02 -0.01 -2.51 -2.51 0.02 0.09 0.07 0.03 85.2.2 Two point lod scores of interest
Chromosome 5q34-5q35
The highest two point lod score obtained from the genome scan was 3.18 (0 = 0, 
GENEHUNTER analysis) for marker D5SI471. A nearby marker D5S1713 yielded a 
two point lod score of 2.63 (0 = 0, GENEHUNTER analysis), and these results were 
highly suggestive of linkage to this region. However, examination of the haplotypes for 
these two markers and the intervening marker D5S1456, shown in figure 9, reveals that 
all the affected individuals share a common allele for each of these markers, but also 
that these haplotypes are not identical by descent. All the affected individuals share 
allele 3 for marker D5S1471, resulting in the high two point lod score, but this allele is 
also present in V:7 and the unaffected individual V:6. All the affected individuals also 
possess a common allele for marker D5S1713, but once again this allele is also shared 
by individuals V:6 and V:7. Although the affected individual V:5 has inherited allele 3 
for marker D5S1471 and allele 1  for marker D5S1713, both of which are shared by all 
the other affected individuals, inspection of the haplotypes for the intervening marker 
D5S1456 shows us that he must have inherited allele 5, which the other affected 
individuals also possess, from his unaffected mother rather than from his affected father. 
Provided that individual V:5 is not a phenocopy the haplotypes suggest that linkage to 
this region is unlikely since this would require a double recombination to have occurred 
around marker D5S1456.
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Figure 9.  The haplotypes for the markers from the Research Genetics Marker 
Set version 8 analysed in the region 5q34-5q35. The boxed alleles indicate 
that there are alleles that are common to most of the affected individuals. 
However, the affected individual V:5 must have inherited allele 4 for marker 
D5S1456 from his unaffected mother, not from his affected father.
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VI :2One marker, D5S1495, 35 centimorgans centromeric to marker D5S1471 yielded a lod 
score of 1.56 (0 = 0, MLINK analysis, affecteds only) on the initial analysis with 
individual V:7 classed as affected. On the subsequent analysis with this person classed 
as unknown with regards to affection status, the two point lod score fell to 1.26 (0 = 0, 
GENEHUNTER analysis). The haplotypes around this marker are shown in figure 10, 
and it can be seen that all individuals, both affecteds and unaffecteds, share allele 2 for 
marker D5S1495.
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Figure 10.  The haplotypes for other markers from the Research Genetics 
Marker Set version 8 analysed in the region 5q34-5q35. All individuals share 
allele 2 for marker D5S1495, but there is no consistent haplotype amongst the 
affected individuals for the adjacent markers as shown.
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A two point lod score of 2.34 (0 = 0.1) was generated for marker D3S4531 using the 
MLINK software with all individuals and with individual V:7 classified as affected, and 
of 1.53 (0 = 0.1) using affecteds only. Analysis with individual V:7 classed as affection 
unknown using the GENEHUNTER software produced a two point lod score of 2.86 (0 
= 0). The allele nominated as 5 is common to all affected individuals, but this appears to 
be a common allele and is also shared by the unaffected individuals IV: 10 and VI: 2 (see 
figure 11). None of the adjacent markers show a particular allele that is common to all 
the affected individuals.
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Figure 11.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 3q25. The boxed alleles indicate 
that there is a common allele in all affected individuals genotyped for marker 
D3S4531, but which is also present in the unaffected individuals IV: 10 and 
VI:12. D3S3053
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A two point lod score of 2.17 (0 = 0) was achieved for the marker D5S1470 when the 
data for the affected individuals alone (including individual V:7 as affected) were 
analysed using the MLINK software, and a score of 1.87 (0 = 0) was calculated for this 
marker with the GENEHUNTER analysis of affecteds only with V:7 affection status 
unknown. The adjacent marker, GATA145D09, yielded a two point lod score of-1.29 
(GENEHUNTER analysis, 0 = 0), although examination of the haplotype reveals that all 
affected individuals share a common allele for this marker as well as for D5S1470 
(figure 12). The common haplotype for these two markers is also present in individual 
V:7 whose affection status has been questioned.
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Figure 12.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 5pl4. The boxed alleles indicate 
that there are alleles that are common to all affected individuals analysed, 
though the unaffected individual V:7 also shares these same alleles.
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Marker D11S2359 produced a lod score of 1.87 (0 = 0, GENEHUNTER analysis). Only 
ten subjects were successfully genotyped for this marker and all of these, both affected 
and unaffected, shared a common allele. This marker is located at the end of the long 
arm of chromosome 11, and the adjacent markers do not show a consistent pattern 
amongst the affected individuals (figure 13).
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Figure 13.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 1  lq25. The boxed alleles indicate 
that there is an allele that is common to all individuals analysed, both 
affecteds and non-affecteds.
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Marker D13S895 yielded a maximum two point lod score of 2.82 (LINKAGE analysis, 
0 = 0) when both affecteds and unaffecteds were included, and a maximum two point 
lod score for affecteds only of 1.83 (0 = 0, GENEHUNTER analysis). Linkage to 
adjacent markers in this region was excluded by two point lod scores less than -2 (0 = 
0, GENEHUNTER analysis). Analysis of the haplotypes revealed that all the affected 
individuals, as well as individual V:7, share allele 2 for marker D13S895, but there are 
no other common alleles in this region (figure 14).
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Figure 14.  Showing the haplotypes for the markers from the Research 
Genetics Marker Set version 8 analysed in the region 13q34. The boxed 
alleles indicate that there is an allele that is common to all affected 
individuals, but which is also shared by the unaffected individual V:7.
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Five markers in this 55.5cM region yielded positive two point lod scores; D2S1370 
achieved the highest two point lod score of 1.67 (0 = 0, GENEHUNTER analysis), and 
the adjacent marker D2S427 produced a two point lod score of 1.13 (0 = 0, 
GENEHUNTER analysis). Two markers, D2S1384 and D1S1649, located 14.8cM 
centromeric to D2S1370 also yielded positive two point lod scores of 1.66 and 1.22 
respectively (0 = 0, GENEHUNTER analysis). A particular allele for each of these 
markers was found to be present in all of the affected individuals studied, but these 
alleles were also present in the phenotypically normal individual VI:2 (figure 15). This 
region was of particular interest because a separate family with an autosomal recessive 
phenotype {Brady, Winter, et al 2002 81 /id} showed potential linkage to this region 
using homozygosity mapping (personal communication M. Bitner-Glindzicz and 
J.Tyson)
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Figure 15.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 2q32 - 2q37. The boxed alleles 
are common to all affected individuals, but are also present in the unaffected 
individual VI :2
D2S1391
D2S1384
D1S1649
D2S434
D2S1363
D2S1370
D2S427
D2S1397
GATA178G09
5  5  5  9
0   I  0   5
3  3  3  3
0 :   0 5 11  13
4  5  4  5Chromosome 8q24
A two point lod score of 1.68 (0 = 0, GENEHUNTER analysis) was generated from the 
genotyping data for marker D8S1985. All the affected individuals share a common 
allele for this marker and for the final marker on this chromosome, D8S1100 (figure
16). The intervening marker, D8S1462, yielded a two point lod score of-2.86. The 
shared alleles are also observed in the unaffected individual VI:2.
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Figure 16. The haplotypes for the markers from the Research Genetics Marker 
Set version 8 analysed in the region 8q24. The boxed alleles indicate that there 
are common alleles for markers D8S1985 and D8S1100 for all affected 
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Marker D16S749 yielded a maximum lod score of 1.34 (0 = 0) in the second analysis 
using LINKAGE software (affecteds only, V:7 classed as affected), and an identical 
score was produced when the analysis was reperformed using the GENEHUNTER 
program and with the alteration made to individual V:7’s affection status.
All the genotyped individuals share a common allele for both marker D16S749 and the 
adjacent marker D16S764, including two unaffected people and individual V:7 (figure
17). Also, individuals IV:9 and IV: 10 are heterozygous for the same alleles for marker 
D16S764, and are identically homozygous for marker D16S749, so that the meioses that 
produced their children are not informative.
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Figure 17.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 16pl2. The boxes indicate that 
there are alleles that are common to all affected individuals, but which are 
also shared by the unaffected individuals IV: 10, V:6, V:7 and VI:2.
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The MLINK analysis of affecteds only, with V:7 classed as affected, produced a two 
point lod score of 1.89 at a recombination fraction of 0.1 for marker D3S2403 (table 
14). At a recombination fraction of zero, all of the two point lod scores for this marker 
excluded linkage. There are no alleles that are common to all of the affected individuals 
in this region as shown in figure 18.
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Figure 18.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 3p25. There are no alleles that 
are common to all affected individuals in this region.
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Marker D8S1459 yielded positive lod scores with all three two point calculations. The 
MLINK analysis of affecteds and unaffecteds, with V:7 classed as affected, produced 
the highest two point lod score for this marker of 1.51 (0 = 0). Linkage to the adjacent 
markers was excluded by the results of the two point lod score analyses. It can be seen 
from the haplotypes (figure 19) that all of the individuals who were genotyped, 
including four unaffected individuals, share allele 3 for D8S1459.
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Figure 19.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 8q22. All individuals, both 
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Using the LINKAGE software the maximum two point lod score for marker DIOS 1427 
was 1.51 at a recombination fraction (0) of 0.1. Unfortunately, attempted polymerase 
chain amplification using the markers adjacent to DIOS 1427 failed  on repeated 
attempts. If candidate genes in other regions of interest are excluded by further 
investigation, it would be appropriate to analyse further microsatellite markers in this 
region.
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Figure 20.  Showing the haplotypes for the markers from the Research 
Genetics Marker Set version 8 analysed in the region 10q22. The boxes 
indicate that there is an allele that is common to all affected individuals typed 
for marker DIOS 1239, but which is also shared by the unaffected individuals 
IV: 10 and V:6.
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7  75.2.3 Genome-wide multipoint linkage analysis
The data from genotyping family R with the Research Genetics screening set version 
8.0 were used to calculate multipoint lod scores for each chromosome using the 
GENEHUNTER version 2 program (www.hgmp.mrc.ac.uk). The disease gene 
frequency was defined as 0.0002 with full penetrance.
Affected individuals only were included in the analysis, and since the affection status of 
individual V:7 had been called into question by this time and he was classed as 
unaffected in the multipoint analyses.
A summary of the most notable multipoint lod scores is shown in table 34, and a plot of 
the multipoint lod scores across each chromosome is shown in figures 21 to 43.
185Table 34.  Summary of the highest lod scores obtained by multipoint analysis
Chromosomal band 
location
Maximum 
Multipoint Lod 
Score using 
GENEHUNTER 
analysis 
(V:7 unknown)
Maximum Two 
Point Lod Score 
using 
GENEHUNTER 
analysis 
(V:7 unknown)
Closest Marker 
analysed to 
multipoint peak
2q32 -  2q37, 237cM 3.03 1.22 D1S1649
5q34-5q35, 201cM 2.86 3.18 D5S1713
3q25, 185cM 2.05 2.86 D3S4531
8p21,21cM 2.52 0.68 D8S1145
16pl2, 36cM 1.70 1.34 D16S749
13q34 , lOlcM 1.60 1.83 D13S895
10q22, 94cM 1.58 1.51 (0 = 0.1) D10S1427
1  lq25, 140cM 1.57 1.87 D11S2359
15ql 1  - 15ql2, 17cM 1.49 -infinity D15S217
14q23, 62cM 1.45 0.72 D14S588
186GENEHUNTER multipoint linkage analysis results graphs
Figure 21.  Chromosome 1  multipoint lod score results
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Figure 40.  Chromosome 19 multipoint lod score results
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Figure 42.  Chromosome 21 multipoint lod score results
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Figure 43.  Chromosome 22 multipoint lod score results
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S5.2.4  Multipoint regions of interest
Chromosome 2q32 - 2q37
The highest multipoint lod score across the genome was 2.97 for microsatellite marker 
D1S1649 on chromosome 2q (the naming of this marker is an anomaly). An adjacent 
peak was identified for marker D2S1370 with a multipoint lod score of 2.44. 
Multipoint linkage analysis using information from just the 8 marker loci from the 
Research Genetics Mapping Set in this region of chromosome 2 gave a maximum two 
point lod score of 3.03 which is suggestive of linkage.
In view of this result and the possible linkage to this region in a family with an 
autosomal recessive pattern of inheritance as noted above, the available individuals 
from our pedigree were genotyped for further markers with a greater density across this 
area.
The Ensembl database (www.ensembl.org) was searched for markers lying between 
D1S1649 and D2S1363, and 11 additional markers were selected at an average density 
of 1.2 Mb apart (figure 44).
210Figure 44.  Schematic illustration of map locations of microsatellite markers for 2q32 -  2q37. (the 
distance of each marker along the chromosome is shown in Mb)
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226.9The haplotypes for the markers of the Research Genetics Marker Set version 8 within 
this region of interest have already been discussed (section 5.2.2, figure 15). An 
examination of the haplotypes of the additional markers studied in this region shows 
that there two distinct haplotype blocks that are shared by the affected individuals. 
These haplotype blocks are separated by a distance of 8.2 Mb. There are common 
alleles in the affected family members successfully genotyped for three adjacent 
markers, D2S2179, D2S2151 and D2S1242 (figure 45). However, the maximum lod 
score produced by multipoint linkage analysis across this region was only 0.6 (figure 
46). Marker D2S2151 appears to be relatively uninformative in the pedigree, with only 
two individuals being heterozygous for this marker. The distance spanned by these three 
markers is 2.2 Mb, and this area potentially overlaps the region of homozygosity 
identified in the recessive family. The unaffected family member VI:2 also shares the 
haplotype for these three markers with the affected members.
The affected individuals also share a common haplotype for markers D2S1370 and 
D2S437 (figure 45). The maximum multipoint lod score in the region of these markers 
was 1.83 (figure 46). The haplotype for these markers seen in the affected individuals is 
also present in the unaffected individual VI:2.
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029427
Figure 45.  The haplotypes for the additional markers analysed in the region 
2q32 - 2q37 in addition to those from the Research Genetics Marker Set 
version 8. The boxed alleles indicate that there are alleles that are common to 
all affected individuals.
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Figure 46.  Plot of the multipoint lod scores for the additional markers analysed in the region 2q32 -  2q37
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The maximum multipoint lod score in this region of 2.52 corresponds to the position of 
marker D8S1145 (figure 27). Two point lod score analysis for this marker produced a 
value of 0.68 (0 = 0, GENEHUNTER analysis) (0.69, 0 = 0, LINKAGE analysis). All 
the individuals who were successfully genotyped for this marker shared a common 
allele, including three subjects who are phenotypically unaffected as shown in figure 47.
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Figure 47.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 8p21. The boxed alleles indicate 
that there is an allele that is common to all affected individuals, but which is 
also shared by V:7 and the unaffected individuals IV: 10, and VI: 12.
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Chromosome 14 yielded a maximum lod score of 1.45 at 62cM along the chromosome, 
which relates to the position of marker D14S588 (figure 35). Only four affected family 
members were successfully genotyped for this marker, and all were homozygous for 
allele 2 of this marker (figure 48).
As noted above, analysis of another pedigree with apparent autosomal transmission of 
hemifacial microsomia has previously mapped the disease gene to 14q32, between 
markers D14S987 and D14S65  (Kelberman, Tyson, et al 2001 55 /id}. However, that 
locus is in the telomeric end of the long arm of chromosome 14, and is distinct from the 
locus with the highest lod score in our genome scan which maps to 14q23, some 26 Mb 
away.
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Two positive peaks were found on multipoint analysis in this region as seen in figure 
36. A lod score of 1.49 was calculated for a point 17 cM from the first marker on 
chromosome 15, D15S817, and a lod score of 1.07 was calculated a further 19cM along 
the chromosome. There are no correspondingly high two point lod scores in this area. 
An examination of the haplotypes, as shown in figure 49, reveals no common haplotype 
amongst the affected individuals studied.
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Figure 49.  The haplotypes for the markers from the Research Genetics 
Marker Set version 8 analysed in the region 15ql 1-15ql2. No haplotype is 
shared by the affected individuals genotyped for the markers shown.
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GATA50C03 1 1 1  1
D15S659 6 4 6  7
D15S648 2 1 4  2Other regions of potential interest identified by multipoint analysis corresponded to the 
regions of the markers that had the highest two point lod scores and have been discussed 
above.
Table 35 Summary of loci for which both the two point and multipoint lod scores were 
strongly positive
Chromosomal band 
location
Maximum 
Multipoint Lod 
Score using 
GENEHUNTER 
analysis 
(V:7 unknown)
Maximum Two 
Point Lod Score 
using 
GENEHUNTER 
analysis 
(V:7 unknown)
Closest Marker 
analysed to 
multipoint peak
3q25, 185cM 2.05 2.86 D3S4531
5q34-5q35, 201cM 2.86 3.18 D5S1713
10q22, 94cM 1.58 1.51 (0 = 0.1) D10S1427
1  lq25, 140cM 1.57 1.87 D11S2359
13q34 , lOlcM 1.60 1.83 D13S895
16pl2, 36cM 1.70 1.34 D16S749
2216. Discussion of genome scan resultsHemifacial microsomia is one of the most commonly recognised craniofacial 
malformations. A wide range of defects have been ascribed to this condition, and other 
terminology such as oculoauriculovertebral spectrum and Goldenhar syndrome are often 
used synonymously. The rationaffor considering these varied phenotypes to be 
manifestations of a single condition is that their characteristic features are all produced 
by the malformation of structures derived from the first and second branchial arches to 
be considered.
A number of theories regarding the embryogenesis of hemifacial microsomia have been 
proposed, including metabolic, teratogenic, vascular and genetic influences, though 
none of these has been shown to be the primary determinant for the development of the 
condition. In fact it is most likely that the malformation complexes currently described 
by the term hemifacial microsomia are actually a conglomerate of aetiologically 
heterogeneous conditions.
Examination of the pedigrees of affected families reveals a small but significant number 
of cases in which hemifacial microsomia is inherited in a Mendelian pattern. The 
observation that 1-2% of cases of hemifacial microsomia have a family history that is 
suggestive of autosomal dominant inheritance suggests that there is a strong genetic 
influence in a proportion of cases of hemifacial microsomia. Other evidence pointing 
towards a major genetic basis include the empirical recurrence risk of 1-2 %, the 
occurrence of the phenotype in association with a number of chromosomal
223rearrangements, and animal models that carry a single gene mutation and that exhibit 
features reminiscent of those seen in hemifacial microsomia. In order to gain a better 
understanding of the factors involved in hemifacial microsomia we undertook a genome 
scan of a family in which the condition appeared to be dominantly segregating, to see if 
a single major disease associated locus could be identified.
6.1 Genotyping difficulties
The genome scan was performed using the Research Genetics Marker Screening Set 
version 8.0 which contains primers for 496 microsatellite markers covering the 
autosomal chromosomes. Blood samples were received from Dr Robert Gorlin from 
which DNA was extracted by the North East Thames Regional Molecular Genetics 
Laboratory at Great Ormond Street hospital. Stock solutions of the resultant DNA, at 
concentrations of 250ng/pl, were aliquoted and further diluted to a concentration of 
50ng/pl for use in the PCR amplifications. These 50ng/pl working stocks were stored at 
4° C when not in use. The PCR protocol that was followed at the start of the project had 
been successfully used by co-workers in our laboratory using similar microsatellite 
markers, and specific bands were observed when the products of the first reactions were 
examined by agarose gel electrophoresis. However, as the genome scan progressed the 
absence of a suitable product for various isolated individuals was frequently noted, 
though there was no obvious pattern with regards to which particular DNA samples 
failed with the different microsatellite markers. Numerous alterations to the PCR
224protocol including stepwise reduction of the annealing temperature, increasing the 
concentration of the primers, and increasing the magnesium concentration were required 
in order to improve the success of the reactions. Despite all of these measures it was not 
possible to successfully amplify the study DNA with 46 of the markers from the set, and 
thus, there are a few regions of the genome which would warrant investigation with 
alternative markers e.g. chromosome 17q21 -  17q25 that spans 33.9 Mb. The potential 
reasons for the failures include degradation of the fluorescent labels attached to the 
primers by repeated exposure to light, suboptimal concentrations of DNA or primers in 
the reaction mix, or the presence of contaminants.
A secondary deleterious effect of the repeated failure of some of the PCR’s was that the 
limited stock of DNA for each individual was depleted more rapidly than had been 
foreseen at the start of the genome scan. Further samples were requested from Dr 
Gorlin, but unfortunately some of these were unobtainable. Thus, 13 pedigree members 
were genotyped for chromosome 1, but only 10 individuals were typed for chromosome 
22.
2256.2 Potential sources of error
When interpreting the results of any linkage analysis consideration must be taken of the 
potential sources of error associated with the techniques used. Errors may occur during 
the initial process of genotyping; sample mislabelling, incorrect allele sizing and 
assignment, or cross contamination could all lead to the assignment of a false genotype 
to an individual. Care was taken to ensure that all samples were correctly identified 
throughout the genotyping and the analysis stages of this study. Polymerase chain 
amplification of a segment of DNA may produce a population of DNA fragments that 
includes fragments of a different size to those of the target DNA locus. These additional 
products tend to differ in size from the original by the size of one or more of the 
nucleotide repeats in the microsatellite marker used. When sufficient amounts of these 
unwanted products are formed, they create spurious ‘stutter’ peaks during the analysis 
of the genotyping reactions (figure 50). Usually the number of additional fragments is 
small in comparison to the intended product but occasionally identification of the true 
size of the original fragment is difficult, though this was rarely the case in this study. 
The Genetic Profiler software used for genotyping in this study automatically called 
alleles according to the highest spectrographic peaks found within the size range of the 
expected products for each marker. However, it was still necessary to review the 
electropherograms for each marker to ensure that the quality of the trace was 
reasonable, and that the alleles called were appropriate and complete; any problems 
relating to stutter were also assessed at the same time.
226Figure 50.  Output from Genetic Profiler analysis of data showing multiple “stutter” 
peaks.
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A more commonly encountered problem was the automatic calling of false alleles by 
the Genetic Profiler software because of spectral overlap. The markers of the Research 
Genetics marker set are labelled with one of three different fluorescent tags, so that the 
products of three PCR’s can be analysed together even if their product sizes overlap. 
The microsatellites are organised into panels of up to 19 markers that are chosen in such 
a way that the pooled products of these markers can be analysed together in a single 
MegaBACE run in order to increase the throughput of samples. However, if there was a 
very large amount of product for one reaction then spectral overlap sometimes resulted 
in spurious peaks for the other marker(s) in the panel with the same product size range. 
This bleed through problem was mitigated by an awareness of its occurrence, and by 
manual examination of the diagrammatic output for all markers superimposed onto one 
picture (figure 51). If these measures failed to separate the true from false alleles, the 
interfering products were reanalysed separately.
227Figure 51.  Output from Genetic Profiler demonstrating spectral overlap. The upper 
spectrograph shows four allele peaks in the expected product size range for a single Hex 
labelled marker. The lower trace reveals two allele peaks relating to a single Tet 
labelled marker analysed simultaneously. Comparison of the two traces suggests that the 
peaks for the two largest alleles on the upper tracing are the result of spectral overlap.If a genotyping error does occur and it results in an offspring being assigned alleles that 
are not present in its parents’ haplotypes then the error may be identified by an 
examination of the haplotypes in relation to the pedigree. Also, the computer programs 
used to generate lod scores will stall if the genotypes of the offspring and parents are 
incompatible. It is possible for genotyping errors to produce a genotype for an 
individual that is incorrect, but which, theoretically, could have been inherited from 
their parents. This type of error is more difficult to identify, though examination of the 
haplotypes in the region of the error will show a false double recombination within a 
short distance.
Misdiagnosis of an individual would also create a false double recombination around 
the disease locus in that individual. Diagnostic errors can occur in dominant conditions 
because of nonpenetrance, variable expression, or the occurrence of a phenocopy. The 
penetrance of a condition is the probability of that character being displayed in an 
individual who has the genotype responsible for that condition. A dominant condition, 
by definition, should be expressed in any individual who possesses the relevant allele, 
but in reality this is not always the case. The effects of the individual’s genetic 
background, environmental influences, or chance occurrence, may mean that the 
character is not manifested, and it may appear that the condition phenotypically “skips” 
a generation. Some dominantly inherited conditions only display an abnormality in adult 
life, which can lead to the misdiagnosis of young children, though this is unlikely to be 
a significant problem in patients with hemifacial microsomia.
229The affected members of a family bearing a dominantly inherited condition may display 
different features of the condition, and this is termed variable expression. The 
explanations for these differences are the same as for non-penetrance, i.e. the effects of 
other genes, environment and chance. The diagnostic criteria for most conditions are 
usually defined from observational studies rather than being based upon the features that 
are known to be produced by the underlying causal mechanism, and this is true for 
hemifacial microsomia. This may lead to the exclusion of the mildest phenotypes, or the 
inclusion of causally unlinked conditions that present a similar phenotype. Phenocopies 
are cases in which the features of the genetic condition of interest are reproduced 
because of environmental effects, and these are another source of misdiagnosis.
It has been noted in section 1  that the definition and diagnosis of hemifacial microsomia 
is not straightforward. The literature contains many reports of conditions that are 
sometimes considered to be synonymous with hemifacial microsomia, e.g. 
oculoauriculovertebral dysplasia and Goldenhar syndrome, but closer scrutiny of these 
papers reveals differences in the diagnostic criteria applied. The challenges and 
complications of misdiagnosis became starkly relevant during the course of this study.
2306.3 Change of affection status of individual V:7
During the course of this project the affection status of individual V:7 was called into 
question (see section 5.2.1). The initial pedigree received from Dr Gorlin indicated that 
V:7 did not display the hemifacial microsomia phenotype. However, we then learned 
that he had a pre-auricular skin tag and we assumed that he was affected in the absence 
of any further information. Direct examination of V:7 some time later revealed that he 
had had a solitary pre-auricular skin tag with no other features of hemifacial 
microsomia, and, therefore, his affection status remained debatable. The difficulty in 
defining the affection status of V:7 arose from the absence of a universally accepted 
minimum phenotype for hemifacial microsomia, and was compounded because the 
clinical details of the individuals studied were conveyed to us from another research 
group. Pre-auricular skin tags or appendages appear to be much more common than 
hemifacial microsomia or microtia alone. Melnick found skin tags at a rate of 17 per 10 
000 amongst a database of over 50 000.pregnancies (Melnick 1980 5 /id}, and Altman 
reported an even higher incidence of 1.5% (Altman 1951  173 /id}.
For most of the markers there was little difference between the results of the analyses 
performed with V:7 classed as affected or as affection unknown. There were 8 markers 
for which, with V:7 classed as affected, the lod score at a recombination fraction of zero 
excluded linkage, but when V:7 was reclassified as affection unknown the two point lod 
scores for these markers changed to positive (table 36), and in the case of marker 
D3S4531 became one of the highest lod scores across the genome scan (table 14). Three
231of these eight markers, D2S1384, D1S1649, and D2S427 are within the region of 
greatest interest, i.e. 2q32 -2q37, given the overall results of the genome scan on family 
R.
Table 36.  Two point lod scores that changed significantly when the affection of 
individual V:7  was reclassified.
Marker Name
MLINK two point lod 
score, 0 = 0, affecteds only 
including V:7
GENEHUNTER two point lod 
score, affecteds only, V:7 
affection unknown
D2S1384 -infinity 1.66
D1S1649 -infinity 1.22
D2S427 -infinity 1.13
D3S4531 -infinity 2.86
D5S1456 -2.83 0.79
D8S1985 -infinity 1.68
D10S1213 -infinity 1.04
D15S652 -infinity 1.27
Predictably, when V:7 was reclassified as affection unknown there were no markers for 
which the two point lod score, at recombination fraction 0=0, changed from being a 
positive value to a negative value that would exclude linkage to that marker.
232All linkage analyses are reliant on accurate pedigree information, and we were reliant 
on Dr Gorlin to ensure that the information used was accurate, and that there were no 
issues with regards to potential problems such as non-paternity.
2336.4 Regions of interested excluded by the results of genome scan
A genome wide search has been performed by other authors in another family affected 
by hemifacial microsomia in which there appears to be an autosomal dominant pattern 
of inheritance {Kelberman, Tyson, et al 2001 55 /id}. The data from this scan were 
suggestive of linkage to chromosomal region 14q32. The markers D14S617 and 
D14S614 used in my genome scan flank the region of chromosome 14q32 that showed 
potential linkage in the work by Kelberman et al, and two other markers used in my 
genome scan, GATA168F06 and D14S605, lie within this region of interest as shown in 
figure 52.
Figure 52.  The relative positions of markers in the region 14q32
Markers of interest in genome scan by Kelberman et al
D14S1142  D14S65
93.9Mb  96.7Mb
D14S617  GATA168F06  D14S605  D14S614
91.3Mb  94.4Mb  95.5Mb  97.3Mb
Markers used in genome scan of family R
234The highest two point lod score amongst these four markers was 0.94 for GATA168F06 
(GENEHUNTER analysis, 0 = 0); the other three markers returned two point lod scores 
that were more negative than -2 at a recombination fraction of zero. The highest 
multipoint lod score across the region of these four markers was -0.6, which again 
corresponded to the position of GATA168F06; it seems unlikely that the disease gene in 
family R is located between these markers, though the results do not definitively 
exclude linkage to the whole of this region.
Graham et al (Graham, Hixon, et al 1995 80 /id} presented a brief report of another 
family showing autosomal dominant transmission of a Goldenhar-like syndrome, and 
showed linkage to the same region of chromosome 8 to which branchio-oto-renal 
syndrome maps. Markers D8S1113, D8S1136 and D8S2323 lie within this region of 
interest, 8ql l-8ql3. Markers D8S1113 and D8S2323 yielded two point lod scores of 
less than -2, and D8S1136 a two point lod score of-1.93 in the GENEHUNTER 
analysis of affecteds only (table 19). The multipoint lod scores are also negative across 
this region, and therefore, linkage to this region appears most unlikely.
It has been noted in section 1.6.4 that the hemifacial microsomia phenotype has been 
associated with a number of chromosomal rearrangements. Hemifacial microsomia with 
deletion of 6q has been reported (Greenberg, Herman, et al 1987 141 /id}, but linkage 
to this region in family R seems unlikely as none of the multipoint lod scores calculated 
for 6q was positive.
235Trisomy 7 and duplication of 7q have been noted in separate reports of hemifacial 
microsomia {Hodes, Gleiser, et al 1981 95 /id} (Hoo, Lorenz, et al 1982 96 /id}, but in 
the study of family R all the two point lod scores for this chromosome calculated using 
only the affected individuals are below -2, and the highest multipoint lod score was 
only 0.41.
Similarly, there are published reports of trisomy 9 mosaicism and hemifacial 
microsomia {Wilson & Barr 1983 42 /id} {de Ravel 2001  162 /id}, but the two point lod 
scores from our genome scan are almost all strongly negative for chromosome 9, and 
apart from the region between the first two markers the multipoint lod scores are all 
negative as well.
The results of our genome scan do not suggest linkage to chromosome 18, several 
rearrangements of which have been reported in association with hemifacial microsomia 
{Bersu & Ramirez-Castro 1977 97 /id} {Greenberg 1987 141 /id} {Verloes 1991  165 
/id} {Clarren & Salk 1983 98 /id} {Sujansky & Smith 1981  110 /id}. For chromosome 
18 all but one of each set of two point lod scores (MLINK including all individuals, 
MLINK affecteds only, and GENEHUNTER) were negative, and all the multipoint lod 
scores calculated were negative as well.
The multipoint lod scores for chromosome 22 exclude linkage to most of this 
chromosome, and all scores were negative. This chromosome was of interest because of 
a number of case reports {Greenberg 1987 141 /id } {Herman, Greenberg, et al 1988 68
236/id} (Kobrynski, Chitayat, et al 1993 70 /id} {Pridjian 1995 171 /id} {Hathout, 
Elmendorf, et al 1998 69 /id} (de Ravel 2001  162 /id}.6.5 Lod scores relative to candidate genes suggested by animal models
There are several candidate genes for hemifacial microsomia that have been suggested 
as a result of animal models (see section 1.6.10). Most of these genes are in close 
proximity to markers used in the genome scan, and the results are summarised below 
(table 37). Only FGF8 would appear to merit further consideration since it is located 
close to marker DIOS 1239 that was associated with a multipoint lod score of 1.47. 
FGF8 is one of the fibroblast growth factors, which are a group of proteins that regulate 
growth and development. Fg/8 has been shown to be required for left right axis 
determination in both chick and mouse studies {Meyers & Martin 1999 7 /id}. Trumpp 
et al {Trumpp, Depew, et al 1999 119 /id} inactivated Fg/8 in mice and showed that the 
gene was required for cell survival and patterning of the first branchial arch. It is also 
known that FGF8 regulates the expression of other potential hemifacial microsomia 
disease genes, having been implicated in HOX gene activation {Dubrulle, McGrew, et 
al 2001  191 /id}, and regulation of DLX-1 and DLX-2 {Shigetani, Nobusada, et al 2000 
190 /id} {Thomas, Liu, et al 2000 133 /id}.
The candidate gene GSC lies with the region 14q32 that has been discussed above. GSC 
lies 94.3Mb along chromosome 14 just proximal to marker GATA168F06, the results 
for which do not encourage further investigation at this stage.
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Table 37.  Maximum lod score results in relation to candidate genes suggested by animal models of hemifacial microsomia
The candidate gene and its position along the chromosome is shown in the central shaded column, together with the markers 
from the Research Genetics Marker Set that are located on either side of the gene locus. The maximum lod score from all of the 
three two point analyses for each of the markers is shown, together with the maximum multipoint lod score in each region.
Chromosomal
region Marker name Maximum two point lod 
score
CANDIDATE
GENE
Marker name
Maximum two point lod 
score
Maximum 
multipoint lod 
score
2q31 D2S1776
169.5Mb
0.01 (MLINK, all
individuals, 0 = 0.4)
DLX-2
172.3Mb
GATA194A05
176Mb
0.5 (MLINK, all
individuals, 0 = 0.4)
-0.82
2q31 D2S1776
169.5Mb
0.01 (MLINK, all
individuals, 0 = 0.4)
DLX-1
172.8Mb
GATA194A05
176Mb
0.5 (MLINK, all
individuals, 0 = 0.4)
-0.82
3p24 D3S3038
21.9Mb
-0.01 (MLINK, all
individuals, 0 = 0.4)
RAR-p
25.3Mb
D3S2466
26Mb
-0.03 (MLINK, all
individuals, 0 = 0.4)
-2.65
4q32.2 D4S1625
143.9Mb
0.03(MLINK, all
individuals, 0 = 0.4)
EDNRA
149Mb
D4S1629
158.7Mb
-0.01 (MLINK, all
individuals, 0 = 0.4)
-3.38
4q34 D4S2368
169.1Mb
0.01 (MLINK, all
individuals, 0 = 0.4)
DHAND
174.8Mb
D4S2431
175.2Mb
-0.1 (MLINK, all
individuals, 0 = 0.4)
-4.332
4
0
Chromosomal
region Marker name
Maximum two point lod 
score
CANDIDATE
GENE Marker name Maximum two point lod 
score
Maximum 
multipoint lod 
score
6p24 D6S1955
10.3Mb
-0.02 (MLINK, affecteds 
only, 0 = 0.4)
AP-2a
10.5Mb
D6S1279
12.3Mb
0.11 (MLINK, affecteds 
only, 0 = 0.3)
-1.83
6p24 D6S1034
12.3Mb
0.02 (MLINK, affecteds 
only, 0 = 0.4)
EDN-1
12.4Mb
D6S1266
19.1Mb
0.08 (MLINK, affecteds 
only, 0 = 0.3)
-1.53
7pl5.2 GATA124D01
21.0Mb
0.36(MLINK, affecteds 
only, 0 = 0.2)
HOXA1
26.9Mb
D7S1808
27.8Mb
-0.14(MLINK, all
individuals, 0 = 0.4)
-2.00
10q24 D10S1239
103.2Mb
0.06 (GENEHUNTER, 
0  = 0)
FGF8
103.5Mb
D10S1246
110.9Mb
0.5 (MLINK, all
individuals, 0 = 0.1)
1.47
12ql3 D12S398
51.5Mb
0.57 (MLINK, affecteds 
only, 0 = 0)
RAR-yl
51.9Mb
D12S1056
58.8Mb
0.01 (MLINK, affecteds 
only, 0 = 0.4)
-1.82
17q21 D17S1294
25.4Mb
0.08 (MLINK, all
individuals, 0 = 0.3)
RAR-a
35.8Mb
D17S1299
36.3Mb
0.28 (MLINK, all
individuals, 0 = 0.2)
-0.57
17q21.3 D17S1299
36.2Mb
0.28(MLINK, all
individuals, 0 = 0.2)
HOXB1
47.1Mb
D17S968
70.1Mb
0.1 (MLINK, all
individuals, 0 = 0.4)
0.186.6 Regions of interest warranting further investigation
The genome scan of family R produced a number of regions in which the maximum two 
point and multipoint lod scores were both positive, and it is amongst these regions that 
the disease locus is most likely to be identified. Chromosome 2q32 -  2q37 produced the 
highest multipoint lod score in the whole genome scan, and it appeared from the lod plot 
(figure 22) that there were two contiguous areas, 40cM and 23cM in size, across in 
which the multipoint lod scores were strongly positive. This finding gained added 
significance because previous work had identified this area as a region of homozygosity 
in a family with recessively inherited hemifacial microsomia (personal communication 
M Bitner-Glindzicz and J.Tyson), and hence the decision was taken to examine further 
microsatellite markers in this region in the limited time available at the end of this 
project. An examination of the haplotypes for these additional markers suggests that 
there are two distinct areas within this region within which there is allele sharing 
amongst the affected individuals who were genotyped. However, the maximum 
multipoint lod score generated by the data from these additional markers was only 0.6 
(figure 46). Therefore, it seems less likely that this is the disease gene locus, although 
there is still an area of interest covered by these markers that overlaps the previously 
described homozygosity region as shown in figure 53.
241Figure 53.  Schematic illustration of map locations of microsatellite markers for 2q32 -  
2q37. (distances along chromosome in Mb). There is a potential overlap of the regions 
of interest between markers D2S434 and D2S151.
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A search of the ensemble database (www.ensembl.org) for known genes in this region 
revealed WNT6 to be the most likely candidate gene. The WNT genes are a family of 
highly conserved developmental control genes, and WNT6 has been shown to be 
expressed in the ectoderm overlying the pharyngeal arches in chick, and is also 
expressed in the inner ear.
242Marker D3S4531 located in the region 3q25 yielded a two point lod score of 2.86 and a 
multipoint lod score of 2.05 (GENEHUNTER analyses). A review of the expression 
patterns and functions of known genes in the vicinity of this marker identified SHOX2 
as a possible candidate gene. SHOX2 is a homeobox gene that has been identified 
through its homology with the murine gene Og-12. Og-12 is highly expressed in 
craniofacial tissues including the ear and palate, as well as in the heart, brain and 
developing limbs {Blaschke, Monaghan, et al 1998 23 /id}. USH3A also lies within this 
region, though this would seem an unlikely candidate for hemifacial microsomia since 
mutations have been associated with Usher syndrome type III, that is characterised by 
sensorineural deafness, variable vestibular dysfunction, and retinitis pigmentosa 
{Ahmed, Riazuddin, et al 2003 9 /id}.
There are two reports in the literature of hemifacial microsomia with cri-du chat 
syndrome caused by deletion of chromosome 5p {Neu, Friedman, et al 1982 66 
/id} {Ladekarl 1968 94 /id}. The critical chromosomal region involved in cri-du-chat 
syndrome has been identified as 5pl2.2- 5pl2.3  (Mainardi, Perfumo, et al 2001  130 
/id}. The telomeric region of 5p was also involved in an unbalanced translocation with 
the short arm of chromosome 8 reported in two siblings with hemifacial microsomia 
{Josifova, Patton, et al 2004 172 /id}. The translocation in these cases resulted in 
monosomy for 5pl5.31 to 5pter and trisomy for the p23.2 to 8pter regions. The most 
positive result from our two point linkage analyses for the short arm of chromosome 5 
was for marker D5S1470, which maps to 5pl4, that yielded two point lod scores of 2.17 
(MLINK analysis, 0 = 0) and 1.87 (GENEHUNTER analysis, 0 = 0). There is a shared
243haplotype amongst the affected members of family R who were genotyped for this 
marker and for the adjacent marker GATA145D09. The multipoint lod scores exclude 
linkage to most of 5p, including the region 5p 15.31 to 5pter, and the critical region for 
cri-du-chat syndrome, although there is a small positive peak in the region of marker 
D5S1470 with a maximum score of 0.45. A review of the expression patterns and 
functions of known genes in this region did not reveal any obvious candidates for a 
hemifacial microsomia disease gene.
Chromosome 5q34-5q35 contained the highest two point lod score in the genome scan 
of family R of 3.18 (0 = 0, GENEHUNTER analysis) for marker D5S1471, and yielded 
a maximum multipoint score of 2.86. However, it has been noted in section 5 that there 
is no haplotype that is identical by descent and exclusive to all the affected individuals 
studied. Potential candidate genes in this region include FOXI1, a member of the 
forkhead family of winged helix transcription regulators, which are important in the 
embryogenesis of mammals. Targeted disruption of this gene in mice causes signs of 
vestibular dysfunction and hearing impairment {Hulander, Wurst, et al 1998 131 /id}. 
Another gene of interest is MSX1, which is a homeobox gene involved in craniofacial 
skeletal formation. MSX1 is expressed in areas of cephalic neural crest cell migration, 
and mice deficient for the gene exhibit craniofacial malformations including cleft lip 
and palate, mandibular hypoplasia, and abnormalities of the malleus. {Satokata & Maas 
1994 103 /id} {Blin-Wakkach, Lezot, et al 2001  104 /id}.
244The multipoint lod scores for chromosomal region 8p21 -   8p23 are positive over quite 
a wide 25cM region, with a maximum multipoint lod score of 2.52. FGF17 is located in 
the region 8p21, and the members of the FGF family are involved in patterning, cell 
proliferation and differentiation during embryogenesis. FGF17 is broadly expressed in 
the midfacial ectoderm in early embryogenesis {Bachler & Neubuser 2001  132 /id}.
The multipoint lod scores for a relatively large section, 25cM, of chromosome 10 were 
positive, with a maximum score of 1.58. The chromosomal region is large because of 
the failure of amplification of three markers in this area. Fibroblast growth factor 8, 
FGF8, maps tol0q24.3, and has been discussed as a candidate gene in section 1.6.10. 
Fg/8 is involved in left-right axis determination in the mouse {Meyers & Martin 1999 7 
/id} ,with Fg/8 being a left determinant. Fg/8 also appears to have an important role in 
brain, limb and tooth development. Thomas et al {Thomas, Liu, et al 2000 133 /id} 
found that Fg/8 is expressed in the epithelium overlying the first branchial arch and 
regulates the mesenchymal expression of Dlx2 in mice.
Retinoids are regulators of cell proliferation, differentiation and morphogenesis during 
embryonic development. CYP26 family members, such as CYP26C1 that maps to 
chromosome 10q23, metabolise retinoic acid and are involved in the control of retinoic 
acid levels in tissues and cells. Murine Cyp26cl has been shown to be expressed in 
prospective rhombomeres 2 and 4, in the first branchial arch and along the mesenchyme 
adjacent to the rostral hindbrain in the early developmental stages (E8.0 -  E8.5) 
{Tahayato, Dolle, et al 2003  134 /id}. Cyp26cl expression persists in rhombomere 2
245and in the maxillary and mandibular components of the first branchial arch at E9.5. It is 
of interest that the hemifacial microsomia phenotype has been associated with the 
exposure of pregnant women to retinoic acid {Lammer, Chen, et al 1985 77 /id}. 
Another member of the retinoic acid metabolising cytochrome p450 family, Cyp26al, is 
also located in this region of interest of chromosome 10, and expression of Cyp26Al has 
been found in the neural-crest derived mesenchyme of the branchial arches in early 
embryonic mice (MacLean, Abu-Abed, et al 2001  135 /id}.
Another candidate gene in this region is CHUK (Jkkl, IkkA). IkkaT mice died within 4 
hours of birth and had abnormal limb and craniofacial development (Takeda, Takeuchi, 
et al 1999 136 /id}. Hu et al {Hu, Baud, et al 1999 137 /id} also generated Ikka deficient 
mice; at embryonic day 18.5 these mice had truncated snouts and no external ears, limbs 
represented by rudimentary protrusions, and heads that were shorter than normal. They 
also had fused sacral and cervical vertebrae, a short sternum, an omphalocele, taut skin 
and they lacked well formed tails. Sil et al {Sil, Maeda, et al 2004 138 /id} found that 
Ikka affects the expression of fibroblast growth factor (FGF) family members, and the 
expression of another candidate gene, Fg/8, is elevated in the limb bud ectoderm of Ikka 
deficient mice.
The homeobox gene NKX2C is located at 10q24.2. This gene is expressed in the 
pharyngeal floor and pouches, as well as in oral, first, and possibly second, branchial 
arch ectoderm {Biben, Wang, et al 2002 139 /id}. Nkx2c deficient mice were bom with
246gut and spleen abnormalities {Pabst, Zweigerdt, et al 1999 142 /id}, and Biben et al 
found that Nkx2c null mice had abnormal sublingual glands and molar teeth.
Marker D11S2019 from the Research Genetics marker set lies within the region 1  lql2- 
13 that has been proposed as a potential hemifacial microsomia disease locus {Singer, 
Haan, et al 1994 53 /id}, but unfortunately this was one of the markers that did not yield 
a satisfactory product despite repeated attempts at PCR amplification.
The homeobox gene BARX2 is located in the region of interest 1  lq25 that yielded a two 
point lod score of 1.87 and a multipoint lod score of 1.57. Jones et al {Jones, Kioussi, et 
al 1997 143 /id} observed expression of Barx2 in the ectodermal lining of the 
mandibular and maxillary processes during craniofacial development in the mouse. 
Intense expression of Barx2 was observed in small groups of cells undergoing tissue 
remodelling including ectodermal cells in indentations around the eye and maxillo-nasal 
groove, and in the first branchial pouch, lung buds, precartilagenous condensations and 
mesenchyme of the limb. Jones et al suggested that BARX2 may control the expression 
of neural cell adhesion molecules, including LI-CAM, and other target genes during 
embryonic development. Smith and Tabin {Smith & Tabin 1999 144 /id} isolated the 
chicken gene cbarx2, and noted its expression in craniofacial structures, regions of the 
neural tube, and muscles in the limb, neck and cloaca.
247Region 13q34 yielded a maximum two point lod score of 2.82 and a multipoint lod 
score of 1.83. Within this region lies CUL-4A that appears to have an essential function 
for early embryonic mammalian development, since homozygous and heterozygous 
mouse mutants for a Cul-4a deletion died during gestation {Li, Ruiz, et al 2002 145 
/id).
Chromosomal region 16pl2 was associated with a maximum two point lod score of 
1.34, and a multipoint lod score of 1.70. A candidate gene within this region is COG7 
that is involved in the determination of Golgi apparatus structure. Two siblings with 
homozygous mutations of COG7 have been reported whose phenotype included low-set 
dysplastic ears, micrognathia, short neck and loose, wrinkled skin (Wu, Steet, et al 2004 
146/id}.
Thus, there are a number of regions that have been identified from the results of the 
genome scan as warranting further investigation, and region 2q32-37 would appear to 
be the most promising at present. The fact that the scan failed to produce a single 
particular locus that was strongly suggestive of linkage was disappointing. Amongst the 
reasons for this failure may have been the fact that some of the attempted PCR 
amplifications failed, and so some areas of the genome were more sparsely covered that 
initially intended. It has been noted above that towards the end of the study some of the 
DNA samples ran out, so that, whilst linkage analysis was still possible, the magnitude 
of the lod scores calculated may have been reduced. The size of family R and the
248availability of DNA from only selected members of the pedigree may also have 
precluded the possibility of a greater lod score.
It is also possible that the genetic defect in hemifacial microsomia is a small deletion, 
and this would be missed by the genome scan if none of the markers analysed fell 
within the deletion. A deletion that included a single marker locus might also be 
overlooked; the affected individual would be typed as a homozygote for the deleted 
marker assuming that the parental alleles were compatible. A small deletion might be 
detected by higher resolution analysis of DNA copy number variations. Gene dosage 
variations have been studied using comparative genomic hybridisation, a technique that 
utilises differentially labelled total genomic DNA from test and reference cell 
populations. This DNA is hybridised to either normal metaphase chromosomes, or, 
more recently, to arrays of mapped sequences. The resulting ratio of fluorescence 
intensities at a locus is proportional to the ratio of copy numbers of the test and normal 
DNA at that locus. This approach has previously been used to locate the gene 
responsible for a large number of cases of CHARGE syndrome, which is also 
characterised by a number of congenital anomalies. A genome wide comparative 
genomic hybridisation profile suggested deletions in chromosomal band 8ql2 in two 
affected individuals. The genes within this interval were sequenced and mutations in the 
gene CHD7 were identified in 10 subjects {Vissers, van Ravenswaaij, et al 2004 192 
/id}. However, a small deletion might still be missed by comparative genomic 
hybridisation depending on the resolution of the chips used.
2496.7 Future work
The results of the genome scan of family R suggest that the most likely locus for the 
disease gene for hemifacial microsomia lies in the region 2q32 -  2q37. However, 
further investigation of the other chromosomal regions of interest that were identified by 
the genome scan is required in order to identify the disease related gene locus with 
greater certainty and accuracy. This would include analysis of further microsatellite 
markers with a greater density across the regions 3q25, 5q34-5q35, 8p21-8p23, 1  lq25, 
13q34, and 16p 12-16p 13 and the region. Further marker studies would also be of 
interest in the region 10q23 -  10q24 that was sparsely covered in the scan, and within 
which the candidate gene Fg/8 lies. A replacement for the failed marker D11S2019 
would allow assessment of the region 1  lql2-l lql3, a previously proposed locus for the 
disease gene.
Candidate genes within the strongest candidate region could then be identified, by 
consideration of the known expression patterns or function of the genes within that 
region or from the phenotype of animal models. These candidate genes could then be 
sequenced in order to identify mutations in affected individuals.
Identification of a gene, the mutation of which is responsible for the development of 
hemifacial microsomia, would help to characterise the phenotypic spectrum of the 
condition. Family members of affected individuals could be screened for mutations and 
counselled appropriately. Sporadic cases could be screened for mutation in an identified
250disease gene, and this would provide information on the degree to which sporadic 
hemifacial microsomia is genetically determined.
This work has added to the epidemiological and phenotypic data previously available on 
hemifacial microsomia. Whilst the genome scan of family R did not identify a specific 
candidate locus, linkage to large sections of the genome was excluded, and the data 
have suggested defined regions of the genome that warrant further investigation. Future 
work directed by the results of this work should lead to further insights into the genetic 
basis of hemifacial microsomia.
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273APPENDIX A
PROJECT: GENETIC BASIS OF MICROTIA
Patient information
1.  Aim of the study:
To determine the genetic basis of the condition called microtia, where the 
individuals affected have a small or deformed ear. This condition can be bilateral 
and rarely may affect more than one member of the same family
2.  Why is this study being done?
Microtia is a condition not fully understood in terms of how or why it occurs. It 
can be associated with other facial anomalies and may just represent one grade 
of a large spectrum. Most cases occur as an isolated finding in a single individual 
within a family, but occasionally more than one family member may be affected, 
suggesting a genetic predisposition in same families. We are aiming to find 
genetic factors which may predispose or protect against the development if 
microtia/hemifacial microsomia.
3.  How is this study being done?
First we will inform the parents about the study before they attend their ENT or 
dental/maxillofacial clinic appointments. When they attend they will be given the 
option to participate in the study. This will involve answering some questions and 
taking blood samples from the child and the parents and occasionally of other 
relatives if they are also affected by the condition. In a few cases it may be 
necessary to visit the patient and his/her parents at home if the appointment is 
not due for a long time.
4.  What are the risks and discomforts?
There are no anticipated risks and the only discomfort may arise from taking the 
required blood sample.
5.  Who will have access to the case/research records?
Your participation will be completely confidential. Any identifying information will 
be removed before the information is entered in the computers. Your hospital 
files and photographic records will be seen by hospital staff only and will not be 
taken out of the hospital.
6.  What are the potential benefits?
This study aims to further the understanding of the genetic involvement in the 
condition, but no results will be available to individuals since it is unlikely to 
benefit them directly for the foreseeable future.
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7.  Do you have to take part in the study?
If you decide, now or at a later stage, that you do not wish to participate in this 
research project, that is entirely your right, and will in no way prejudice any 
present or future treatment.
8.  Who do you speak to if problems arise?
If you have any complaints about the way in which this research project has 
been, or is being conducted, please, in the first instance, discuss them with the 
researcher.  If the problems are not resolved, or you wish to comment in any 
other way, please contact the Chairman of the Research Ethics Committee, by 
Post via the Research and Development Office, Institute of Child Health,   
, or if urgent, by telephone on   
 ext.  , and the Committee administration will put you in contact with 
him.
9.  What are the arrangements for compensation?
This  project  has  been  approved  by  an  independent  research  ethics  committee 
who  believes  that  it  is  of  minimal  risk  to  you.  However,  research  can  carry 
unforeseen  risks  and  we want you  to  be  informed  of your rights  in  the  unlikely 
event that any harm should occur as a result of taking part in this study.
No special compensation arrangements have been made for this project but you 
have  the  right to  claim  damages  in  a  court of law.  This  would  require  you  to 
prove fault on the part of the Hospital and/or any manufacturer involved.
10.  Researcher who will have contact with the family:
You will be contacted by Mr Jerome Lim, Research Fellow in ENT or Dr. Maria 
Bitner-Glindzicz, Clinical and Molecular Geneticist.
Contact numbers:
•  Mr Jerome Lim   Ext.   or page him via switchboard on the 
same number.
•  Dr. M. Bitner-Glindzicz   Ext. 
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Information for Parents
We would like to invite your child to participate in a study that looks at what 
causes some children to be born with deformed ears.
1.  Aim of the study:
To determine the genetic basis of the condition called microtia, where the 
individuals affected have a small or deformed ear. This condition can be bilateral 
and rarely may affect more than one member of the same family
2.  Why is this study being done?
Microtia is a condition not fully understood in terms of how or why it occurs. It 
can be associated with other facial anomalies and may just represent one grade 
of a large spectrum. Most cases occur as an isolated finding in a single individual 
within a family, but occasionally more than one family member may be affected, 
suggesting a genetic predisposition in same families. We are aiming to find 
genetic factors which may predispose or protect against the development if 
microtia/hemifacial microsomia.
3.  How is this study being done?
First we will inform you about the study before you attend the ENT or 
dental/maxillofacial clinic appointments. When you attend you will be given the 
option to participate in the study. This will involve answering some questions and 
taking blood samples from you and your child and occasionally of other relatives 
if they are also affected by the condition. In a few cases it may be necessary to 
visit the patient and his/her parents at home if the appointment is not due for a 
long time.
4.  What are the risks and discomforts?
There are no anticipated risks and the only discomfort may arise from taking the 
required blood sample.
5.  Who will have access to the case/research records?
Your participation will be completely confidential. Any identifying information will 
be removed before the information is entered in the computers. Your hospital 
files and photographic records will be seen by hospital staff only and will not be 
taken out of the hospital.  The research records may be reviewed by regulatory 
authorities.  Your GP will be contacted if you wish to participate in the study.
6.  What are the potential benefits?
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This study aims to further the understanding of the genetic involvement in the 
condition and although the study will not be of direct benefit to the patients 
participating in it, we are hoping that the results obtained will benefit future 
patients.
7.  Do you have to take part in the study?
If you decide, now or at a later stage, that you do not wish to participate in this 
research project, that is entirely your right, and will in no way prejudice any 
present or future treatment.
8.  Who do you speak to if problems arise?
If you have any complaints about the way in which this research project has 
been, or is being conducted, please, in the first instance, discuss them with the 
researcher.  If the problems are not resolved, or you wish to comment in any 
other way, please contact the Chairman of the Research Ethics Committee, by 
Post via the Research and Development Office, Institute of Child Health,   
, or if urgent, by telephone on   
 ext.  , and the Committee administration will put you in contact with 
him.
9.  What are the arrangements for compensation?
This  project  has  been  approved  by an  independent  research  ethics  committee 
who  believes  that  it  is  of  minimal  risk  to  you.  However,  research  can  carry 
unforeseen  risks  and  we want you  to  be  informed  of your rights  in  the  unlikely 
event that any harm should occur as a result of taking part in this study.
No special compensation arrangements have been made for this project but you 
have  the  right to  claim  damages  in  a  court of law.  This  would  require  you  to 
prove fault on the part of the Hospital and/or any manufacturer involved.
10.  Researcher who will have contact with the family:
You will be contacted by Mr Jerome Lim, Research Fellow in ENT or Dr. Maria 
Bitner-Glindzicz, Clinical and Molecular Geneticist.
Contact numbers:
•  Mr Jerome Lim   Ext.   or page him via switchboard on the 
same number.
•  Dr. M. Bitner-Glindzicz   Ext. 
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Great Ormond Street Hospital for Children NHS Trust and Institute of 
Child Health Research Ethics Committee
Title:  Genetic basis of microtia/hemifacial microsomia.
NOTES FOR PARENTS OR GUARDIANS
1.  Your child has been asked to take part in a research study.  The person organising that study is 
responsible for explaining the project to you before you give consent.
2.  Please  ask  the  researcher  any  questions  you  may  have  about  this  project,  before  you  decide 
whether you wish to participate.
3.  If you decide, now or at any other stage, that you do not wish your child to participate in the 
research project, that is entirely your right, and if your child is a patient it will not in any way 
prejudice any present or future treatment.
4.  You will be  given an information sheet which describes the research project.  This information 
sheet is for you to keep and refer to. Please read it carefully.
5.  If you have  any complaints  about the way in which this research project has been or is being 
conducted, please, in the first instance, discuss them with the researcher.  If the problems are not 
resolved, or you wish to comment in any other way, please contact the Chairman of the Research 
Ethics Committee, by post via The Research and Development Office, Institute of Child Health, 30 
Guilford Street, London WON IEH or if urgent, by telephone on 020 7242 9789 ext 2620 and the 
committee administration will put you in contact with him.
to me to my/our satisfaction, and I/We give permission for our child to take part in this study.  I/We 
have read both the notes written above and the Information Sheet provided, and understand what the 
research study involves.
Consent Form for PARENTS OR GUARDIANS 
of Children Participating in Research Studies
CONSENT
I/We being the parent(s)/guardian(s) of
agree that the Research Project named above has been explained
SIGNED (Parent (s)/Guardian (s)) DATE
SIGNED (Researcher) DATE
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Great Ormond Street Hospital for Children NHS Trust and 
Institute of Child Health Research Ethics Committee
Assent Form for CHILDREN Participating in Research Studies
Title:  Genetic basis of microtia/hemifacial microsomia.
NOTES FOR CHILDREN
1.  You have been asked to take part in some research.  The person organising that study must 
explain the project to you before you agree to take part.
2.  Please  ask  the  researcher  any  questions  you  like  about  this  project,  before  you  decide 
whether to join in.
3.  If you decide, now or at any other time, that you do not wish to be involved in the research 
project, just tell us and we will stop the research.  If you are a patient your treatment will 
carry on as it would normally.
4.  You will be given an information sheet which describes the research.  This information is 
for you to keep and refer to at any time.  Please read it carefully.
5.  If you have any complaints about the research project, discuss them with the researcher.  If 
the problems are not resolved, or you wish to comment in any other way, please contact the 
Chairman of the Research Ethics Committee, by post via The Research and Development 
Office,  Institute  of Child Health    or if urgent,  by 
telephone  on    ext    and the  committee  administration will put you in 
contact with him.
ASSENT
I agree that the Research Project named
above has been explained to me to my satisfaction, and I agree to take part in this study.  I have read 
both the notes written above and the Information Sheet about the project, and understand what the 
research study involves.
SIGNED DATE
SIGNED (Researcher) DATE
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HFM - MICROTIA
NAME 
HOSP. #
SURNAME
DOB
ADDRESS
POSTCODE 
TEL HOME 
TEL. WORK
GP
ADDRESS
POSTCODE
TEL:
BLOOD SAMPLES DOB ECACC DNA
PROBAND □ □
FATHER □ □
MOTHER □ □
OTHER □ □
□ □
□ □APPENDIX B
MEDICAL HISTORY
Pregnancy
Bleeding
When
Medical problems 
DM
Multiple pregnancy
Medication
Delivery
Weeks
How long
HT
Alcohol
Type
Times
Other
Smoking
Problems
Family History
# Pregnancies (including proband)
Problems
Other medical
Parents
Medical Hx.
Tags/pits
Uncles/Aunts
Medical Hx.
Bleeding 
Tags/pits
Grand-parents
Medical Hx.
Tags/pits
Cousins
Medical Hx.
Tags/pits Tags/pits
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PROBAND
Head  Plagiocephaly  yes/no 
Neck
Hydrocephalus  yes/no
Face
Ears
Mandibular hypoplasia 
Cleft  Lip
Facial palsy
Eyes
Microtia
Tags
EAM
HL
V
Micropthalmia
Side
Pits
Mouth
Macrostomia 
Mental development 
Other  Cardiac
Maxillary hypoplasia 
Palate  Midline  Lateral
Grade
Epibulbar dermoid
Renal
Syndrome?
282A
d
d
e
n
d
u
m
Summary ideogram displaying multipoint lod score plots and their chromosomal relationships. Excursion of the plot to the left of the midline 
represents a positive lod score, and to the right of the midline indicates a negative lod score.
1 O  H1  -12: